

Disclaimer

The following report(s) provides findings from an FDA-initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also be initiated for various other reasons. Some examples include determining a rate or count of an identified health outcome of interest, examining medical product use, exploring the feasibility of future, more detailed analyses within Sentinel, and seeking to better understand Sentinel capabilities.

Data obtained through Sentinel are intended to complement other types of evidence such as preclinical studies, clinical trials, postmarket studies, and adverse event reports, all of which are used by FDA to inform regulatory decisions regarding medical product safety. The information contained in this report is provided as part of FDA's commitment to place knowledge acquired from Sentinel in the public domain as soon as possible. Any public health actions taken by FDA regarding products involved in Sentinel queries will continue to be communicated through existing channels.

FDA wants to emphasize that the fact that FDA has initiated a query involving a medical product and is reporting findings related to that query does not mean that FDA is suggesting health care practitioners should change their prescribing practices for the medical product or that patients taking the medical product should stop using it. Patients who have questions about the use of an identified medical product should contact their health care practitioners.

The following report contains a description of the request, request specifications, and results from the modular program run(s).

If you are using a web page screen reader and are unable to access this document, please contact the Sentinel Operations Center for assistance at info@sentinelssystem.org.

Overview for Request: cder_mpl1p_wp050, Report 3 of 4

Request ID: cder_mpl1p_wp050_cnodes_v03

Request Description: We estimated the prevalent utilization for all, branded, impurity identified, no impurity identified, recalled, and unclassified valsartan and recalled Angiotensin Receptor Blockers (ARBs) over time in the Sentinel Distributed Database (SDD), Canadian Network for Observational Drug Effect Studies (CNODES), and the Danish National Prescription Registry (DNPR).

Sentinel Routine Querying Module: Cohort Identification and Descriptive Analysis (CIDA) tool, version 10.1.1, with custom programming.

Data Source: We distributed this query to CNODES on July 29, 2022. The study period included data from May 1, 2012 through December 31, 2020. Please see Appendix A for a list of dates of available data for each Data Partner. This report will only include the data obtained from CNODES.

Study Design: We defined a prevalent cohort to estimate the proportion of valsartan utilization by impurity status over time and to obtain usage of valsartan and recalled ARB products. We identified individuals over 18 years of age with use of valsartan products (all, branded, impurity identified, no impurity identified, recalled, and unclassified) or recalled ARB products and followed them on their exposed time until any of the censoring criteria were met.

For monthly and quarterly assessment, the valsartan episodes with treatment duration that cross multiple months or quarters were counted in the relevant month and quarter.

This is a Type 2 analysis in the Query Request Package (QRP) documentation. This is report 3 of 3 and contains results for prevalent utilization of all, branded, impurity identified, no impurity identified, recalled, and unclassified valsartan and recalled Angiotensin Receptor Blockers (ARBs) over time.

Exposures of Interest: We captured first qualifying dispensings of the exposures of interest using outpatient dispensing data and Drug Identification Numbers (DINs) within CNODES. No exposure washout was taken into account. Cohort re-entry was allowed.

Valsartan groups were defined by impurity or recalled status using provided lists of DINs.

Valsartan with impurity were defined using Lot numbers that had any N-nitrosodimethylamine (NDMA or NDEA) impurity detected, which then mapped to a provided list of DINs. Similarly, products that had no detection of NDMA or NDEA were classified as valsartan without impurity.

Recalled ARB products (irbesartan, losartan, valsartan) were also defined using a provided list of DINs that were recalled.

Branded valsartan was defined as Novartis or Sandoz valsartan products or as those with brand names Diovan, Entresto or Exforge. Unclassified valsartan included valsartan products that were not classified in any of the above categories.

Please see Appendix B for a list of generic and brand names and manufacturer names. Please see Appendix C for a list of generic and manufacturer names. Please see Appendix D for a list of generic and manufacturer names.

Cohort Eligibility Criteria: We required members to be enrolled in health plans with medical and drug coverage in the 183 days prior to their index date in order to be included in the cohort. A gap in coverage of up to 45 days was allowed and treated as continuous enrollment. The following age groups were included in the cohort: 18-44, 45-64, and 65+ years. The following sex groups were included in the cohort: male and female.

Follow-up Time: We created exposure episodes based on the number of days of product supplied per dispensing in the outpatient pharmacy dispensing data. We bridged together episodes less than 30 days apart and added 30 days to the end of each episode. If dispensings overlapped, we allowed for a maximum of 33% overlap of the previous dispensing's days supply before truncating the previous dispensing's days' supply at the next dispensing date. If there is less than 33% overlap in the dispensings, then the next dispensing date is pushed forward to the end of the previous dispensing.

Overview for Request: cder_mpl1p_wp050, Report 3 of 4

Follow-up begins on the day of the index dispensing and continues until the first occurrence of any of the following: 1) disenrollment; 2) death; 3) the end of the data provided by each Data Partner; or 4) product discontinuation.

Baseline Characteristics: We assessed the following characteristics in the 183 days prior to and including the index date of the prevalent cohort index dates: age, calendar year, sex, angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, and stroke. These conditions are defined in any care setting and position using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) diagnosis codes. Please see Appendix E for a list of diagnosis codes used to define baseline characteristics in this request.

Please see Appendix F for the parameter specifications used in the analyses.

Limitations: Algorithms used to define exposure criteria are imperfect; thus, it is possible that there may be misclassification. Therefore, data should be interpreted with this limitation in mind.

Notes: Please contact the Sentinel Operations Center (info@sentinelssystem.org) for questions and to provide comments/suggestions for future enhancements to this document. For more information on Sentinel's routine querying modules, please refer to the documentation (<https://dev.sentinelssystem.org/projects/SENTINEL/repos/sentinel-routine-querying-tool-documentation/browse>).

Table of Contents

<u>Glossary</u>	Glossary of Terms for Analyses Using Cohort Identification and Descriptive Analysis (CIDA) Module
<u>Table 1a</u>	Aggregated Baseline Table for Members Dispensed Prevalent All Valsartan Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1b</u>	Aggregated Baseline Table for Members Dispensed Prevalent Valsartan with Impurity Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1c</u>	Aggregated Baseline Table for Members Dispensed Prevalent Valsartan without Impurity Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1d</u>	Aggregated Baseline Table for Members Dispensed Prevalent Branded Valsartan Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1e</u>	Aggregated Baseline Table for Members Dispensed Prevalent Unclassified Valsartan Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1f</u>	Aggregated Baseline Table for Members Dispensed Prevalent Recalled Valsartan Dispensings Between May 1, 2012 and December 31, 2020
<u>Table 1g</u>	Aggregated Baseline Table for Members Dispensed Prevalent Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan) Between May 1, 2012 and December 31, 2020
<u>Table 2a</u>	Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, Overall
<u>Table 2b</u>	Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Age Group
<u>Table 2c</u>	Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month
<u>Table 2d</u>	Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter
<u>Appendix A</u>	Dates of Available Data for Each Data Partner (DP) as of Request Distribution Date (July 28, 2022)
<u>Appendix B</u>	List of Generic and Brand Names of Medical Products Used to Define Branded Valsartans in this Request
<u>Appendix C</u>	List of Generic Names, Brand Names, and Manufacturers of Medical Products Used to Define Impurity Identified, No Impurity Identified, Recalled, and Unclassified Valsartans in this Request
<u>Appendix D</u>	List of Generic Names and Manufacturers of Medical Products Used to Define Recalled Non-Valsartan Angiotensin Receptor Blockers (ARBs) in this Request
<u>Appendix E</u>	List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request
<u>Appendix F</u>	Specifications Defining Parameters for this Request

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Amount Supplied - number of units (pills, tablets, vials) dispensed. Net amount per NDC per dispensing.

Blackout Period - number of days at the beginning of a treatment episode that events are to be ignored. If an event occurs during the blackout period, the episode is excluded.

Care Setting - type of medical encounter or facility where the exposure, event, or condition code was recorded. Possible care settings include: Inpatient Hospital Stay (IP), Non-Acute Institutional Stay (IS), Emergency Department (ED), Ambulatory Visit (AV), and Other Ambulatory Visit (OA). For laboratory results, possible care settings include: Emergency Department (E), Home (H), Inpatient (I), Outpatient (O), or Unknown or Missing (U). The Care Setting, along with the Principal Diagnosis Indicator (PDX), forms the Care Setting/PDX parameter.

Ambulatory Visit (AV) - includes visits at outpatient clinics, same-day surgeries, urgent care visits, and other same-day ambulatory hospital encounters, but excludes emergency department encounters.

Emergency Department (ED) - includes ED encounters that become inpatient stays (in which case inpatient stays would be a separate encounter). Excludes urgent care visits.

Inpatient Hospital Stay (IP) - includes all inpatient stays, same-day hospital discharges, hospital transfers, and acute hospital care where the discharge is after the admission date.

Non-Acute Institutional Stay (IS) - includes hospice, skilled nursing facility (SNF), rehab center, nursing home, residential, overnight non-hospital dialysis and other non-hospital stays.

Other Ambulatory Visit (OA) - includes other non overnight AV encounters such as hospice visits, home health visits, skilled nursing facility visits, other non-hospital visits, as well as telemedicine, telephone and email consultations.

Charlson/Elixhauser Combined Comorbidity Score - calculated based on comorbidities observed during a requester-defined window around the exposure episode start date (e.g., in the 183 days prior to index).

Code Days - the minimum number of times the diagnosis must be found during the evaluation period in order to fulfill the algorithm to identify the corresponding patient characteristic.

Cohort Definition (drug/exposure) - indicates how the cohort will be defined: 01: Cohort includes only the first valid treatment episode during the query period; 02: Cohort includes all valid treatment episodes during the query period; 03: Cohort includes all valid treatment episodes during the query period until an event occurs.

Computed Start Marketing Date - represents the first observed dispensing date among all valid users within a GROUP (scenario) within each Data Partner site.

Days Supplied - number of days supplied for all dispensings in qualifying treatment episodes.

Eligible Members - number of members eligible for an incident treatment episode (defined by the drug/exposure and event washout periods) with drug and medical coverage during the query period.

Enrollment Gap - number of days allowed between two consecutive enrollment periods without breaking a "continuously enrolled" sequence.

Episodes - treatment episodes; length of episode is determined by days supplied in one dispensing or consecutive dispensings bridged by the episode gap.

Episode Gap - number of days allowed between two (or more) consecutive exposures (dispensings/procedures) to be considered the same treatment episode.

Event Deduplication - specifies how events are counted by the Modular Program (MP) algorithm: 0: Counts all occurrences of a health outcome of interest (HOI) during an exposure episode; 1: de-duplicates occurrences of the same HOI code and code type on the same day; 2: de-duplicates occurrences of the same HOI group on the same day (e.g., de-duplicates at the group level).

Exposure Episode Length - number of days after exposure initiation that is considered "exposed time."

Exposure Extension Period - number of days post treatment period in which the outcomes/events are counted for a treatment episode. Extensions are added after any episode gaps have been bridged.

Lookback Period - number of days wherein a member is required to have evidence of pre-existing condition (diagnosis/procedure/drug dispensing).

**Glossary of Terms for Analyses Using
Cohort Identification and Descriptive Analysis (CIDA) Module***

Maximum Episode Duration - truncates exposure episodes after a requester-specified number of exposed days. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Member-Years - sum of all days of enrollment with medical and drug coverage in the query period preceded by an exposure washout period all divided by 365.25.

Minimum Days Supplied - specifies a minimum number of days in length of the days supplied for the episode to be considered.

Minimum Episode Duration - specifies a minimum number of days in length of the episode for it to be considered. Applied after any gaps are bridged and extension days added to the length of the exposure episode.

Monitoring Period - used to define time periods of interest for both sequential analysis and simple cohort characterization requests.

Principal Diagnosis (PDX) - diagnosis or condition established to be chiefly responsible for admission of the patient to the hospital. 'P' = principal diagnosis, 'S' = secondary diagnosis, 'X' = unspecified diagnosis, '.' = blank. Along with the Care Setting values, forms the Caresetting/PDX parameter.

Query Period - period in which the modular program looks for exposures and outcomes of interest.

Switch Evaluation Step Value - value used to differentiate evaluation step. Each switch pattern can support up to 2 evaluation steps (0 = switch pattern evaluation start; 1 = first evaluation; 2 = second evaluation).

Switch Gap Inclusion Indicator - indicator for whether gaps in treatment episodes that are included in a switch episode will be counted as part of the switch episode duration.

Switch Pattern Cohort Inclusion Date - indicates which date to use for inclusion into the switch pattern cohort of interest as well as optionally as the index date of the treatment episode initiating the switch pattern. Valid options are the product approval date, product marketing date, other requester defined date, or computed start marketing date.

Switch Pattern Cohort Inclusion Strategy - indicates how the switch pattern cohort inclusion date will be used: 01: used only as a switch cohort entry date. First treatment episode dispensing date is used as index for computing time to first switch; 02: used as switch cohort entry date and as initial switch step index date for computing time to first switch.

Treatment Episode Truncation Indicator - indicates whether the exposure episode will be truncated at the occurrence of a requester-specified code.

Washout Period (drug/exposure) - number of days a user is required to have no evidence of prior exposure (drug dispensing/procedure) and continuous drug and medical coverage prior to an incident treatment episode.

Washout Period (event/outcome) - number of days a user is required to have no evidence of a prior event (procedure/diagnosis) and continuous drug and medical coverage prior to an incident treatment episode.

Years at Risk - number of days supplied plus any episode gaps and exposure extension periods all divided by 365.25.

*all terms may not be used in this report

Table 1a. Aggregated Baseline Table for Members Dispensed Prevalent All Valsartan Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	391,207	
Number of unique patients	186,453	
Demographics		
Age (years)	71.1	10.6
Age		
18-44 years	10,959	2.8%
45-64 years	67,335	17.2%
≥ 65 years	312,913	80.0%
Sex		
Female	99,884	53.6%
Male	86,569	46.4%
Race (Unknown)	186,453	100.0%
Year		
2012	36,532	9.3%
2013	49,869	12.7%
2014	48,862	12.5%
2015	48,063	12.3%
2016	47,895	12.2%
2017	53,896	13.8%
2018	42,196	10.8%
2019	33,375	8.5%
2020	30,519	7.8%
Recorded History of:		
Angina	18,688	4.8%
Atrial fibrillation	30,141	7.7%
Diabetes	96,486	24.7%
Heart failure	32,257	8.2%
Hyperlipidemia	19,369	5.0%
Hypertension	183,007	46.8%
Myocardial infarction	6,675	1.7%
Renal disorders	19,323	4.9%
Stroke	8,005	2.0%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1b. Aggregated Baseline Table for Members Dispensed Prevalent Valsartan with Impurity Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	48,557	
Number of unique patients	33,199	
Demographics		
Age (years)	72.4	10.7
Age		
18-44 years	951	2.0%
45-64 years	7,694	15.8%
≥ 65 years	39,912	82.2%
Sex		
Female	18,849	56.8%
Male	14,350	43.2%
Race (Unknown)	33,199	100.0%
Year		
2012	3,597	7.4%
2013	5,788	11.9%
2014	4,125	8.5%
2015	5,122	10.5%
2016	4,305	8.9%
2017	4,608	9.5%
2018	7,058	14.5%
2019	8,745	18.0%
2020	5,209	10.7%
Recorded History of:		
Angina	1,777	3.7%
Atrial fibrillation	3,206	6.6%
Diabetes	15,737	32.4%
Heart failure	2,056	4.2%
Hyperlipidemia	2,186	4.5%
Hypertension	24,890	51.3%
Myocardial infarction	515	1.1%
Renal disorders	3,231	6.7%
Stroke	1,124	2.3%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1c. Aggregated Baseline Table for Members Dispensed Prevalent Valsartan without Impurity Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	34,214	
Number of unique patients	24,950	
Demographics		
Age (years)	73.2	10.6
Age		
18-44 years	684	2.0%
45-64 years	4,818	14.1%
≥ 65 years	28,712	83.9%
Sex		
Female	14,427	57.8%
Male	10,523	42.2%
Race (Unknown)	24,950	100.0%
Year		
2012	2,654	7.8%
2013	2,732	8.0%
2014	3,004	8.8%
2015	2,519	7.4%
2016	2,459	7.2%
2017	1,482	4.3%
2018	7,029	20.5%
2019	10,630	31.1%
2020	1,705	5.0%
Recorded History of:		
Angina	1,317	3.8%
Atrial fibrillation	2,407	7.0%
Diabetes	10,343	30.2%
Heart failure	1,609	4.7%
Hyperlipidemia	1,642	4.8%
Hypertension	16,548	48.4%
Myocardial infarction	403	1.2%
Renal disorders	2,072	6.1%
Stroke	758	2.2%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1d. Aggregated Baseline Table for Members Dispensed Prevalent Branded Valsartan Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	195,380	
Number of unique patients	103,430	
Demographics		
Age (years)	71.5	10
Age		
18-44 years	4,031	2.1%
45-64 years	31,246	16.0%
≥ 65 years	160,103	81.9%
Sex		
Female	53,342	51.6%
Male	50,088	48.4%
Race (Unknown)	103,430	100.0%
Year		
2012	15,216	7.8%
2013	18,234	9.3%
2014	21,694	11.1%
2015	19,589	10.0%
2016	16,863	8.6%
2017	21,322	10.9%
2018	28,935	14.8%
2019	26,266	13.4%
2020	27,261	14.0%
Recorded History of:		
Angina	9,788	5.0%
Atrial fibrillation	16,867	8.6%
Diabetes	48,940	25.0%
Heart failure	22,572	11.6%
Hyperlipidemia	9,044	4.6%
Hypertension	90,249	46.2%
Myocardial infarction	3,312	1.7%
Renal disorders	8,641	4.4%
Stroke	3,085	1.6%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1e. Aggregated Baseline Table for Members Dispensed Prevalent Unclassified Valsartan Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	110,275	
Number of unique patients	64,409	
Demographics		
Age (years)	71.3	11.2
Age		
18-44 years	3,107	2.8%
45-64 years	22,987	20.8%
≥ 65 years	84,181	76.3%
Sex		
Female	37,479	58.2%
Male	26,930	41.8%
Race (Unknown)	64,409	100.0%
Year		
2012	12,619	11.4%
2013	17,540	15.9%
2014	16,860	15.3%
2015	13,485	12.2%
2016	11,556	10.5%
2017	11,263	10.2%
2018	13,050	11.8%
2019	10,183	9.2%
2020	3,719	3.4%
Recorded History of:		
Angina	3,636	3.3%
Atrial fibrillation	6,425	5.8%
Diabetes	29,275	26.5%
Heart failure	3,934	3.6%
Hyperlipidemia	5,701	5.2%
Hypertension	55,975	50.8%
Myocardial infarction	1,165	1.1%
Renal disorders	5,238	4.7%
Stroke	2,150	1.9%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1f. Aggregated Baseline Table for Members Dispensed Prevalent Recalled Valsartan Dispensings Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	268,305	
Number of unique patients	144,879	
Demographics		
Age (years)	72	10.9
Age		
18-44 years	6,845	2.6%
45-64 years	44,252	16.5%
≥ 65 years	217,208	81.0%
Sex		
Female	83,675	57.8%
Male	61,204	42.2%
Race (Unknown)	144,879	100.0%
Year		
2012	29,192	10.9%
2013	37,529	14.0%
2014	38,433	14.3%
2015	38,570	14.4%
2016	37,196	13.9%
2017	41,913	15.6%
2018	22,431	8.4%
2019	912	0.3%
2020	22,129	8.2%
Recorded History of:		
Angina	11,472	4.3%
Atrial fibrillation	18,390	6.9%
Diabetes	68,639	25.6%
Heart failure	12,518	4.7%
Hyperlipidemia	13,946	5.2%
Hypertension	131,437	49.0%
Myocardial infarction	3,990	1.5%
Renal disorders	14,278	5.3%
Stroke	6,173	2.3%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 1g. Aggregated Baseline Table for Members Dispensed Prevalent Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan) Between May 1, 2012 and December 31, 2020

Characteristic ¹	Number/Mean	Percent/Standard Deviation ²
Number of episodes	404,043	
Number of unique patients	217,992	
Demographics		
Age (years)	71.8	10.9
Age		
18-44 years	10,250	2.5%
45-64 years	69,075	17.1%
≥ 65 years	324,718	80.4%
Sex		
Female	127,063	58.3%
Male	90,929	41.7%
Race (Unknown)	217,992	100.0%
Year		
2012	67,540	16.7%
2013	59,941	14.8%
2014	61,945	15.3%
2015	49,993	12.4%
2016	48,409	12.0%
2017	52,584	13.0%
2018	35,119	8.7%
2019	5,989	1.5%
2020	22,523	5.6%
Recorded History of:		
Angina	15,136	3.7%
Atrial fibrillation	25,062	6.2%
Diabetes	104,191	25.8%
Heart failure	16,233	4.0%
Hyperlipidemia	20,402	5.0%
Hypertension	194,291	48.1%
Myocardial infarction	4,881	1.2%
Renal disorders	20,522	5.1%
Stroke	8,190	2.0%

¹All metrics are based on total number of episodes per group, except for sex, race, and hispanic origin which are based on total number of unique patients

²Value represents standard deviation where no % follows the value

Table 2a. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, Overall

Level	Prevalent Users	Eligible Members ¹	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member-Years ¹
All Valsartan Dispensings											
	186,453	7,570,902	391,207	183,443,887	502,242.0	4,252,289	4,275,214	167,356,683	184,539,895	15,292,083,095	41,867,441.7
Valsartan with Impurity Dispensings											
	33,199	7,570,902	48,557	14,704,033	40,257.4	363,366	363,928	12,920,302	13,184,208	15,292,083,095	41,867,441.7
Valsartan without Impurity Dispensings											
	24,950	7,570,902	34,214	8,392,545	22,977.5	194,477	194,495	7,154,437	7,649,558	15,292,083,095	41,867,441.7
Branded Valsartan Dispensings											
	103,430	7,570,902	195,380	83,723,486	229,222.4	1,833,335	1,837,811	76,138,267	88,292,976	15,292,083,095	41,867,441.7
Unclassified Valsartan Dispensings											
	64,409	7,570,902	110,275	39,367,697	107,782.9	1,003,498	1,008,629	34,913,260	36,635,036	15,292,083,095	41,867,441.7
Recalled Valsartan Dispensings											
	144,879	7,570,902	268,305	108,141,807	296,076.1	2,577,163	2,597,158	97,010,563	102,634,767	15,292,083,095	41,867,441.7
Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan)											
	217,992	7,570,902	404,043	148,734,142	407,211.9	3,389,177	3,413,795	132,448,426	139,871,992	15,292,083,095	41,867,441.7

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 2b. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Age Group

Age Group	Prevalent Users	Eligible Members ¹	Prevalent Episodes	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ¹	Eligible Member-Years ¹
All Valsartan Dispensings											
18-44 years	5,229	2,338,290	10,959	3,821,609	10,463.0	100,186	100,756	3,273,827	3,551,933	3,398,815,737	9,305,450.3
45-64 years	31,256	1,750,867	67,335	29,712,640	81,348.8	733,568	737,494	26,386,120	28,435,176	2,919,928,922	7,994,329.7
More than 65 years	153,906	4,295,899	312,913	149,909,638	410,430.2	3,418,535	3,436,964	137,696,736	152,552,786	8,973,338,436	24,567,661.7
Valsartan with Impurity Dispensings											
18-44 years	609	2,338,290	951	211,884	580.1	5,541	5,576	172,793	179,147	3,398,815,737	9,305,450.3
45-64 years	5,135	1,750,867	7,694	2,155,616	5,901.8	56,745	56,810	1,843,138	1,887,656	2,919,928,922	7,994,329.7
More than 65 years	27,770	4,295,899	39,912	12,336,533	33,775.6	301,080	301,542	10,904,371	11,117,405	8,973,338,436	24,567,661.7
Valsartan without Impurity Dispensings											
18-44 years	462	2,338,290	684	149,773	410.1	4,084	4,084	120,398	124,867	3,398,815,737	9,305,450.3
45-64 years	3,384	1,750,867	4,818	1,154,193	3,160.0	28,291	28,293	963,282	1,018,586	2,919,928,922	7,994,329.7
More than 65 years	21,281	4,295,899	28,712	7,088,579	19,407.5	162,102	162,118	6,070,757	6,506,104	8,973,338,436	24,567,661.7
Branded Valsartan Dispensings											
18-44 years	2,141	2,338,290	4,031	1,348,730	3,692.6	36,422	36,527	1,156,621	1,349,768	3,398,815,737	9,305,450.3
45-64 years	16,285	1,750,867	31,246	13,140,735	35,977.4	331,148	332,000	11,688,211	13,092,831	2,919,928,922	7,994,329.7
More than 65 years	86,978	4,295,899	160,103	69,234,021	189,552.4	1,465,765	1,469,284	63,293,435	73,850,377	8,973,338,436	24,567,661.7
Unclassified Valsartan Dispensings											
18-44 years	1,783	2,338,290	3,107	965,578	2,643.6	25,261	25,363	814,823	827,578	3,398,815,737	9,305,450.3
45-64 years	13,117	1,750,867	22,987	8,871,505	24,288.9	216,676	217,752	7,805,937	8,016,249	2,919,928,922	7,994,329.7
More than 65 years	50,758	4,295,899	84,181	29,530,614	80,850.4	761,561	765,514	26,292,500	27,791,208	8,973,338,436	24,567,661.7
Recalled Valsartan Dispensings											
18-44 years	3,744	2,338,290	6,845	2,001,072	5,478.6	48,411	48,835	1,677,058	1,758,863	3,398,815,737	9,305,450.3
45-64 years	24,060	1,750,867	44,252	16,893,768	46,252.6	398,109	401,166	14,774,873	15,518,070	2,919,928,922	7,994,329.7
More than 65 years	119,751	4,295,899	217,208	89,246,967	244,344.9	2,130,643	2,147,157	80,558,632	85,357,834	8,973,338,436	24,567,661.7
Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan)											
18-44 years	5,726	2,338,290	10,250	2,747,308	7,521.7	66,974	67,594	2,284,029	2,383,115	3,398,815,737	9,305,450.3
45-64 years	37,674	1,750,867	69,075	23,206,299	63,535.4	544,182	547,686	20,088,766	20,964,358	2,919,928,922	7,994,329.7
More than 65 years	178,996	4,295,899	324,718	122,780,535	336,154.8	2,778,021	2,798,515	110,075,631	116,524,519	8,973,338,436	24,567,661.7

¹Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
All Valsartan Dispensings											
2012											
May	5,561	4,286,649	5,561	4,052,724	11,095.8	92,195	92,434	3,777,457	4,020,147	132,685,099	363,272.0
June	11,265	4,282,255	11,266	4,769,523	13,058.2	99,445	100,171	4,488,502	4,707,945	128,287,490	351,232.0
July	15,757	4,324,763	15,859	3,333,829	9,127.5	78,557	79,236	3,105,385	3,292,190	133,806,182	366,341.4
August	19,293	4,325,498	19,440	2,874,200	7,869.1	69,295	69,731	2,655,916	2,804,153	133,807,594	366,345.2
September	22,338	4,319,919	22,615	2,609,547	7,144.6	60,872	61,221	2,400,082	2,489,780	129,415,342	354,319.9
October	25,326	4,368,295	25,730	3,134,318	8,581.3	73,106	73,846	2,899,845	3,048,951	135,121,612	369,942.8
November	27,903	4,361,839	28,256	2,725,421	7,461.8	63,316	63,692	2,511,621	2,628,557	130,664,483	357,739.9
December	29,898	4,446,008	30,230	2,296,254	6,286.8	54,310	54,584	2,111,123	2,205,652	134,929,967	369,418.1
2013											
January	31,945	4,399,127	32,404	2,624,011	7,184.2	62,802	63,295	2,417,301	2,497,667	136,028,101	372,424.6
February	33,447	4,392,277	33,824	2,260,027	6,187.6	55,295	55,380	2,084,527	2,167,878	122,786,673	336,171.6
March	35,175	4,392,361	35,650	2,463,137	6,743.7	59,305	59,592	2,268,109	2,384,698	135,930,571	372,157.6
April	37,545	4,431,874	38,081	3,303,815	9,045.4	75,445	75,871	3,059,494	3,214,564	132,685,823	363,274.0
May	39,960	4,430,838	40,584	3,292,013	9,013.0	73,435	73,689	3,042,192	3,174,973	137,147,065	375,488.2
June	41,747	4,426,347	42,305	2,725,269	7,461.4	61,517	61,730	2,510,836	2,627,282	132,600,343	363,040.0
July	43,399	4,467,139	43,987	2,755,069	7,543.0	63,530	63,696	2,545,466	2,646,805	138,136,950	378,198.4
August	44,805	4,467,093	45,434	2,513,378	6,881.3	57,645	58,154	2,321,326	2,415,603	138,195,986	378,360.0
September	46,174	4,461,357	46,758	2,457,591	6,728.5	57,951	58,276	2,260,361	2,378,358	133,656,979	365,932.9
October	47,832	4,507,745	48,535	2,952,986	8,084.8	68,235	68,750	2,730,417	2,861,226	139,452,619	381,800.5
November	49,188	4,501,398	49,764	2,393,182	6,552.2	54,063	54,221	2,204,501	2,340,718	134,846,788	369,190.4
December	50,349	4,595,065	50,897	2,205,727	6,039.0	49,786	50,128	2,028,502	2,139,583	139,269,845	381,300.1
2014											
January	51,591	4,531,255	52,191	2,321,759	6,356.6	54,644	54,962	2,131,059	2,216,653	140,156,968	383,728.9
February	52,324	4,525,425	52,879	1,939,797	5,310.9	48,364	48,544	1,771,659	1,846,583	126,514,507	346,377.8
March	53,472	4,524,556	54,154	2,325,260	6,366.2	53,914	54,354	2,132,478	2,238,378	140,036,195	383,398.2
April	54,777	4,551,212	55,493	2,800,334	7,666.9	63,046	63,177	2,580,279	2,711,976	136,259,621	373,058.5
May	56,420	4,549,461	57,240	2,889,548	7,911.2	62,170	62,891	2,662,386	2,790,796	140,812,634	385,524.0
June	57,761	4,543,585	58,493	2,770,502	7,585.2	60,927	61,148	2,547,935	2,675,781	136,112,338	372,655.3
July	58,881	4,567,206	59,584	2,572,826	7,044.0	58,149	58,306	2,367,903	2,473,599	141,244,393	386,706.1
August	59,596	4,566,372	60,265	2,042,144	5,591.1	46,887	46,994	1,872,625	1,930,210	141,287,064	386,822.9
September	60,612	4,560,192	61,319	2,280,908	6,244.8	50,278	50,570	2,089,086	2,190,652	136,611,694	374,022.4

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
October	61,739	4,603,390	62,513	2,491,930	6,822.5	55,726	55,831	2,285,877	2,396,806	142,414,439	389,909.5
November	62,621	4,596,452	63,241	2,133,181	5,840.3	47,652	48,509	1,952,561	2,062,393	137,689,334	376,972.9
December	63,500	4,690,727	64,113	2,030,440	5,559.0	47,433	47,684	1,855,858	1,942,990	142,159,405	389,211.2
2015											
January	64,277	4,630,053	64,965	2,077,785	5,688.7	49,546	49,730	1,899,471	1,969,220	143,195,395	392,047.6
February	64,679	4,622,633	65,254	1,792,403	4,907.3	41,740	41,883	1,632,783	1,703,977	128,891,444	352,885.5
March	65,396	4,608,204	66,118	2,167,318	5,933.8	49,109	49,922	1,979,668	2,076,161	142,621,979	390,477.7
April	66,334	4,649,181	67,153	2,700,157	7,392.6	59,602	59,852	2,476,401	2,556,498	139,200,373	381,109.9
May	67,683	4,646,557	68,498	2,583,953	7,074.5	53,178	53,419	2,366,772	2,466,503	143,820,934	393,760.3
June	68,707	4,639,786	69,439	2,412,277	6,604.5	51,249	51,419	2,207,546	2,281,361	139,000,288	380,562.0
July	69,504	4,670,939	70,284	2,209,945	6,050.5	48,110	48,299	2,019,003	2,107,115	144,470,455	395,538.5
August	70,008	4,668,567	70,740	1,878,232	5,142.3	39,444	39,692	1,715,591	1,808,738	144,458,311	395,505.3
September	70,644	4,661,777	71,400	2,061,866	5,645.1	45,729	45,914	1,875,330	1,964,699	139,666,252	382,385.4
October	71,479	4,702,725	72,257	2,212,404	6,057.2	48,415	48,702	2,015,234	2,103,123	145,490,180	398,330.4
November	72,251	4,694,981	72,944	1,951,829	5,343.8	40,721	40,894	1,775,126	1,891,460	140,653,325	385,087.8
December	73,042	4,787,323	73,641	1,848,204	5,060.1	40,366	40,710	1,680,234	1,751,360	145,235,622	397,633.5
2016											
January	73,663	4,728,935	74,320	1,855,265	5,079.4	41,450	41,691	1,686,917	1,752,652	146,290,949	400,522.8
February	74,107	4,722,828	74,693	1,580,721	4,327.8	33,840	33,955	1,429,393	1,484,076	136,754,625	374,413.8
March	74,641	4,721,494	75,389	1,963,182	5,374.9	42,373	42,543	1,783,442	1,866,882	146,130,012	400,082.2
April	75,449	4,763,745	76,229	2,344,165	6,418.0	47,332	47,623	2,136,010	2,222,290	142,710,057	390,718.8
May	76,651	4,761,475	77,509	2,358,660	6,457.7	48,771	49,017	2,153,253	2,242,889	147,398,347	403,554.7
June	77,586	4,755,765	78,370	2,055,988	5,629.0	40,435	40,781	1,867,601	1,947,840	142,485,590	390,104.3
July	78,155	4,789,659	78,886	1,752,222	4,797.3	35,758	36,024	1,584,288	1,674,307	148,216,944	405,795.9
August	78,784	4,789,879	79,553	1,726,218	4,726.1	35,595	35,769	1,559,265	1,645,885	148,205,722	405,765.2
September	79,282	4,784,732	80,037	1,658,578	4,540.9	34,755	34,948	1,493,102	1,557,092	143,351,972	392,476.3
October	79,998	4,827,419	80,713	1,790,064	4,900.9	37,613	37,779	1,610,365	1,685,143	149,343,093	408,879.1
November	80,787	4,821,453	81,506	1,737,649	4,757.4	38,117	38,281	1,564,975	1,642,199	144,440,669	395,457.0
December	81,406	4,912,147	82,065	1,506,095	4,123.5	32,250	32,307	1,348,592	1,433,495	149,183,801	408,443.0
2017											
January	81,944	4,857,235	82,657	1,535,017	4,202.6	31,797	31,973	1,374,610	1,440,809	150,243,373	411,343.9
February	82,301	4,851,355	82,879	1,347,858	3,690.2	30,047	30,099	1,206,045	1,265,697	135,630,174	371,335.2
March	82,877	4,850,456	83,605	1,518,672	4,157.9	33,437	33,586	1,355,548	1,424,817	150,130,820	411,035.8

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
April	83,616	4,891,603	84,410	1,918,734	5,253.2	40,879	41,046	1,728,041	1,873,082	146,479,438	401,038.8
May	85,747	4,889,744	86,603	2,563,609	7,018.8	68,512	68,964	2,333,283	3,035,503	151,368,694	414,424.9
June	87,708	4,884,153	88,513	2,617,186	7,165.5	76,705	77,036	2,399,289	3,373,246	146,327,856	400,623.8
July	89,017	4,921,396	89,742	1,935,745	5,299.8	42,628	42,789	1,747,461	2,283,257	152,222,185	416,761.6
August	90,079	4,919,731	90,878	1,743,015	4,772.1	39,915	40,023	1,565,633	2,003,928	152,243,262	416,819.3
September	90,808	4,914,080	91,592	1,510,810	4,136.4	35,197	35,360	1,344,236	1,640,458	147,221,895	403,071.6
October	91,685	4,958,838	92,470	1,580,060	4,326.0	36,484	36,691	1,404,989	1,702,127	153,436,332	420,085.8
November	92,729	4,952,573	93,520	1,512,707	4,141.6	34,948	35,198	1,343,570	1,643,024	148,367,041	406,206.8
December	93,481	5,042,973	94,119	1,300,923	3,561.7	29,071	29,149	1,147,075	1,390,975	153,189,411	419,409.7
2018											
January	94,323	4,992,614	95,129	1,352,413	3,702.7	31,743	32,127	1,190,637	1,461,277	154,431,953	422,811.6
February	94,925	4,985,839	95,573	1,141,803	3,126.1	26,691	26,758	1,000,616	1,222,559	139,376,510	381,592.1
March	95,668	4,984,547	96,460	1,274,375	3,489.0	29,420	29,479	1,113,492	1,377,592	154,273,405	422,377.6
April	96,709	5,049,617	97,617	1,382,434	3,784.9	30,502	30,555	1,203,050	1,478,499	151,180,495	413,909.6
May	98,325	5,031,720	99,231	1,362,755	3,731.0	28,262	28,475	1,179,985	1,458,461	155,771,746	426,479.8
June	99,380	5,025,755	100,234	1,253,991	3,433.2	27,966	28,018	1,088,751	1,359,838	150,569,782	412,237.6
July	98,608	5,248,660	99,037	790,896	2,165.4	18,341	18,449	700,088	911,495	161,952,956	443,403.0
August	95,723	5,248,208	96,088	677,972	1,856.2	17,583	17,608	614,456	811,676	162,396,424	444,617.2
September	74,198	5,235,593	74,576	769,439	2,106.6	20,333	20,502	701,357	908,086	156,845,849	429,420.5
October	59,013	5,283,082	59,459	1,025,598	2,807.9	25,337	25,394	935,861	1,212,876	163,464,232	447,540.7
November	46,933	5,278,167	47,272	954,383	2,613.0	25,811	26,128	871,665	1,170,947	158,110,467	432,882.9
December	42,064	5,429,048	42,342	800,782	2,192.4	22,677	22,960	728,304	950,251	163,374,349	447,294.6
2019											
January	41,576	5,316,625	41,921	836,247	2,289.5	21,741	21,916	763,169	1,015,129	164,467,392	450,287.2
February	41,519	5,311,855	41,795	761,857	2,085.9	21,296	21,346	692,792	921,248	148,509,516	406,596.9
March	42,278	5,312,443	42,614	965,938	2,644.6	31,946	32,042	880,635	1,130,658	164,414,377	450,142.0
April	43,038	5,214,113	43,459	1,046,520	2,865.2	29,206	29,406	953,727	1,254,717	156,117,229	427,425.7
May	44,033	5,211,995	44,424	1,039,969	2,847.3	28,346	28,478	949,327	1,254,606	161,342,295	441,731.1
June	44,998	5,205,736	45,350	948,820	2,597.7	25,934	26,069	855,260	1,094,183	155,963,476	427,004.7
July	46,302	5,223,640	46,641	1,014,770	2,778.3	27,529	27,674	921,007	1,185,087	161,568,359	442,350.1
August	47,061	5,221,898	47,441	771,495	2,112.2	21,865	21,906	691,677	915,257	161,611,118	442,467.1
September	48,002	5,215,948	48,390	825,599	2,260.4	24,168	24,285	743,280	992,651	156,283,152	427,880.0
October	49,094	5,254,359	49,483	856,331	2,344.5	25,256	25,336	767,941	1,025,382	162,602,146	445,180.4

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
November	50,145	5,247,916	50,530	744,851	2,039.3	21,072	21,157	668,129	906,624	157,212,130	430,423.4
December	50,997	5,373,067	51,349	667,696	1,828.1	19,527	19,584	594,050	786,022	162,420,105	444,682.0
2020											
January	51,897	5,259,458	52,284	712,910	1,951.8	24,877	24,926	635,354	828,706	162,724,680	445,515.9
February	52,327	5,252,970	52,703	636,382	1,742.3	20,949	21,015	568,806	747,837	152,125,842	416,497.9
March	52,084	5,251,502	52,557	610,243	1,670.8	17,155	17,242	543,109	703,563	162,554,255	445,049.3
April	50,882	5,298,182	51,249	421,446	1,153.9	11,969	12,008	373,811	474,871	158,709,408	434,522.7
May	49,888	5,293,078	50,327	427,625	1,170.8	11,619	11,694	384,575	484,286	163,826,607	448,532.8
June	49,577	5,285,134	50,125	457,303	1,252.0	10,929	10,994	411,199	531,940	158,335,959	433,500.2
July	49,704	5,326,190	50,273	406,248	1,112.2	9,616	9,665	366,025	472,219	164,802,453	451,204.5
August	49,951	5,325,550	50,299	299,949	821.2	8,226	8,262	268,872	357,318	164,812,943	451,233.2
September	50,806	5,320,262	51,072	216,774	593.5	6,662	6,671	195,953	266,242	159,403,596	436,423.3
October	51,766	5,358,929	52,141	179,018	490.1	5,923	5,934	165,385	224,667	165,862,390	454,106.5
November	52,311	5,350,641	52,755	119,066	326.0	4,608	4,618	111,995	152,687	160,309,387	438,903.2
December	52,841	5,470,775	53,125	39,823	109.0	2,791	2,798	39,532	55,003	165,525,188	453,183.3
Valsartan with Impurity Dispensings											
2012											
May	419	4,286,649	419	243,377	666.3	5,675	5,675	223,851	223,675	132,685,099	363,272.0
June	791	4,282,255	791	231,429	633.6	4,989	4,989	212,906	213,612	128,287,490	351,232.0
July	1,209	4,324,763	1,216	198,932	544.6	4,742	4,743	179,514	181,098	133,806,182	366,341.4
August	1,640	4,325,498	1,645	216,186	591.9	4,708	4,709	195,780	199,585	133,807,594	366,345.2
September	2,043	4,319,919	2,053	206,775	566.1	4,512	4,517	187,509	192,950	129,415,342	354,319.9
October	2,472	4,368,295	2,492	233,264	638.6	4,967	4,983	210,142	212,081	135,121,612	369,942.8
November	2,797	4,361,839	2,809	207,793	568.9	5,330	5,468	187,767	191,803	130,664,483	357,739.9
December	3,017	4,446,008	3,038	175,840	481.4	4,465	4,466	158,203	161,940	134,929,967	369,418.1
2013											
January	3,200	4,399,127	3,220	180,734	494.8	3,881	3,892	164,774	165,869	136,028,101	372,424.6
February	3,336	4,392,277	3,353	169,970	465.4	4,612	4,616	153,672	157,078	122,786,673	336,171.6
March	3,498	4,392,361	3,522	170,790	467.6	4,788	4,791	154,757	156,454	135,930,571	372,157.6
April	3,711	4,431,874	3,737	221,749	607.1	5,229	5,232	200,561	205,469	132,685,823	363,274.0
May	4,115	4,430,838	4,149	256,230	701.5	7,195	7,205	228,443	234,307	137,147,065	375,488.2
June	4,435	4,426,347	4,466	246,919	676.0	6,204	6,259	221,801	229,666	132,600,343	363,040.0
July	4,724	4,467,139	4,753	208,799	571.7	4,318	4,321	185,490	188,088	138,136,950	378,198.4

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
August	4,916	4,467,093	4,949	188,329	515.6	4,368	4,369	167,157	169,845	138,195,986	378,360.0
September	5,083	4,461,357	5,120	185,576	508.1	5,243	5,258	165,877	169,737	133,656,979	365,932.9
October	5,268	4,507,745	5,297	182,705	500.2	5,114	5,116	163,522	164,710	139,452,619	381,800.5
November	5,350	4,501,398	5,384	171,793	470.3	4,579	4,599	154,424	156,313	134,846,788	369,190.4
December	5,261	4,595,065	5,283	152,952	418.8	4,561	4,562	138,869	142,630	139,269,845	381,300.1
2014											
January	4,996	4,531,255	5,026	154,603	423.3	3,931	3,931	139,030	139,849	140,156,968	383,728.9
February	4,691	4,525,425	4,713	104,525	286.2	2,508	2,508	93,103	94,804	126,514,507	346,377.8
March	4,396	4,524,556	4,426	155,583	426.0	4,359	4,359	140,820	140,778	140,036,195	383,398.2
April	4,263	4,551,212	4,292	193,487	529.7	4,191	4,191	176,622	179,232	136,259,621	373,058.5
May	4,227	4,549,461	4,252	165,590	453.4	4,178	4,178	151,095	153,395	140,812,634	385,524.0
June	4,200	4,543,585	4,226	133,960	366.8	3,539	3,539	121,067	121,420	136,112,338	372,655.3
July	4,194	4,567,206	4,241	151,150	413.8	3,106	3,116	135,587	135,892	141,244,393	386,706.1
August	4,201	4,566,372	4,229	131,774	360.8	3,300	3,332	118,339	118,792	141,287,064	386,822.9
September	4,252	4,560,192	4,286	137,261	375.8	3,450	3,450	123,342	124,412	136,611,694	374,022.4
October	4,371	4,603,390	4,401	151,865	415.8	3,693	3,703	135,127	139,165	142,414,439	389,909.5
November	4,431	4,596,452	4,453	142,805	391.0	3,739	3,744	129,410	131,493	137,689,334	376,972.9
December	4,564	4,690,727	4,588	167,845	459.5	3,842	3,844	150,302	154,101	142,159,405	389,211.2
2015											
January	4,765	4,630,053	4,799	208,818	571.7	5,693	5,733	186,650	194,984	143,195,395	392,047.6
February	4,875	4,622,633	4,894	158,155	433.0	3,672	3,672	141,120	144,211	128,891,444	352,885.5
March	5,097	4,608,204	5,123	203,948	558.4	4,997	4,997	182,982	184,849	142,621,979	390,477.7
April	5,270	4,649,181	5,318	205,230	561.9	5,235	5,243	184,524	185,514	139,200,373	381,109.9
May	5,432	4,646,557	5,470	164,860	451.4	3,835	3,835	147,013	147,584	143,820,934	393,760.3
June	5,554	4,639,786	5,585	178,190	487.9	3,567	3,567	159,874	162,019	139,000,288	380,562.0
July	5,613	4,670,939	5,646	154,374	422.7	4,002	4,013	138,502	139,528	144,470,455	395,538.5
August	5,597	4,668,567	5,638	130,998	358.7	3,682	3,682	117,567	119,857	144,458,311	395,505.3
September	5,615	4,661,777	5,647	135,663	371.4	3,317	3,320	119,934	120,701	139,666,252	382,385.4
October	5,672	4,702,725	5,707	162,481	444.8	3,812	3,814	145,212	146,634	145,490,180	398,330.4
November	5,739	4,694,981	5,773	136,987	375.0	3,642	3,651	121,655	125,341	140,653,325	385,087.8
December	5,762	4,787,323	5,797	129,856	355.5	3,199	3,200	116,710	118,153	145,235,622	397,633.5
2016											
January	5,771	4,728,935	5,801	116,872	320.0	3,175	3,175	103,168	104,369	146,290,949	400,522.8

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
February	5,742	4,722,828	5,767	96,876	265.2	2,412	2,412	85,177	86,533	136,754,625	374,413.8
March	5,769	4,721,494	5,811	146,645	401.5	3,718	3,756	130,959	131,998	146,130,012	400,082.2
April	5,716	4,763,745	5,744	145,863	399.4	3,455	3,455	131,067	131,502	142,710,057	390,718.8
May	5,680	4,761,475	5,726	135,347	370.6	3,039	3,043	120,583	122,491	147,398,347	403,554.7
June	5,699	4,755,765	5,744	137,606	376.7	3,262	3,262	121,760	125,158	142,485,590	390,104.3
July	5,735	4,789,659	5,775	137,492	376.4	3,031	3,032	122,147	125,629	148,216,944	405,795.9
August	5,758	4,789,879	5,786	118,318	323.9	2,811	2,812	104,636	109,612	148,205,722	405,765.2
September	5,737	4,784,732	5,769	112,480	308.0	2,882	2,882	99,924	103,085	143,351,972	392,476.3
October	5,739	4,827,419	5,762	121,635	333.0	3,201	3,216	108,696	111,387	149,343,093	408,879.1
November	5,785	4,821,453	5,819	144,586	395.9	3,630	3,639	128,648	132,564	144,440,669	395,457.0
December	5,778	4,912,147	5,806	118,717	325.0	2,997	3,002	105,635	107,819	149,183,801	408,443.0
2017											
January	5,779	4,857,235	5,808	121,020	331.3	3,576	3,576	107,294	111,047	150,243,373	411,343.9
February	5,761	4,851,355	5,775	103,382	283.0	1,844	1,844	91,038	93,503	135,630,174	371,335.2
March	5,797	4,850,456	5,827	110,962	303.8	3,129	3,132	96,918	102,911	150,130,820	411,035.8
April	5,826	4,891,603	5,856	125,331	343.1	2,684	2,684	109,580	112,797	146,479,438	401,038.8
May	5,871	4,889,744	5,904	133,465	365.4	3,021	3,021	117,581	119,458	151,368,694	414,424.9
June	5,943	4,884,153	5,983	121,370	332.3	2,616	2,616	106,128	107,060	146,327,856	400,623.8
July	5,974	4,921,396	6,005	94,844	259.7	1,908	1,909	82,212	84,716	152,222,185	416,761.6
August	6,065	4,919,731	6,096	100,035	273.9	2,593	2,593	84,967	86,918	152,243,262	416,819.3
September	6,145	4,914,080	6,182	106,203	290.8	2,880	2,880	90,623	93,152	147,221,895	403,071.6
October	6,226	4,958,838	6,256	89,851	246.0	2,769	2,769	76,371	77,400	153,436,332	420,085.8
November	6,314	4,952,573	6,336	89,555	245.2	1,957	1,957	75,827	77,467	148,367,041	406,206.8
December	6,323	5,042,973	6,351	69,892	191.4	1,453	1,453	58,476	62,672	153,189,411	419,409.7
2018											
January	6,316	4,992,614	6,353	64,250	175.9	1,516	1,516	52,775	53,378	154,431,953	422,811.6
February	6,287	4,985,839	6,316	64,129	175.6	1,717	1,717	52,944	54,036	139,376,510	381,592.1
March	6,327	4,984,547	6,366	71,890	196.8	1,568	1,568	57,970	59,210	154,273,405	422,377.6
April	6,419	5,049,617	6,456	70,692	193.5	1,354	1,354	55,372	56,761	151,180,495	413,909.6
May	6,630	5,031,720	6,666	79,704	218.2	1,285	1,286	62,084	63,835	155,771,746	426,479.8
June	6,925	5,025,755	6,960	79,432	217.5	1,373	1,373	59,266	61,274	150,569,782	412,237.6
July	8,073	5,248,660	8,084	292,040	799.6	8,122	8,122	241,790	265,266	161,952,956	443,403.0
August	8,668	5,248,208	8,680	326,610	894.2	6,522	6,550	289,547	308,238	162,396,424	444,617.2

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
September	6,888	5,235,593	6,899	244,185	668.5	3,887	3,889	216,764	228,183	156,845,849	429,420.5
October	5,618	5,283,082	5,634	191,437	524.1	4,014	4,016	169,647	182,661	163,464,232	447,540.7
November	4,379	5,278,167	4,389	79,374	217.3	1,966	1,967	69,128	75,418	158,110,467	432,882.9
December	3,608	5,429,048	3,624	62,864	172.1	1,453	1,453	55,244	58,070	163,374,349	447,294.6
2019											
January	3,450	5,316,625	3,480	95,831	262.4	2,460	2,461	84,577	89,913	164,467,392	450,287.2
February	3,369	5,311,855	3,380	99,736	273.1	2,475	2,477	87,847	93,167	148,509,516	406,596.9
March	3,564	5,312,443	3,585	126,293	345.8	3,408	3,410	109,736	113,246	164,414,377	450,142.0
April	4,020	5,214,113	4,039	192,002	525.7	4,635	4,636	166,318	179,353	156,117,229	427,425.7
May	4,651	5,211,995	4,670	195,756	536.0	4,995	4,999	166,828	179,466	161,342,295	441,731.1
June	5,256	5,205,736	5,273	180,355	493.8	4,378	4,379	149,572	161,846	155,963,476	427,004.7
July	6,141	5,223,640	6,174	230,668	631.5	5,539	5,543	191,958	203,098	161,568,359	442,350.1
August	6,854	5,221,898	6,892	188,190	515.2	4,724	4,727	153,910	159,513	161,611,118	442,467.1
September	7,417	5,215,948	7,452	149,297	408.8	3,532	3,532	121,053	125,533	156,283,152	427,880.0
October	7,749	5,254,359	7,781	121,195	331.8	2,633	2,635	97,742	98,713	162,602,146	445,180.4
November	7,821	5,247,916	7,860	107,588	294.6	2,718	2,719	87,123	93,297	157,212,130	430,423.4
December	7,724	5,373,067	7,749	120,738	330.6	3,434	3,436	94,730	96,985	162,420,105	444,682.0
2020											
January	7,775	5,259,458	7,829	185,304	507.3	7,813	7,814	147,567	128,698	162,724,680	445,515.9
February	7,477	5,252,970	7,510	132,251	362.1	5,404	5,404	105,404	82,545	152,125,842	416,497.9
March	7,191	5,251,502	7,227	93,605	256.3	2,675	2,676	71,656	56,056	162,554,255	445,049.3
April	6,346	5,298,182	6,383	51,856	142.0	1,946	1,949	39,193	32,109	158,709,408	434,522.7
May	5,333	5,293,078	5,367	34,518	94.5	1,026	1,026	27,277	24,466	163,826,607	448,532.8
June	4,282	5,285,134	4,322	33,844	92.7	906	906	28,631	26,835	158,335,959	433,500.2
July	3,507	5,326,190	3,546	48,704	133.3	1,353	1,353	43,134	41,558	164,802,453	451,204.5
August	2,945	5,325,550	2,961	31,274	85.6	891	891	27,632	26,420	164,812,943	451,233.2
September	2,809	5,320,262	2,816	23,569	64.5	737	737	21,207	20,310	159,403,596	436,423.3
October	2,784	5,358,929	2,797	16,301	44.6	472	472	15,133	14,585	165,862,390	454,106.5
November	2,668	5,350,641	2,688	7,621	20.9	261	261	7,167	6,949	160,309,387	438,903.2
December	2,565	5,470,775	2,575	2,433	6.7	162	162	2,355	2,353	165,525,188	453,183.3
Valsartan without Impurity Dispensings											
2012											
May	476	4,286,649	476	168,666	461.8	3,704	3,704	148,745	158,311	132,685,099	363,272.0

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
June	860	4,282,255	860	141,026	386.1	2,284	2,284	125,992	135,769	128,287,490	351,232.0
July	1,224	4,324,763	1,229	138,959	380.4	2,909	2,909	122,929	127,337	133,806,182	366,341.4
August	1,468	4,325,498	1,472	118,011	323.1	2,396	2,396	104,799	109,845	133,807,594	366,345.2
September	1,667	4,319,919	1,687	118,744	325.1	2,390	2,390	106,602	111,447	129,415,342	354,319.9
October	1,778	4,368,295	1,793	110,119	301.5	2,087	2,087	97,676	103,245	135,121,612	369,942.8
November	1,924	4,361,839	1,940	125,128	342.6	2,480	2,480	111,567	123,349	130,664,483	357,739.9
December	2,032	4,446,008	2,038	87,728	240.2	2,326	2,326	77,894	81,148	134,929,967	369,418.1
2013											
January	2,045	4,399,127	2,064	78,608	215.2	1,567	1,567	69,307	73,141	136,028,101	372,424.6
February	2,057	4,392,277	2,067	82,284	225.3	2,057	2,057	72,911	77,174	122,786,673	336,171.6
March	2,095	4,392,361	2,115	87,646	240.0	1,719	1,719	78,042	80,253	135,930,571	372,157.6
April	2,146	4,431,874	2,167	88,810	243.1	1,988	1,988	78,641	81,890	132,685,823	363,274.0
May	2,197	4,430,838	2,216	93,215	255.2	1,810	1,810	82,611	87,434	137,147,065	375,488.2
June	2,224	4,426,347	2,241	75,853	207.7	1,574	1,574	67,443	71,332	132,600,343	363,040.0
July	2,272	4,467,139	2,300	104,500	286.1	2,302	2,302	92,622	98,923	138,136,950	378,198.4
August	2,282	4,467,093	2,307	88,215	241.5	2,008	2,008	78,619	84,829	138,195,986	378,360.0
September	2,339	4,461,357	2,366	90,667	248.2	2,007	2,007	80,497	84,823	133,656,979	365,932.9
October	2,384	4,507,745	2,406	90,630	248.1	2,162	2,163	81,073	87,022	139,452,619	381,800.5
November	2,438	4,501,398	2,454	67,249	184.1	1,189	1,189	58,622	62,082	134,846,788	369,190.4
December	2,424	4,595,065	2,451	68,958	188.8	1,395	1,395	60,559	63,366	139,269,845	381,300.1
2014											
January	2,444	4,531,255	2,454	84,093	230.2	1,816	1,816	74,970	79,513	140,156,968	383,728.9
February	2,452	4,525,425	2,468	78,208	214.1	1,653	1,653	69,790	73,733	126,514,507	346,377.8
March	2,534	4,524,556	2,557	98,853	270.6	2,646	2,646	86,721	93,416	140,036,195	383,398.2
April	2,658	4,551,212	2,687	104,384	285.8	2,186	2,186	91,574	98,802	136,259,621	373,058.5
May	2,835	4,549,461	2,853	105,449	288.7	1,811	1,811	91,463	97,197	140,812,634	385,524.0
June	2,874	4,543,585	2,903	81,725	223.8	1,616	1,616	71,707	75,325	136,112,338	372,655.3
July	2,898	4,567,206	2,922	84,704	231.9	1,685	1,687	74,839	77,827	141,244,393	386,706.1
August	2,850	4,566,372	2,871	61,428	168.2	1,288	1,288	53,986	55,190	141,287,064	386,822.9
September	2,743	4,560,192	2,769	69,557	190.4	1,390	1,390	60,718	62,586	136,611,694	374,022.4
October	2,739	4,603,390	2,762	88,328	241.8	1,891	1,891	77,743	80,952	142,414,439	389,909.5
November	2,725	4,596,452	2,751	66,388	181.8	1,640	1,640	57,488	61,333	137,689,334	376,972.9
December	2,737	4,690,727	2,751	66,363	181.7	1,129	1,129	58,060	62,928	142,159,405	389,211.2

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2015											
January	2,751	4,630,053	2,769	70,774	193.8	1,521	1,521	61,880	64,878	143,195,395	392,047.6
February	2,734	4,622,633	2,753	53,956	147.7	1,426	1,426	47,183	49,985	128,891,444	352,885.5
March	2,740	4,608,204	2,758	68,761	188.3	1,570	1,570	60,451	62,836	142,621,979	390,477.7
April	2,743	4,649,181	2,758	74,391	203.7	1,859	1,859	65,088	70,735	139,200,373	381,109.9
May	2,774	4,646,557	2,797	70,509	193.0	1,741	1,741	61,217	64,594	143,820,934	393,760.3
June	2,769	4,639,786	2,793	77,880	213.2	1,851	1,851	68,861	70,334	139,000,288	380,562.0
July	2,776	4,670,939	2,789	57,239	156.7	1,056	1,056	49,840	51,623	144,470,455	395,538.5
August	2,735	4,668,567	2,752	67,240	184.1	1,332	1,332	60,165	64,573	144,458,311	395,505.3
September	2,735	4,661,777	2,764	72,313	198.0	1,610	1,610	63,511	65,941	139,666,252	382,385.4
October	2,774	4,702,725	2,797	73,440	201.1	1,441	1,441	63,789	67,329	145,490,180	398,330.4
November	2,813	4,694,981	2,833	61,996	169.7	1,342	1,342	54,120	57,520	140,653,325	385,087.8
December	2,812	4,787,323	2,845	62,469	171.0	1,193	1,193	53,968	56,437	145,235,622	397,633.5
2016											
January	2,777	4,728,935	2,801	64,507	176.6	1,540	1,540	55,778	58,836	146,290,949	400,522.8
February	2,838	4,722,828	2,847	58,691	160.7	1,212	1,212	50,309	53,641	136,754,625	374,413.8
March	2,877	4,721,494	2,895	65,698	179.9	1,325	1,325	57,166	62,776	146,130,012	400,082.2
April	2,903	4,763,745	2,917	59,944	164.1	1,222	1,222	51,358	54,183	142,710,057	390,718.8
May	2,921	4,761,475	2,946	64,688	177.1	1,438	1,438	56,675	60,172	147,398,347	403,554.7
June	2,940	4,755,765	2,959	58,242	159.5	1,470	1,470	49,502	50,791	142,485,590	390,104.3
July	2,925	4,789,659	2,945	49,403	135.3	952	952	42,225	43,475	148,216,944	405,795.9
August	2,947	4,789,879	2,962	54,856	150.2	1,173	1,173	47,134	50,532	148,205,722	405,765.2
September	2,922	4,784,732	2,941	42,369	116.0	971	971	36,187	38,615	143,351,972	392,476.3
October	2,926	4,827,419	2,944	40,410	110.6	869	869	34,014	35,609	149,343,093	408,879.1
November	2,938	4,821,453	2,956	40,289	110.3	811	811	33,405	35,517	144,440,669	395,457.0
December	2,935	4,912,147	2,943	37,415	102.4	1,125	1,125	32,142	33,342	149,183,801	408,443.0
2017											
January	2,871	4,857,235	2,889	31,120	85.2	577	577	26,079	26,419	150,243,373	411,343.9
February	2,687	4,851,355	2,694	23,860	65.3	761	761	20,761	19,937	135,630,174	371,335.2
March	2,437	4,850,456	2,443	29,422	80.6	947	947	25,108	25,449	150,130,820	411,035.8
April	2,044	4,891,603	2,048	34,160	93.5	809	809	29,703	31,044	146,479,438	401,038.8
May	1,747	4,889,744	1,758	33,027	90.4	961	961	28,136	27,882	151,368,694	414,424.9
June	1,545	4,884,153	1,550	20,267	55.5	620	620	17,133	17,638	146,327,856	400,623.8

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
July	1,459	4,921,396	1,467	19,407	53.1	516	516	16,450	17,222	152,222,185	416,761.6
August	1,455	4,919,731	1,460	34,248	93.8	922	923	28,999	30,740	152,243,262	416,819.3
September	1,468	4,914,080	1,482	31,394	86.0	842	842	26,124	26,568	147,221,895	403,071.6
October	1,487	4,958,838	1,495	36,296	99.4	798	798	31,171	33,307	153,436,332	420,085.8
November	1,513	4,952,573	1,520	35,133	96.2	661	661	29,595	31,527	148,367,041	406,206.8
December	1,499	5,042,973	1,504	26,279	71.9	405	405	22,198	24,209	153,189,411	419,409.7
2018											
January	1,488	4,992,614	1,492	25,485	69.8	712	712	21,284	22,630	154,431,953	422,811.6
February	1,494	4,985,839	1,501	25,859	70.8	772	772	21,359	21,682	139,376,510	381,592.1
March	1,566	4,984,547	1,573	31,048	85.0	787	787	25,836	26,169	154,273,405	422,377.6
April	1,618	5,049,617	1,627	25,783	70.6	638	638	20,838	21,801	151,180,495	413,909.6
May	1,706	5,031,720	1,717	39,565	108.3	989	989	32,663	32,686	155,771,746	426,479.8
June	1,793	5,025,755	1,804	39,889	109.2	592	592	31,710	34,045	150,569,782	412,237.6
July	3,090	5,248,660	3,095	275,955	755.5	8,592	8,592	226,308	241,460	161,952,956	443,403.0
August	4,406	5,248,208	4,409	410,984	1,125.2	9,684	9,685	358,006	389,374	162,396,424	444,617.2
September	4,978	5,235,593	4,995	298,011	815.9	5,420	5,420	260,484	284,547	156,845,849	429,420.5
October	5,270	5,283,082	5,275	240,209	657.7	4,626	4,626	208,541	225,510	163,464,232	447,540.7
November	5,283	5,278,167	5,299	132,664	363.2	3,468	3,469	113,207	126,352	158,110,467	432,882.9
December	5,139	5,429,048	5,160	112,202	307.2	2,578	2,578	93,286	102,205	163,374,349	447,294.6
2019											
January	5,046	5,316,625	5,077	111,598	305.5	2,646	2,649	93,173	101,527	164,467,392	450,287.2
February	4,952	5,311,855	4,979	98,984	271.0	2,849	2,849	82,100	88,978	148,509,516	406,596.9
March	5,074	5,312,443	5,096	108,235	296.3	3,062	3,069	88,418	90,922	164,414,377	450,142.0
April	5,308	5,214,113	5,337	152,786	418.3	3,613	3,614	127,401	133,612	156,117,229	427,425.7
May	5,487	5,211,995	5,510	140,604	385.0	3,990	3,990	118,741	121,860	161,342,295	441,731.1
June	5,586	5,205,736	5,608	141,961	388.7	3,906	3,906	117,430	124,412	155,963,476	427,004.7
July	6,058	5,223,640	6,081	208,297	570.3	7,023	7,023	171,408	179,922	161,568,359	442,350.1
August	6,666	5,221,898	6,691	196,600	538.3	4,812	4,812	157,382	170,906	161,611,118	442,467.1
September	7,362	5,215,948	7,393	191,036	523.0	5,886	5,886	149,582	162,826	156,283,152	427,880.0
October	8,351	5,254,359	8,386	198,644	543.9	4,493	4,494	150,886	174,985	162,602,146	445,180.4
November	8,909	5,247,916	8,944	129,757	355.3	2,588	2,588	94,527	115,294	157,212,130	430,423.4
December	9,017	5,373,067	9,041	80,302	219.9	1,853	1,853	57,164	68,369	162,420,105	444,682.0
2020											

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
January	8,580	5,259,458	8,614	62,563	171.3	1,814	1,814	43,619	53,627	162,724,680	445,515.9
February	7,183	5,252,970	7,200	35,554	97.3	1,169	1,169	24,413	29,743	152,125,842	416,497.9
March	5,390	5,251,502	5,401	22,391	61.3	652	652	15,394	17,792	162,554,255	445,049.3
April	3,475	5,298,182	3,488	10,623	29.1	284	284	6,230	8,610	158,709,408	434,522.7
May	2,187	5,293,078	2,194	7,654	21.0	260	260	4,942	5,221	163,826,607	448,532.8
June	1,346	5,285,134	1,347	8,875	24.3	203	203	6,123	6,264	158,335,959	433,500.2
July	774	5,326,190	777	3,702	10.1	128	128	2,655	3,029	164,802,453	451,204.5
August	460	5,325,550	461	4,105	11.2	134	134	2,905	2,764	164,812,943	451,233.2
September	349	5,320,262	351	1,826	5.0	174	174	1,156	1,107	159,403,596	436,423.3
October	291	5,358,929	291	1,435	3.9	67	67	1,007	1,074	165,862,390	454,106.5
November	205	5,350,641	205	448	1.2	16	16	318	259	160,309,387	438,903.2
December	169	5,470,775	169	322	0.9	23	23	306	257	165,525,188	453,183.3
Branded Valsartan Dispensings											
2012											
May	2,101	4,286,649	2,101	1,290,341	3,532.8	26,817	26,841	1,186,294	1,239,712	132,685,099	363,272.0
June	4,569	4,282,255	4,569	1,686,339	4,616.9	29,583	29,594	1,556,712	1,595,581	128,287,490	351,232.0
July	6,715	4,324,763	6,752	1,491,569	4,083.7	28,278	28,508	1,375,532	1,425,570	133,806,182	366,341.4
August	8,317	4,325,498	8,364	1,209,020	3,310.1	23,289	23,290	1,116,863	1,141,827	133,807,594	366,345.2
September	9,557	4,319,919	9,651	962,171	2,634.3	18,093	18,132	880,607	900,164	129,415,342	354,319.9
October	10,670	4,368,295	10,806	1,048,485	2,870.6	19,759	19,761	957,332	989,319	135,121,612	369,942.8
November	11,609	4,361,839	11,737	959,860	2,628.0	17,513	17,531	877,667	908,587	130,664,483	357,739.9
December	12,405	4,446,008	12,526	917,054	2,510.8	17,177	17,188	839,369	863,352	134,929,967	369,418.1
2013											
January	13,153	4,399,127	13,308	948,894	2,597.9	17,290	17,323	866,675	880,967	136,028,101	372,424.6
February	13,629	4,392,277	13,770	888,861	2,433.6	17,042	17,048	814,783	837,085	122,786,673	336,171.6
March	14,240	4,392,361	14,396	927,330	2,538.9	18,603	18,604	850,665	877,935	135,930,571	372,157.6
April	14,980	4,431,874	15,148	1,084,347	2,968.8	22,126	22,200	997,933	1,025,795	132,685,823	363,274.0
May	15,805	4,430,838	16,003	1,104,123	3,022.9	20,699	20,705	1,013,116	1,045,803	137,147,065	375,488.2
June	16,318	4,426,347	16,509	899,360	2,462.3	15,387	15,391	823,935	842,779	132,600,343	363,040.0
July	16,829	4,467,139	17,017	948,362	2,596.5	17,286	17,290	871,702	894,811	138,136,950	378,198.4
August	17,229	4,467,093	17,425	795,910	2,179.1	13,942	14,102	726,053	740,839	138,195,986	378,360.0
September	17,518	4,461,357	17,692	772,493	2,115.0	15,368	15,400	706,471	727,386	133,656,979	365,932.9
October	17,949	4,507,745	18,174	904,507	2,476.4	18,113	18,180	828,191	861,889	139,452,619	381,800.5

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
November	18,292	4,501,398	18,477	784,577	2,148.1	14,442	14,444	718,136	730,062	134,846,788	369,190.4
December	18,671	4,595,065	18,848	776,543	2,126.1	14,807	14,810	711,420	737,658	139,269,845	381,300.1
2014											
January	19,169	4,531,255	19,368	914,952	2,505.0	17,245	17,246	838,478	855,759	140,156,968	383,728.9
February	19,440	4,525,425	19,622	729,815	1,998.1	14,148	14,153	669,326	688,338	126,514,507	346,377.8
March	19,799	4,524,556	20,009	770,156	2,108.6	15,056	15,059	705,061	729,486	140,036,195	383,398.2
April	20,194	4,551,212	20,432	968,506	2,651.6	21,353	21,374	886,259	911,669	136,259,621	373,058.5
May	20,579	4,549,461	20,841	1,004,555	2,750.3	18,235	18,250	922,735	940,426	140,812,634	385,524.0
June	20,936	4,543,585	21,165	1,061,669	2,906.7	19,587	19,591	969,610	991,430	136,112,338	372,655.3
July	21,431	4,567,206	21,625	1,066,667	2,920.4	21,081	21,089	979,371	1,005,789	141,244,393	386,706.1
August	21,685	4,566,372	21,877	839,276	2,297.8	17,633	17,637	768,658	788,131	141,287,064	386,822.9
September	22,046	4,560,192	22,276	894,956	2,450.3	16,210	16,217	819,474	842,054	136,611,694	374,022.4
October	22,829	4,603,390	23,073	1,141,724	3,125.9	21,816	21,829	1,043,198	1,077,690	142,414,439	389,909.5
November	24,170	4,596,452	24,374	1,336,178	3,658.3	26,906	26,929	1,218,645	1,249,035	137,689,334	376,972.9
December	25,974	4,690,727	26,171	1,460,479	3,998.6	29,077	29,100	1,329,692	1,358,492	142,159,405	389,211.2
2015											
January	27,136	4,630,053	27,350	1,249,628	3,421.3	25,173	25,196	1,139,391	1,170,410	143,195,395	392,047.6
February	27,698	4,622,633	27,896	916,102	2,508.2	16,807	16,813	840,832	863,726	128,891,444	352,885.5
March	27,989	4,608,204	28,249	833,764	2,282.7	15,761	15,765	758,087	777,433	142,621,979	390,477.7
April	28,061	4,649,181	28,372	1,046,238	2,864.4	18,486	18,494	957,986	973,248	139,200,373	381,109.9
May	28,212	4,646,557	28,511	1,005,145	2,751.9	17,699	17,700	915,985	940,195	143,820,934	393,760.3
June	28,241	4,639,786	28,492	877,333	2,402.0	16,751	16,753	800,178	814,029	139,000,288	380,562.0
July	28,152	4,670,939	28,430	833,530	2,282.1	14,810	14,834	760,034	781,737	144,470,455	395,538.5
August	27,656	4,668,567	27,916	652,350	1,786.0	11,711	11,719	592,304	615,794	144,458,311	395,505.3
September	27,365	4,661,777	27,609	691,673	1,893.7	13,443	13,475	627,494	645,205	139,666,252	382,385.4
October	27,329	4,702,725	27,578	834,645	2,285.1	16,176	16,178	761,100	782,452	145,490,180	398,330.4
November	27,310	4,694,981	27,527	714,176	1,955.3	12,696	12,696	649,362	668,331	140,653,325	385,087.8
December	27,285	4,787,323	27,471	663,844	1,817.5	12,846	12,927	605,874	620,554	145,235,622	397,633.5
2016											
January	27,234	4,728,935	27,416	658,541	1,803.0	12,218	12,219	600,554	607,977	146,290,949	400,522.8
February	27,191	4,722,828	27,389	617,487	1,690.6	11,535	11,546	560,827	576,301	136,754,625	374,413.8
March	27,254	4,721,494	27,505	721,085	1,974.2	14,954	14,960	656,299	672,904	146,130,012	400,082.2
April	27,444	4,763,745	27,688	892,713	2,444.1	15,975	16,000	815,364	840,423	142,710,057	390,718.8

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
May	27,752	4,761,475	27,999	860,891	2,357.0	15,432	15,437	784,616	813,402	147,398,347	403,554.7
June	27,914	4,755,765	28,163	777,378	2,128.3	13,716	13,730	707,288	736,728	142,485,590	390,104.3
July	27,980	4,789,659	28,223	630,075	1,725.1	11,503	11,519	572,577	590,361	148,216,944	405,795.9
August	28,063	4,789,879	28,280	624,550	1,709.9	11,086	11,091	566,616	596,085	148,205,722	405,765.2
September	28,103	4,784,732	28,370	651,072	1,782.5	13,659	13,669	591,925	613,714	143,351,972	392,476.3
October	28,258	4,827,419	28,503	678,377	1,857.3	12,881	12,890	612,846	638,040	149,343,093	408,879.1
November	28,473	4,821,453	28,693	675,263	1,848.8	13,330	13,346	612,328	638,339	144,440,669	395,457.0
December	28,615	4,912,147	28,826	597,215	1,635.1	11,183	11,259	539,619	571,946	149,183,801	408,443.0
2017											
January	28,720	4,857,235	28,950	609,733	1,669.4	11,882	11,887	551,899	571,406	150,243,373	411,343.9
February	28,747	4,851,355	28,911	519,392	1,422.0	9,572	9,572	470,572	487,578	135,630,174	371,335.2
March	28,863	4,850,456	29,104	647,484	1,772.7	13,032	13,032	585,680	626,562	150,130,820	411,035.8
April	28,759	4,891,603	29,004	771,352	2,111.8	17,066	17,086	702,845	786,259	146,479,438	401,038.8
May	29,476	4,889,744	29,741	1,381,749	3,783.0	44,766	45,049	1,281,024	1,956,821	151,368,694	414,424.9
June	30,410	4,884,153	30,641	1,606,146	4,397.4	55,552	55,730	1,503,667	2,460,746	146,327,856	400,623.8
July	30,873	4,921,396	31,086	1,037,769	2,841.3	24,733	24,800	960,432	1,469,117	152,222,185	416,761.6
August	31,359	4,919,731	31,612	947,751	2,594.8	23,453	23,486	876,012	1,284,218	152,243,262	416,819.3
September	31,701	4,914,080	31,951	765,132	2,094.8	20,784	20,825	700,183	973,407	147,221,895	403,071.6
October	31,982	4,958,838	32,237	823,712	2,255.2	21,171	21,306	752,058	1,033,181	153,436,332	420,085.8
November	32,383	4,952,573	32,608	842,334	2,306.2	22,230	22,370	772,093	1,052,521	148,367,041	406,206.8
December	32,622	5,042,973	32,823	767,596	2,101.6	18,668	18,697	700,599	921,910	153,189,411	419,409.7
2018											
January	32,981	4,992,614	33,231	824,183	2,256.5	21,145	21,218	751,854	1,002,306	154,431,953	422,811.6
February	33,251	4,985,839	33,470	703,656	1,926.5	18,658	18,678	641,405	844,439	139,376,510	381,592.1
March	33,844	4,984,547	34,106	821,661	2,249.6	21,168	21,198	748,683	998,791	154,273,405	422,377.6
April	34,619	5,049,617	34,914	964,955	2,641.9	23,612	23,650	879,530	1,146,100	151,180,495	413,909.6
May	35,593	5,031,720	35,879	994,046	2,721.5	21,621	21,776	903,811	1,176,502	155,771,746	426,479.8
June	36,273	5,025,755	36,560	989,217	2,708.3	24,637	24,686	907,266	1,165,721	150,569,782	412,237.6
July	40,822	5,248,660	41,082	1,419,021	3,885.1	36,203	36,409	1,219,548	1,466,301	161,952,956	443,403.0
August	41,724	5,248,208	41,946	859,370	2,352.8	21,696	21,777	772,332	985,721	162,396,424	444,617.2
September	39,331	5,235,593	39,565	661,538	1,811.2	16,862	16,905	600,099	800,926	156,845,849	429,420.5
October	37,025	5,283,082	37,324	794,861	2,176.2	19,800	19,840	716,859	972,104	163,464,232	447,540.7
November	35,594	5,278,167	35,839	733,987	2,009.5	19,403	19,613	665,235	938,931	158,110,467	432,882.9

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
December	34,103	5,429,048	34,295	553,401	1,515.1	14,791	14,889	501,479	714,666	163,374,349	447,294.6
2019											
January	33,551	5,316,625	33,788	557,976	1,527.7	14,740	14,864	506,873	736,160	164,467,392	450,287.2
February	33,082	5,311,855	33,274	489,899	1,341.3	13,658	13,694	444,737	656,658	148,509,516	406,596.9
March	32,970	5,312,443	33,194	563,496	1,542.8	16,152	16,175	511,522	753,082	164,414,377	450,142.0
April	33,010	5,214,113	33,288	684,965	1,875.3	19,234	19,385	625,101	911,825	156,117,229	427,425.7
May	33,251	5,211,995	33,522	710,641	1,945.6	19,907	20,006	648,017	941,227	161,342,295	441,731.1
June	33,415	5,205,736	33,632	605,001	1,656.4	16,325	16,351	547,843	777,420	155,963,476	427,004.7
July	33,787	5,223,640	34,014	640,257	1,752.9	17,368	17,470	584,619	832,584	161,568,359	442,350.1
August	34,039	5,221,898	34,280	534,774	1,464.1	14,974	14,996	484,982	703,628	161,611,118	442,467.1
September	34,574	5,215,948	34,814	594,417	1,627.4	16,209	16,302	534,959	778,900	156,283,152	427,880.0
October	35,819	5,254,359	36,071	732,124	2,004.4	20,866	20,941	650,226	915,986	162,602,146	445,180.4
November	37,836	5,247,916	38,090	749,962	2,053.3	19,995	20,053	652,862	899,282	157,212,130	430,423.4
December	40,443	5,373,067	40,671	764,221	2,092.3	20,279	20,353	645,861	843,535	162,420,105	444,682.0
2020											
January	42,545	5,259,458	42,805	676,920	1,853.3	19,390	19,439	573,931	770,192	162,724,680	445,515.9
February	43,133	5,252,970	43,374	451,460	1,236.0	13,952	14,015	395,219	571,186	152,125,842	416,497.9
March	42,934	5,251,502	43,306	446,167	1,221.5	12,936	12,999	390,260	543,232	162,554,255	445,049.3
April	41,851	5,298,182	42,218	433,771	1,187.6	12,643	12,673	360,836	467,190	158,709,408	434,522.7
May	42,284	5,293,078	42,635	495,115	1,355.6	12,781	12,821	400,959	507,802	163,826,607	448,532.8
June	42,886	5,285,134	43,285	413,314	1,131.6	9,484	9,529	348,791	466,660	158,335,959	433,500.2
July	42,643	5,326,190	43,026	273,475	748.7	6,623	6,662	243,627	341,377	164,802,453	451,204.5
August	40,592	5,325,550	40,829	201,457	551.6	5,737	5,761	178,685	263,129	164,812,943	451,233.2
September	39,376	5,320,262	39,545	146,171	400.2	4,554	4,560	131,583	197,896	159,403,596	436,423.3
October	39,124	5,358,929	39,361	117,280	321.1	3,984	3,994	108,631	164,593	165,862,390	454,106.5
November	38,319	5,350,641	38,611	80,227	219.6	3,232	3,236	75,570	115,490	160,309,387	438,903.2
December	38,223	5,470,775	38,417	28,196	77.2	2,015	2,021	27,959	42,952	165,525,188	453,183.3
Unclassified Valsartan Dispensings											
2012											
May	1,644	4,286,649	1,644	652,154	1,785.5	16,659	16,773	584,270	619,137	132,685,099	363,272.0
June	3,158	4,282,255	3,158	649,130	1,777.2	14,478	14,522	585,249	627,476	128,287,490	351,232.0
July	4,423	4,324,763	4,434	547,628	1,499.3	13,013	13,173	492,936	537,531	133,806,182	366,341.4
August	5,586	4,325,498	5,619	590,625	1,617.0	17,402	17,474	528,740	568,896	133,807,594	366,345.2

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
September	6,605	4,319,919	6,656	543,532	1,488.1	14,383	14,401	484,412	514,484	129,415,342	354,319.9
October	7,566	4,368,295	7,644	597,731	1,636.5	15,225	15,254	533,680	589,634	135,121,612	369,942.8
November	8,889	4,361,839	8,954	1,119,002	3,063.7	30,420	30,591	1,016,968	1,055,839	130,664,483	357,739.9
December	10,161	4,446,008	10,215	1,164,500	3,188.2	31,288	31,312	1,059,162	1,087,294	134,929,967	369,418.1
2013											
January	10,950	4,399,127	11,022	798,268	2,185.5	21,472	21,625	717,251	738,806	136,028,101	372,424.6
February	11,505	4,392,277	11,602	645,875	1,768.3	17,588	17,622	586,619	623,893	122,786,673	336,171.6
March	12,217	4,392,361	12,302	669,349	1,832.6	19,095	19,145	605,437	632,445	135,930,571	372,157.6
April	13,000	4,431,874	13,115	750,649	2,055.2	18,727	18,762	677,582	728,790	132,685,823	363,274.0
May	13,811	4,430,838	13,925	765,724	2,096.4	20,095	20,363	689,876	738,245	137,147,065	375,488.2
June	14,374	4,426,347	14,483	593,870	1,625.9	17,960	18,087	530,834	564,270	132,600,343	363,040.0
July	14,846	4,467,139	14,953	589,498	1,614.0	14,419	14,506	526,125	560,806	138,136,950	378,198.4
August	15,241	4,467,093	15,348	515,649	1,411.8	14,522	14,545	459,006	475,876	138,195,986	378,360.0
September	15,505	4,461,357	15,620	502,611	1,376.1	14,852	14,884	447,796	489,413	133,656,979	365,932.9
October	15,883	4,507,745	16,033	579,274	1,586.0	16,046	16,232	516,749	551,736	139,452,619	381,800.5
November	16,117	4,501,398	16,237	462,760	1,267.0	13,453	13,469	412,034	446,951	134,846,788	369,190.4
December	16,260	4,595,065	16,376	435,964	1,193.6	12,036	12,158	388,739	420,821	139,269,845	381,300.1
2014											
January	16,230	4,531,255	16,349	471,188	1,290.0	15,227	15,516	420,691	453,163	140,156,968	383,728.9
February	16,023	4,525,425	16,137	438,752	1,201.2	14,621	14,697	391,308	413,328	126,514,507	346,377.8
March	16,164	4,524,556	16,290	682,487	1,868.5	18,629	18,663	615,300	641,029	140,036,195	383,398.2
April	16,469	4,551,212	16,603	812,068	2,223.3	20,265	20,376	732,996	760,606	136,259,621	373,058.5
May	16,969	4,549,461	17,116	727,980	1,993.1	18,816	18,874	649,576	672,931	140,812,634	385,524.0
June	17,166	4,543,585	17,308	630,397	1,725.9	16,158	16,199	564,984	594,836	136,112,338	372,655.3
July	17,317	4,567,206	17,439	506,242	1,386.0	13,481	13,519	450,004	470,894	141,244,393	386,706.1
August	17,108	4,566,372	17,236	429,142	1,174.9	11,764	11,785	381,723	399,420	141,287,064	386,822.9
September	16,902	4,560,192	17,023	419,498	1,148.5	10,946	11,001	373,916	400,130	136,611,694	374,022.4
October	17,236	4,603,390	17,395	486,877	1,333.0	13,093	13,109	424,840	450,712	142,414,439	389,909.5
November	17,631	4,596,452	17,722	403,497	1,104.7	10,546	10,569	346,537	372,708	137,689,334	376,972.9
December	17,947	4,690,727	18,060	368,514	1,008.9	9,422	9,474	317,960	335,157	142,159,405	389,211.2
2015											
January	17,712	4,630,053	17,827	341,314	934.5	9,489	9,504	299,690	310,637	143,195,395	392,047.6
February	16,930	4,622,633	17,029	293,273	802.9	9,259	9,266	259,031	275,627	128,891,444	352,885.5

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
March	16,343	4,608,204	16,449	416,088	1,139.2	14,064	14,276	372,265	397,936	142,621,979	390,477.7
April	15,532	4,649,181	15,650	446,162	1,221.5	12,181	12,189	398,803	421,966	139,200,373	381,109.9
May	15,248	4,646,557	15,365	528,483	1,446.9	13,531	13,683	473,740	487,943	143,820,934	393,760.3
June	15,526	4,639,786	15,633	880,861	2,411.7	22,622	22,910	800,791	828,640	139,000,288	380,562.0
July	15,716	4,670,939	15,848	714,330	1,955.7	17,639	17,761	648,912	671,316	144,470,455	395,538.5
August	15,751	4,668,567	15,851	506,693	1,387.2	12,671	12,702	458,615	466,247	144,458,311	395,505.3
September	15,752	4,661,777	15,881	445,803	1,220.5	10,892	11,039	399,169	415,321	139,666,252	382,385.4
October	15,785	4,702,725	15,906	421,266	1,153.4	10,787	10,805	375,848	391,727	145,490,180	398,330.4
November	15,918	4,694,981	16,031	359,783	985.0	8,798	8,838	317,572	341,129	140,653,325	385,087.8
December	16,071	4,787,323	16,184	347,358	951.0	9,656	9,722	305,826	318,940	145,235,622	397,633.5
2016											
January	16,259	4,728,935	16,370	363,544	995.3	10,443	10,481	320,377	338,251	146,290,949	400,522.8
February	16,340	4,722,828	16,435	309,829	848.3	7,303	7,321	272,963	282,436	136,754,625	374,413.8
March	16,503	4,721,494	16,625	404,913	1,108.6	10,362	10,415	359,457	371,387	146,130,012	400,082.2
April	16,495	4,763,745	16,613	427,876	1,171.5	10,572	10,618	378,559	383,846	142,710,057	390,718.8
May	16,507	4,761,475	16,610	384,660	1,053.1	9,271	9,290	340,425	358,408	147,398,347	403,554.7
June	16,410	4,755,765	16,527	356,049	974.8	8,455	8,634	315,234	324,413	142,485,590	390,104.3
July	16,246	4,789,659	16,347	296,452	811.6	7,252	7,295	260,381	273,255	148,216,944	405,795.9
August	16,114	4,789,879	16,233	279,853	766.2	7,274	7,274	246,480	253,492	148,205,722	405,765.2
September	15,891	4,784,732	15,981	270,110	739.5	7,075	7,105	236,129	242,676	143,351,972	392,476.3
October	15,610	4,827,419	15,700	286,046	783.2	7,624	7,672	252,179	262,125	149,343,093	408,879.1
November	15,365	4,821,453	15,460	287,248	786.4	7,470	7,526	251,605	268,300	144,440,669	395,457.0
December	15,183	4,912,147	15,274	285,232	780.9	7,513	7,513	249,454	257,300	149,183,801	408,443.0
2017											
January	15,127	4,857,235	15,235	361,274	989.1	10,991	10,997	321,704	334,182	150,243,373	411,343.9
February	15,248	4,851,355	15,338	438,839	1,201.5	10,773	10,774	396,937	404,628	135,630,174	371,335.2
March	15,683	4,850,456	15,765	700,402	1,917.6	15,544	15,613	640,535	653,344	150,130,820	411,035.8
April	15,746	4,891,603	15,837	584,886	1,601.3	11,694	11,720	534,867	548,035	146,479,438	401,038.8
May	15,821	4,889,744	15,929	517,794	1,417.6	9,888	9,893	467,844	481,453	151,368,694	414,424.9
June	15,679	4,884,153	15,792	350,739	960.3	7,123	7,128	312,195	321,993	146,327,856	400,623.8
July	15,510	4,921,396	15,618	274,165	750.6	5,631	5,650	239,933	248,423	152,222,185	416,761.6
August	15,363	4,919,731	15,447	214,454	587.1	4,969	5,024	185,087	197,675	152,243,262	416,819.3
September	15,271	4,914,080	15,379	243,294	666.1	5,243	5,266	209,828	217,550	147,221,895	403,071.6

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
October	15,105	4,958,838	15,202	234,000	640.7	4,821	4,853	202,995	212,480	153,436,332	420,085.8
November	14,738	4,952,573	14,846	197,907	541.8	3,982	3,987	170,238	173,676	148,367,041	406,206.8
December	14,254	5,042,973	14,334	189,984	520.1	4,183	4,200	164,643	166,996	153,189,411	419,409.7
2018											
January	14,116	4,992,614	14,213	198,001	542.1	4,338	4,368	168,641	177,147	154,431,953	422,811.6
February	14,007	4,985,839	14,087	190,106	520.5	4,134	4,136	164,038	167,939	139,376,510	381,592.1
March	14,136	4,984,547	14,243	264,289	723.6	5,491	5,537	229,836	238,131	154,273,405	422,377.6
April	14,337	5,049,617	14,447	256,684	702.8	5,644	5,651	220,222	230,393	151,180,495	413,909.6
May	14,593	5,031,720	14,712	260,361	712.8	5,612	5,613	224,994	231,140	155,771,746	426,479.8
June	14,607	5,025,755	14,701	187,535	513.4	3,502	3,516	160,392	165,549	150,569,782	412,237.6
July	15,852	5,248,660	15,938	447,755	1,225.9	10,869	11,203	372,736	395,469	161,952,956	443,403.0
August	15,771	5,248,208	15,859	336,926	922.5	8,439	8,456	291,644	305,822	162,396,424	444,617.2
September	14,343	5,235,593	14,433	366,777	1,004.2	7,760	7,847	319,526	341,325	156,845,849	429,420.5
October	13,314	5,283,082	13,393	356,877	977.1	6,760	6,765	310,789	328,521	163,464,232	447,540.7
November	12,629	5,278,167	12,720	247,366	677.3	5,753	5,777	212,866	225,416	158,110,467	432,882.9
December	12,306	5,429,048	12,382	245,007	670.8	6,023	6,039	207,573	219,695	163,374,349	447,294.6
2019											
January	12,424	5,316,625	12,506	246,371	674.5	5,067	5,070	209,097	221,707	164,467,392	450,287.2
February	12,517	5,311,855	12,600	195,583	535.5	4,470	4,488	164,044	175,432	148,509,516	406,596.9
March	13,024	5,312,443	13,114	248,008	679.0	7,039	7,040	207,144	214,823	164,414,377	450,142.0
April	13,342	5,214,113	13,431	228,989	626.9	5,011	5,042	192,457	202,906	156,117,229	427,425.7
May	13,528	5,211,995	13,619	214,805	588.1	4,559	4,565	178,522	188,145	161,342,295	441,731.1
June	13,526	5,205,736	13,624	194,276	531.9	4,183	4,184	159,566	165,036	155,963,476	427,004.7
July	13,510	5,223,640	13,567	169,133	463.1	3,406	3,410	138,633	145,603	161,568,359	442,350.1
August	13,051	5,221,898	13,142	125,224	342.8	2,631	2,632	103,575	106,317	161,611,118	442,467.1
September	12,339	5,215,948	12,429	122,849	336.3	2,624	2,625	100,277	107,394	156,283,152	427,880.0
October	11,418	5,254,359	11,488	108,274	296.4	2,217	2,217	89,174	91,718	162,602,146	445,180.4
November	10,550	5,247,916	10,612	88,978	243.6	1,988	1,988	72,896	73,574	157,212,130	430,423.4
December	9,555	5,373,067	9,619	79,132	216.7	1,828	1,828	64,031	66,055	162,420,105	444,682.0
2020											
January	8,873	5,259,458	8,929	82,937	227.1	1,859	1,859	66,512	69,579	162,724,680	445,515.9
February	8,072	5,252,970	8,119	64,904	177.7	1,484	1,484	52,052	53,881	152,125,842	416,497.9
March	7,568	5,251,502	7,631	72,089	197.4	1,683	1,687	58,911	61,623	162,554,255	445,049.3

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
April	7,024	5,298,182	7,060	40,010	109.5	951	951	32,593	33,427	158,709,408	434,522.7
May	6,607	5,293,078	6,667	46,999	128.7	1,095	1,095	39,994	40,447	163,826,607	448,532.8
June	6,278	5,285,134	6,342	49,996	136.9	986	986	42,619	43,793	158,335,959	433,500.2
July	6,065	5,326,190	6,120	42,071	115.2	875	875	35,976	36,384	164,802,453	451,204.5
August	5,794	5,325,550	5,831	23,898	65.4	543	543	20,289	20,515	164,812,943	451,233.2
September	5,765	5,320,262	5,810	24,610	67.4	595	595	21,210	21,942	159,403,596	436,423.3
October	5,704	5,358,929	5,752	16,577	45.4	410	410	14,741	14,838	165,862,390	454,106.5
November	5,593	5,350,641	5,635	9,505	26.0	288	288	8,695	8,869	160,309,387	438,903.2
December	5,555	5,470,775	5,588	3,396	9.3	235	235	3,384	3,473	165,525,188	453,183.3
Recalled Valsartan Dispensings											
2012											
May	4,160	4,286,649	4,160	2,409,248	6,596.2	55,727	56,148	2,202,678	2,371,343	132,685,099	363,272.0
June	8,943	4,282,255	8,945	3,091,951	8,465.3	66,303	67,127	2,853,191	3,047,810	128,287,490	351,232.0
July	13,019	4,324,763	13,078	2,587,950	7,085.4	65,710	66,054	2,375,413	2,545,555	133,806,182	366,341.4
August	16,033	4,325,498	16,122	2,038,924	5,582.3	49,129	49,417	1,864,073	1,973,245	133,807,594	366,345.2
September	18,378	4,319,919	18,542	1,751,580	4,795.6	42,058	42,751	1,592,717	1,664,439	129,415,342	354,319.9
October	20,359	4,368,295	20,610	1,876,980	5,138.9	50,609	51,076	1,708,229	1,794,888	135,121,612	369,942.8
November	22,031	4,361,839	22,250	1,651,757	4,522.3	41,083	41,469	1,501,487	1,571,919	130,664,483	357,739.9
December	23,354	4,446,008	23,527	1,593,423	4,362.6	41,645	42,026	1,453,626	1,541,562	134,929,967	369,418.1
2013											
January	24,743	4,399,127	25,004	1,666,327	4,562.2	43,097	43,418	1,515,251	1,590,356	136,028,101	372,424.6
February	25,682	4,392,277	25,876	1,385,617	3,793.6	39,261	39,418	1,263,129	1,323,680	122,786,673	336,171.6
March	26,862	4,392,361	27,143	1,500,069	4,107.0	39,823	40,367	1,361,511	1,453,563	135,930,571	372,157.6
April	28,362	4,431,874	28,682	1,919,852	5,256.3	48,459	48,810	1,750,001	1,856,160	132,685,823	363,274.0
May	29,889	4,430,838	30,246	1,925,827	5,272.6	45,883	46,110	1,756,096	1,863,403	137,147,065	375,488.2
June	30,898	4,426,347	31,171	1,677,349	4,592.3	41,664	41,828	1,530,046	1,622,164	132,600,343	363,040.0
July	31,740	4,467,139	32,074	1,628,493	4,458.6	39,858	40,040	1,482,190	1,558,675	138,136,950	378,198.4
August	32,417	4,467,093	32,763	1,507,918	4,128.5	37,813	37,974	1,370,781	1,460,872	138,195,986	378,360.0
September	33,118	4,461,357	33,455	1,459,334	3,995.4	36,300	36,642	1,325,583	1,403,090	133,656,979	365,932.9
October	34,258	4,507,745	34,626	1,811,941	4,960.8	42,630	42,999	1,651,036	1,734,899	139,452,619	381,800.5
November	35,666	4,501,398	35,976	1,888,949	5,171.7	48,675	48,867	1,726,977	1,861,079	134,846,788	369,190.4
December	37,178	4,595,065	37,470	1,883,244	5,156.0	43,446	43,807	1,718,708	1,827,491	139,269,845	381,300.1
2014											

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
January	38,591	4,531,255	38,913	1,796,734	4,919.2	45,172	45,660	1,638,012	1,716,964	140,156,968	383,728.9
February	39,422	4,525,425	39,720	1,444,530	3,954.9	36,229	36,386	1,308,546	1,368,723	126,514,507	346,377.8
March	40,630	4,524,556	41,016	1,522,683	4,168.9	37,172	37,568	1,371,159	1,440,552	140,036,195	383,398.2
April	41,491	4,551,212	41,886	1,604,441	4,392.7	39,402	39,734	1,448,576	1,519,570	136,259,621	373,058.5
May	42,436	4,549,461	42,904	1,623,456	4,444.8	37,103	37,757	1,468,588	1,565,719	140,812,634	385,524.0
June	43,255	4,543,585	43,682	1,842,093	5,043.4	43,898	44,173	1,675,070	1,793,633	136,112,338	372,655.3
July	44,084	4,567,206	44,489	1,965,932	5,382.4	49,105	49,237	1,793,803	1,924,332	141,244,393	386,706.1
August	44,593	4,566,372	44,977	1,592,045	4,358.8	36,164	36,375	1,449,410	1,528,393	141,287,064	386,822.9
September	45,268	4,560,192	45,659	1,588,515	4,349.1	36,180	36,571	1,441,601	1,532,613	136,611,694	374,022.4
October	45,848	4,603,390	46,271	1,576,401	4,316.0	34,810	35,107	1,426,563	1,502,768	142,414,439	389,909.5
November	46,168	4,596,452	46,499	1,309,417	3,585.0	32,207	32,648	1,182,741	1,273,973	137,689,334	376,972.9
December	46,238	4,690,727	46,547	1,334,016	3,652.3	34,969	35,158	1,205,327	1,281,591	142,159,405	389,211.2
2015											
January	46,386	4,630,053	46,783	1,686,938	4,618.6	44,471	44,738	1,529,660	1,613,884	143,195,395	392,047.6
February	46,289	4,622,633	46,620	1,593,870	4,363.8	39,630	39,785	1,441,734	1,520,717	128,891,444	352,885.5
March	47,108	4,608,204	47,515	1,798,286	4,923.4	42,949	43,426	1,629,391	1,729,225	142,621,979	390,477.7
April	47,907	4,649,181	48,354	1,823,043	4,991.2	40,621	40,959	1,653,390	1,735,925	139,200,373	381,109.9
May	48,826	4,646,557	49,254	1,754,414	4,803.3	37,411	37,685	1,591,210	1,682,183	143,820,934	393,760.3
June	49,577	4,639,786	49,981	1,657,100	4,536.9	37,823	38,103	1,494,762	1,559,275	139,000,288	380,562.0
July	50,127	4,670,939	50,544	1,466,895	4,016.1	36,164	36,427	1,323,445	1,398,315	144,470,455	395,538.5
August	50,404	4,668,567	50,814	1,310,286	3,587.4	29,822	30,000	1,180,845	1,265,870	144,458,311	395,505.3
September	50,833	4,661,777	51,262	1,315,274	3,601.0	31,904	32,098	1,179,669	1,254,347	139,666,252	382,385.4
October	51,295	4,702,725	51,748	1,382,115	3,784.0	32,637	32,777	1,241,595	1,305,193	145,490,180	398,330.4
November	51,837	4,694,981	52,227	1,250,399	3,423.4	28,884	29,505	1,118,588	1,195,514	140,653,325	385,087.8
December	52,232	4,787,323	52,563	1,170,083	3,203.5	27,818	28,048	1,045,022	1,101,837	145,235,622	397,633.5
2016											
January	52,465	4,728,935	52,834	1,161,846	3,181.0	28,283	28,370	1,038,837	1,098,793	146,290,949	400,522.8
February	52,724	4,722,828	53,052	1,097,495	3,004.8	26,363	26,539	980,076	1,033,011	136,754,625	374,413.8
March	53,186	4,721,494	53,588	1,324,626	3,626.6	30,957	31,221	1,185,984	1,254,357	146,130,012	400,082.2
April	53,756	4,763,745	54,184	1,457,084	3,989.3	31,461	31,766	1,305,049	1,369,811	142,710,057	390,718.8
May	54,521	4,761,475	55,021	1,448,757	3,966.5	30,618	30,798	1,297,346	1,353,970	147,398,347	403,554.7
June	54,955	4,755,765	55,388	1,277,985	3,498.9	28,016	28,293	1,137,854	1,192,709	142,485,590	390,104.3
July	55,303	4,789,659	55,701	1,153,137	3,157.1	25,510	25,746	1,026,333	1,091,584	148,216,944	405,795.9

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
August	55,967	4,789,879	56,428	1,279,075	3,501.9	29,083	29,399	1,139,336	1,196,273	148,205,722	405,765.2
September	56,603	4,784,732	57,007	1,236,242	3,384.6	25,890	26,240	1,100,244	1,158,349	143,351,972	392,476.3
October	57,439	4,827,419	57,850	1,287,807	3,525.8	28,385	28,547	1,143,946	1,208,072	149,343,093	408,879.1
November	58,161	4,821,453	58,566	1,138,134	3,116.0	26,371	26,577	1,005,509	1,052,777	144,440,669	395,457.0
December	58,666	4,912,147	59,037	1,066,539	2,920.0	23,373	23,519	941,414	996,898	149,183,801	408,443.0
2017											
January	59,308	4,857,235	59,706	1,148,066	3,143.2	24,910	25,079	1,011,460	1,061,716	150,243,373	411,343.9
February	60,112	4,851,355	60,459	1,166,619	3,194.0	26,670	26,775	1,027,269	1,091,983	135,630,174	371,335.2
March	61,264	4,850,456	61,698	1,257,854	3,443.8	26,587	26,728	1,106,532	1,161,523	150,130,820	411,035.8
April	62,081	4,891,603	62,540	1,228,190	3,362.6	26,006	26,180	1,075,510	1,131,477	146,479,438	401,038.8
May	63,129	4,889,744	63,623	1,217,705	3,333.9	25,197	25,392	1,063,232	1,113,525	151,368,694	414,424.9
June	63,689	4,884,153	64,174	1,002,484	2,744.7	21,102	21,297	868,539	901,830	146,327,856	400,623.8
July	64,125	4,921,396	64,546	871,204	2,385.2	17,919	17,991	748,696	783,204	152,222,185	416,761.6
August	64,655	4,919,731	65,133	848,679	2,323.6	20,018	20,166	723,790	761,690	152,243,262	416,819.3
September	65,345	4,914,080	65,798	847,737	2,321.0	26,242	26,515	721,122	752,614	147,221,895	403,071.6
October	66,361	4,958,838	66,824	919,161	2,516.5	25,627	25,806	777,155	807,467	153,436,332	420,085.8
November	67,056	4,952,573	67,545	785,428	2,150.4	16,440	16,601	657,744	690,643	148,367,041	406,206.8
December	67,472	5,042,973	67,849	637,869	1,746.4	13,086	13,150	526,810	550,638	153,189,411	419,409.7
2018											
January	67,841	4,992,614	68,322	611,738	1,674.8	12,190	12,250	495,353	523,273	154,431,953	422,811.6
February	67,910	4,985,839	68,280	479,929	1,314.0	9,544	9,591	384,023	404,428	139,376,510	381,592.1
March	68,139	4,984,547	68,596	500,740	1,371.0	9,470	9,499	394,121	414,647	154,273,405	422,377.6
April	68,272	5,049,617	68,788	475,530	1,301.9	8,551	8,589	360,703	378,068	151,180,495	413,909.6
May	68,906	5,031,720	69,408	442,828	1,212.4	7,355	7,380	325,489	340,012	155,771,746	426,479.8
June	69,398	5,025,755	69,873	415,066	1,136.4	5,624	5,639	292,764	313,019	150,569,782	412,237.6
July	67,472	5,248,660	67,518	113,684	311.2	1,369	1,369	81,602	85,581	161,952,956	443,403.0
August	63,203	5,248,208	63,211	18,849	51.6	250	250	16,294	16,719	162,396,424	444,617.2
September	37,471	5,235,593	37,477	15,137	41.4	353	353	12,822	13,891	156,845,849	429,420.5
October	20,466	5,283,082	20,474	19,355	53.0	532	532	16,178	17,823	163,464,232	447,540.7
November	6,349	5,278,167	6,354	19,966	54.7	438	438	17,172	18,572	158,110,467	432,882.9
December	1,378	5,429,048	1,380	25,265	69.2	581	581	21,255	22,182	163,374,349	447,294.6
2019											
January	997	5,316,625	999	19,639	53.8	488	488	16,518	16,110	164,467,392	450,287.2

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
February	823	5,311,855	828	16,699	45.7	408	408	14,451	14,763	148,509,516	406,596.9
March	793	5,312,443	799	20,449	56.0	473	473	16,969	17,971	164,414,377	450,142.0
April	808	5,214,113	814	17,145	46.9	478	478	14,054	14,745	156,117,229	427,425.7
May	789	5,211,995	791	14,588	39.9	241	241	12,039	12,463	161,342,295	441,731.1
June	734	5,205,736	738	14,064	38.5	393	395	11,936	12,107	155,963,476	427,004.7
July	731	5,223,640	735	15,309	41.9	393	393	12,556	12,780	161,568,359	442,350.1
August	669	5,221,898	671	9,871	27.0	237	237	8,266	8,580	161,611,118	442,467.1
September	657	5,215,948	659	12,787	35.0	417	417	11,040	11,995	156,283,152	427,880.0
October	634	5,254,359	637	13,587	37.2	318	318	10,993	11,856	162,602,146	445,180.4
November	605	5,247,916	606	8,141	22.3	234	235	6,604	6,519	157,212,130	430,423.4
December	591	5,373,067	594	8,090	22.1	148	148	6,388	6,905	162,420,105	444,682.0
2020											
January	695	5,259,458	699	33,568	91.9	1,284	1,302	28,892	31,101	162,724,680	445,515.9
February	3,562	5,252,970	3,565	599,020	1,640.0	20,769	20,928	528,156	562,734	152,125,842	416,497.9
March	6,759	5,251,502	6,768	645,221	1,766.5	17,072	17,178	568,460	609,878	162,554,255	445,049.3
April	8,042	5,298,182	8,054	265,011	725.6	7,515	7,547	232,585	253,995	158,709,408	434,522.7
May	8,600	5,293,078	8,643	188,582	516.3	5,816	5,868	168,457	177,636	163,826,607	448,532.8
June	10,102	5,285,134	10,389	494,162	1,352.9	14,940	15,060	461,899	513,778	158,335,959	433,500.2
July	11,781	5,326,190	11,972	470,695	1,288.7	13,752	13,842	439,939	482,859	164,802,453	451,204.5
August	12,703	5,325,550	12,760	218,237	597.5	6,968	6,982	201,441	216,832	164,812,943	451,233.2
September	14,225	5,320,262	14,274	199,893	547.3	5,648	5,673	186,788	201,560	159,403,596	436,423.3
October	15,326	5,358,929	15,414	117,205	320.9	3,513	3,526	110,611	119,514	165,862,390	454,106.5
November	15,893	5,350,641	15,995	57,644	157.8	2,259	2,269	54,093	57,853	160,309,387	438,903.2
December	16,396	5,470,775	16,454	18,691	51.2	1,310	1,313	18,435	19,797	165,525,188	453,183.3
Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan)											
2012											
May	14,857	4,286,649	14,857	6,998,430	19,160.7	136,300	137,310	6,358,293	6,766,029	132,685,099	363,272.0
June	28,335	4,282,255	28,337	6,527,517	17,871.4	126,090	127,215	5,938,642	6,319,095	128,287,490	351,232.0
July	36,879	4,324,763	37,025	4,147,957	11,356.5	94,637	95,108	3,750,312	3,975,411	133,806,182	366,341.4
August	42,768	4,325,498	42,965	3,049,130	8,348.1	68,091	68,420	2,739,867	2,889,177	133,807,594	366,345.2
September	46,523	4,319,919	46,891	2,486,337	6,807.2	56,790	57,820	2,230,168	2,323,103	129,415,342	354,319.9
October	48,915	4,368,295	49,514	2,620,878	7,175.6	67,008	67,513	2,350,637	2,475,018	135,121,612	369,942.8
November	50,914	4,361,839	51,422	2,432,751	6,660.5	57,276	57,684	2,163,577	2,262,672	130,664,483	357,739.9

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
December	52,915	4,446,008	53,248	2,212,220	6,056.7	54,044	54,478	1,973,917	2,086,417	134,929,967	369,418.1
2013											
January	54,431	4,399,127	54,916	2,207,205	6,043.0	53,023	53,359	1,973,412	2,065,726	136,028,101	372,424.6
February	54,467	4,392,277	54,841	1,804,795	4,941.3	48,565	48,841	1,624,303	1,702,274	122,786,673	336,171.6
March	54,529	4,392,361	54,958	1,876,978	5,138.9	48,901	49,456	1,685,135	1,791,324	135,930,571	372,157.6
April	54,715	4,431,874	55,260	2,509,183	6,869.8	61,296	61,656	2,261,070	2,391,640	132,685,823	363,274.0
May	55,603	4,430,838	56,196	2,787,168	7,630.9	63,324	63,574	2,506,116	2,627,982	137,147,065	375,488.2
June	56,738	4,426,347	57,152	2,425,166	6,639.7	56,361	56,529	2,180,000	2,293,489	132,600,343	363,040.0
July	57,965	4,467,139	58,497	2,391,154	6,546.6	54,441	54,685	2,143,366	2,237,945	138,136,950	378,198.4
August	58,162	4,467,093	58,666	2,087,821	5,716.1	49,430	49,606	1,876,164	1,983,135	138,195,986	378,360.0
September	58,049	4,461,357	58,574	1,946,980	5,330.5	45,816	46,167	1,751,069	1,843,833	133,656,979	365,932.9
October	57,940	4,507,745	58,521	2,288,151	6,264.6	51,894	52,310	2,063,745	2,174,853	139,452,619	381,800.5
November	57,643	4,501,398	58,084	2,270,926	6,217.5	56,726	57,002	2,056,962	2,207,193	134,846,788	369,190.4
December	58,070	4,595,065	58,496	2,267,196	6,207.2	51,233	51,620	2,052,601	2,178,790	139,269,845	381,300.1
2014											
January	58,554	4,531,255	59,028	2,147,060	5,878.3	52,811	53,304	1,940,076	2,030,284	140,156,968	383,728.9
February	59,403	4,525,425	59,831	1,935,667	5,299.6	47,687	47,984	1,732,293	1,807,681	126,514,507	346,377.8
March	61,756	4,524,556	62,316	2,264,702	6,200.4	54,669	55,149	2,006,355	2,093,561	140,036,195	383,398.2
April	63,583	4,551,212	64,126	2,269,356	6,213.2	53,690	54,081	2,019,153	2,112,263	136,259,621	373,058.5
May	65,367	4,549,461	66,013	2,204,334	6,035.1	50,089	50,879	1,969,212	2,089,267	140,812,634	385,524.0
June	67,383	4,543,585	67,977	2,720,052	7,447.1	67,148	67,739	2,455,087	2,622,553	136,112,338	372,655.3
July	69,338	4,567,206	69,950	2,803,273	7,674.9	66,114	66,434	2,533,712	2,723,333	141,244,393	386,706.1
August	70,610	4,566,372	71,168	2,223,130	6,086.6	49,405	49,741	2,001,884	2,113,335	141,287,064	386,822.9
September	71,965	4,560,192	72,548	2,065,132	5,654.0	45,286	45,696	1,843,601	1,957,549	136,611,694	374,022.4
October	73,043	4,603,390	73,668	1,958,540	5,362.2	42,674	42,987	1,744,923	1,840,637	142,414,439	389,909.5
November	73,311	4,596,452	73,830	1,554,355	4,255.6	37,416	37,899	1,382,785	1,489,127	137,689,334	376,972.9
December	72,663	4,690,727	73,127	1,553,986	4,254.6	39,815	40,008	1,386,678	1,470,660	142,159,405	389,211.2
2015											
January	71,196	4,630,053	71,757	1,928,179	5,279.1	49,975	50,269	1,732,627	1,829,750	143,195,395	392,047.6
February	67,656	4,622,633	68,100	1,807,155	4,947.7	44,541	44,698	1,622,423	1,708,227	128,891,444	352,885.5
March	65,310	4,608,204	65,805	2,070,542	5,668.8	48,614	49,094	1,864,058	1,978,656	142,621,979	390,477.7
April	63,027	4,649,181	63,576	2,224,537	6,090.5	49,208	49,553	2,009,836	2,108,566	139,200,373	381,109.9
May	61,833	4,646,557	62,338	2,284,226	6,253.9	48,391	48,752	2,069,604	2,180,812	143,820,934	393,760.3

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
June	61,302	4,639,786	61,779	2,213,244	6,059.5	48,522	48,831	2,002,129	2,093,075	139,000,288	380,562.0
July	60,750	4,670,939	61,221	1,887,911	5,168.8	43,895	44,195	1,707,428	1,797,220	144,470,455	395,538.5
August	60,077	4,668,567	60,540	1,617,705	4,429.0	35,452	35,636	1,459,370	1,555,517	144,458,311	395,505.3
September	60,086	4,661,777	60,575	1,659,496	4,543.5	38,264	38,554	1,491,324	1,582,569	139,666,252	382,385.4
October	60,549	4,702,725	61,063	1,767,622	4,839.5	39,394	39,539	1,587,244	1,671,353	145,490,180	398,330.4
November	61,237	4,694,981	61,667	1,569,825	4,297.9	34,960	35,604	1,404,952	1,494,179	140,653,325	385,087.8
December	61,993	4,787,323	62,373	1,500,981	4,109.5	35,971	36,271	1,339,131	1,416,321	145,235,622	397,633.5
2016											
January	62,498	4,728,935	62,917	1,456,119	3,986.6	35,600	35,793	1,302,639	1,374,308	146,290,949	400,522.8
February	63,025	4,722,828	63,411	1,381,807	3,783.2	31,939	32,238	1,233,671	1,297,614	136,754,625	374,413.8
March	63,725	4,721,494	64,191	1,613,959	4,418.8	38,164	38,438	1,443,669	1,526,027	146,130,012	400,082.2
April	64,660	4,763,745	65,163	1,889,769	5,173.9	42,060	42,391	1,694,296	1,778,786	142,710,057	390,718.8
May	65,925	4,761,475	66,496	1,934,995	5,297.7	40,033	40,328	1,738,040	1,816,751	147,398,347	403,554.7
June	66,900	4,755,765	67,397	1,747,470	4,784.3	36,416	36,731	1,558,968	1,633,940	142,485,590	390,104.3
July	67,525	4,789,659	67,985	1,545,520	4,231.4	33,444	33,714	1,379,706	1,470,713	148,216,944	405,795.9
August	68,505	4,789,879	69,040	1,653,108	4,526.0	36,970	37,393	1,474,304	1,553,226	148,205,722	405,765.2
September	69,416	4,784,732	69,916	1,580,280	4,326.6	33,076	33,466	1,407,656	1,490,330	143,351,972	392,476.3
October	70,633	4,827,419	71,134	1,647,003	4,509.2	35,071	35,245	1,463,881	1,545,486	149,343,093	408,879.1
November	71,492	4,821,453	71,971	1,394,293	3,817.4	31,490	31,732	1,232,058	1,293,514	144,440,669	395,457.0
December	72,001	4,912,147	72,448	1,290,226	3,532.4	27,645	27,819	1,137,634	1,203,937	149,183,801	408,443.0
2017											
January	72,632	4,857,235	73,100	1,345,960	3,685.0	29,118	29,298	1,183,917	1,244,127	150,243,373	411,343.9
February	73,360	4,851,355	73,780	1,350,781	3,698.2	30,858	30,965	1,188,385	1,262,682	135,630,174	371,335.2
March	74,470	4,850,456	74,989	1,456,377	3,987.3	31,324	31,502	1,279,035	1,344,166	150,130,820	411,035.8
April	75,203	4,891,603	75,743	1,442,204	3,948.5	30,890	31,065	1,260,971	1,325,114	146,479,438	401,038.8
May	76,422	4,889,744	77,006	1,477,230	4,044.4	30,271	30,473	1,286,035	1,350,814	151,368,694	414,424.9
June	76,893	4,884,153	77,451	1,235,729	3,383.2	25,563	25,759	1,070,498	1,113,552	146,327,856	400,623.8
July	77,269	4,921,396	77,765	1,080,615	2,958.6	22,131	22,228	929,678	979,065	152,222,185	416,761.6
August	77,624	4,919,731	78,169	1,035,507	2,835.1	23,512	23,667	885,480	933,176	152,243,262	416,819.3
September	78,193	4,914,080	78,708	1,053,434	2,884.1	30,581	30,866	896,604	937,994	147,221,895	403,071.6
October	79,251	4,958,838	79,787	1,197,983	3,279.9	31,867	32,140	1,014,488	1,058,389	153,436,332	420,085.8
November	80,245	4,952,573	80,791	1,073,608	2,939.4	23,211	23,395	901,278	944,265	148,367,041	406,206.8
December	80,726	5,042,973	81,162	882,864	2,417.1	17,679	17,745	734,499	766,060	153,189,411	419,409.7

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2018											
January	80,946	4,992,614	81,494	834,759	2,285.4	16,178	16,251	683,172	721,349	154,431,953	422,811.6
February	80,521	4,985,839	80,946	639,046	1,749.6	12,717	12,779	516,136	543,129	139,376,510	381,592.1
March	80,274	4,984,547	80,790	641,294	1,755.8	12,239	12,275	510,874	534,479	154,273,405	422,377.6
April	79,820	5,049,617	80,390	619,419	1,695.9	11,514	11,570	481,271	506,784	151,180,495	413,909.6
May	80,128	5,031,720	80,706	617,158	1,689.7	11,234	11,264	469,770	495,251	155,771,746	426,479.8
June	80,186	5,025,755	80,720	609,546	1,668.8	10,505	10,595	455,427	484,919	150,569,782	412,237.6
July	78,186	5,248,660	78,293	369,133	1,010.6	6,572	6,580	293,723	313,846	161,952,956	443,403.0
August	73,899	5,248,208	73,969	228,482	625.5	4,502	4,542	188,400	196,496	162,396,424	444,617.2
September	48,122	5,235,593	48,178	160,985	440.8	3,252	3,272	129,939	136,183	156,845,849	429,420.5
October	30,916	5,283,082	30,977	157,862	432.2	2,764	2,798	126,261	133,497	163,464,232	447,540.7
November	16,967	5,278,167	17,021	186,477	510.5	3,311	3,317	146,174	154,413	158,110,467	432,882.9
December	13,189	5,429,048	13,232	293,848	804.5	5,290	5,293	219,398	230,034	163,374,349	447,294.6
2019											
January	14,284	5,316,625	14,339	301,085	824.3	4,598	4,617	218,547	224,210	164,467,392	450,287.2
February	14,538	5,311,855	14,580	179,928	492.6	2,455	2,456	129,143	135,456	148,509,516	406,596.9
March	13,439	5,312,443	13,449	62,140	170.1	1,272	1,272	46,461	49,209	164,414,377	450,142.0
April	11,297	5,214,113	11,312	27,780	76.1	916	916	21,802	22,908	156,117,229	427,425.7
May	7,201	5,211,995	7,206	22,396	61.3	432	432	17,902	18,624	161,342,295	441,731.1
June	3,985	5,205,736	3,992	19,439	53.2	503	505	16,025	16,293	155,963,476	427,004.7
July	1,911	5,223,640	1,915	22,756	62.3	737	737	18,382	18,909	161,568,359	442,350.1
August	1,200	5,221,898	1,202	15,411	42.2	395	395	12,450	13,013	161,611,118	442,467.1
September	1,075	5,215,948	1,079	17,329	47.4	652	652	14,379	15,853	156,283,152	427,880.0
October	977	5,254,359	981	16,281	44.6	446	446	12,708	13,775	162,602,146	445,180.4
November	898	5,247,916	899	11,932	32.7	379	380	9,601	9,723	157,212,130	430,423.4
December	823	5,373,067	826	10,191	27.9	241	241	7,692	8,263	162,420,105	444,682.0
2020											
January	885	5,259,458	889	35,733	97.8	1,325	1,343	30,439	32,698	162,724,680	445,515.9
February	3,723	5,252,970	3,726	600,494	1,644.1	20,806	20,965	529,192	564,160	152,125,842	416,497.9
March	6,893	5,251,502	6,902	647,305	1,772.2	17,193	17,299	569,843	611,657	162,554,255	445,049.3
April	8,152	5,298,182	8,165	267,723	733.0	7,614	7,646	234,031	255,464	158,709,408	434,522.7
May	8,701	5,293,078	8,744	190,442	521.4	5,878	5,930	169,992	179,109	163,826,607	448,532.8
June	10,203	5,285,134	10,490	496,405	1,359.1	14,986	15,106	463,727	515,581	158,335,959	433,500.2

Table 2c. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Month

Month	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
July	11,878	5,326,190	12,070	472,906	1,294.7	13,826	13,916	441,757	484,963	164,802,453	451,204.5
August	12,804	5,325,550	12,861	221,193	605.6	7,161	7,177	204,014	219,563	164,812,943	451,233.2
September	14,347	5,320,262	14,398	203,019	555.8	5,780	5,805	189,494	204,347	159,403,596	436,423.3
October	15,457	5,358,929	15,545	118,361	324.1	3,553	3,566	111,533	120,535	165,862,390	454,106.5
November	16,055	5,350,641	16,157	59,422	162.7	2,329	2,339	55,725	59,723	160,309,387	438,903.2
December	16,695	5,470,775	16,754	20,668	56.6	1,472	1,477	20,411	21,940	165,525,188	453,183.3

¹Total number of users by year month may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple exposure episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
All Valsartan Dispensings											
2012											
Q2: April - June	11,267	4,295,288	11,268	8,822,247	24,154.0	191,640	192,605	8,265,959	8,728,092	260,972,589	714,504.0
Q3: July - September	23,049	4,341,292	23,963	8,817,576	24,141.2	208,724	210,188	8,161,383	8,586,124	397,029,118	1,087,006.5
Q4: October - December	31,424	4,471,611	33,525	8,155,993	22,329.9	190,732	192,122	7,522,589	7,883,159	400,716,062	1,097,100.8
2013											
Q1: January - March	37,225	4,415,575	39,753	7,347,175	20,115.5	177,402	178,267	6,769,937	7,050,243	394,745,345	1,080,753.9
Q2: April - June	43,940	4,449,786	47,326	9,321,097	25,519.8	210,397	211,290	8,612,522	9,016,819	402,433,231	1,101,802.1
Q3: July - September	48,534	4,483,237	51,915	7,726,038	21,152.7	179,126	180,126	7,127,153	7,440,766	409,989,915	1,122,491.2
Q4: October - December	52,610	4,619,995	56,102	7,551,895	20,676.0	172,084	173,099	6,963,420	7,341,527	413,569,252	1,132,290.9
2014											
Q1: January - March	56,067	4,546,590	59,495	6,586,816	18,033.7	156,922	157,860	6,035,196	6,301,614	406,707,670	1,113,504.9
Q2: April - June	60,404	4,568,552	64,890	8,460,384	23,163.3	186,143	187,216	7,790,600	8,178,553	413,184,593	1,131,237.8
Q3: July - September	63,193	4,582,849	67,127	6,895,878	18,879.9	155,314	155,870	6,329,614	6,594,460	419,143,151	1,147,551.4
Q4: October - December	66,060	4,717,888	69,920	6,655,551	18,221.9	150,811	152,024	6,094,296	6,402,189	422,263,178	1,156,093.6
2015											
Q1: January - March	68,360	4,645,087	72,208	6,037,506	16,529.8	140,395	141,535	5,511,922	5,749,358	414,708,818	1,135,410.9
Q2: April - June	71,457	4,665,610	76,160	7,696,387	21,071.6	164,029	164,690	7,050,719	7,304,362	422,021,595	1,155,432.2
Q3: July - September	73,557	4,685,143	77,769	6,150,043	16,837.9	133,283	133,905	5,609,924	5,880,553	428,595,018	1,173,429.2
Q4: October - December	75,742	4,814,313	79,803	6,012,437	16,461.2	129,502	130,306	5,470,594	5,745,943	431,379,127	1,181,051.7
2016											
Q1: January - March	77,716	4,744,390	81,549	5,399,168	14,782.1	117,663	118,189	4,899,752	5,103,610	429,175,586	1,175,018.7
Q2: April - June	80,489	4,780,488	85,289	6,758,813	18,504.6	136,538	137,421	6,156,864	6,413,019	432,593,994	1,184,377.8
Q3: July - September	82,195	4,805,865	86,428	5,137,018	14,064.4	106,108	106,741	4,636,655	4,877,284	439,774,638	1,204,037.3
Q4: October - December	84,316	4,937,563	88,426	5,033,808	13,781.8	107,980	108,367	4,523,932	4,760,837	442,967,563	1,212,779.1
2017											
Q1: January - March	86,107	4,873,161	89,892	4,401,547	12,050.8	95,281	95,658	3,936,203	4,131,324	436,004,367	1,193,714.9
Q2: April - June	90,850	4,907,955	95,868	7,099,529	19,437.5	186,096	187,046	6,460,613	8,281,831	444,175,988	1,216,087.6
Q3: July - September	94,121	4,936,448	98,469	5,189,570	14,208.3	117,740	118,172	4,657,330	5,927,643	451,687,342	1,236,652.5
Q4: October - December	96,735	5,069,944	101,121	4,393,690	12,029.3	100,503	101,038	3,895,634	4,736,126	454,992,784	1,245,702.4
2018											
Q1: January - March	99,265	5,009,441	103,595	3,768,591	10,317.8	87,854	88,364	3,304,745	4,061,427	448,081,868	1,226,781.3
Q2: April - June	102,880	5,065,454	108,186	3,999,180	10,949.2	86,730	87,048	3,471,786	4,296,798	457,522,023	1,252,627.0

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
Q3: July - September	100,419	5,266,840	102,703	2,238,307	6,128.2	56,257	56,559	2,015,901	2,631,257	481,195,229	1,317,440.7
Q4: October - December	61,806	5,455,501	63,950	2,780,763	7,613.3	73,825	74,482	2,535,830	3,334,074	484,949,048	1,327,718.1
2019											
Q1: January - March	44,888	5,335,320	46,693	2,564,042	7,020.0	74,983	75,304	2,336,596	3,067,035	477,391,285	1,307,026.1
Q2: April - June	47,080	5,230,851	49,374	3,035,309	8,310.2	83,486	83,953	2,758,314	3,603,507	473,423,000	1,296,161.5
Q3: July - September	50,037	5,238,302	52,140	2,611,864	7,150.9	73,562	73,865	2,355,964	3,092,995	479,462,629	1,312,697.1
Q4: October - December	53,036	5,398,994	55,173	2,268,878	6,211.8	65,855	66,077	2,030,120	2,718,028	482,234,381	1,320,285.8
2020											
Q1: January - March	55,605	5,274,674	58,067	1,959,535	5,364.9	62,981	63,183	1,747,269	2,280,106	477,404,777	1,307,063.0
Q2: April - June	53,605	5,314,177	56,291	1,306,374	3,576.7	34,517	34,696	1,169,585	1,491,097	480,871,974	1,316,555.7
Q3: July - September	52,617	5,342,086	54,817	922,971	2,527.0	24,504	24,598	830,850	1,095,779	489,018,992	1,338,861.0
Q4: October - December	54,711	5,497,741	56,928	337,907	925.1	13,322	13,350	316,912	432,356	491,696,965	1,346,192.9
Valsartan with Impurity Dispensings											
2012											
Q2: April - June	791	4,295,288	791	474,806	1,299.9	10,664	10,664	436,757	437,288	260,972,589	714,504.0
Q3: July - September	2,126	4,341,292	2,165	621,893	1,702.7	13,962	13,969	562,803	573,633	397,029,118	1,087,006.5
Q4: October - December	3,260	4,471,611	3,372	616,897	1,689.0	14,762	14,917	556,112	565,824	400,716,062	1,097,100.8
2013											
Q1: January - March	3,842	4,415,575	3,957	521,494	1,427.8	13,281	13,299	473,203	479,402	394,745,345	1,080,753.9
Q2: April - June	4,860	4,449,786	5,033	724,898	1,984.7	18,628	18,696	650,805	669,441	402,433,231	1,101,802.1
Q3: July - September	5,583	4,483,237	5,770	582,704	1,595.4	13,929	13,948	518,524	527,670	409,989,915	1,122,491.2
Q4: October - December	5,833	4,619,995	6,031	507,450	1,389.3	14,254	14,277	456,815	463,653	413,569,252	1,132,290.9
2014											
Q1: January - March	5,477	4,546,590	5,633	414,711	1,135.4	10,798	10,798	372,953	375,431	406,707,670	1,113,504.9
Q2: April - June	4,748	4,568,552	4,924	493,037	1,349.9	11,908	11,908	448,784	454,047	413,184,593	1,131,237.8
Q3: July - September	4,691	4,582,849	4,905	420,185	1,150.4	9,856	9,898	377,268	379,095	419,143,151	1,147,551.4
Q4: October - December	5,042	4,717,888	5,176	462,515	1,266.3	11,274	11,291	414,839	424,759	422,263,178	1,156,093.6
2015											
Q1: January - March	5,552	4,645,087	5,727	570,921	1,563.1	14,362	14,402	510,752	524,043	414,708,818	1,135,410.9
Q2: April - June	5,983	4,665,610	6,201	548,280	1,501.1	12,637	12,645	491,411	495,118	422,021,595	1,155,432.2
Q3: July - September	6,159	4,685,143	6,369	421,035	1,152.7	11,001	11,015	376,003	380,085	428,595,018	1,173,429.2
Q4: October - December	6,227	4,814,313	6,425	429,324	1,175.4	10,653	10,665	383,577	390,128	431,379,127	1,181,051.7

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2016											
Q1: January - March	6,272	4,744,390	6,468	360,393	986.7	9,305	9,343	319,304	322,899	429,175,586	1,175,018.7
Q2: April - June	6,289	4,780,488	6,532	418,816	1,146.7	9,756	9,760	373,410	379,150	432,593,994	1,184,377.8
Q3: July - September	6,247	4,805,865	6,436	368,290	1,008.3	8,724	8,726	326,707	338,326	439,774,638	1,204,037.3
Q4: October - December	6,334	4,937,563	6,517	384,938	1,053.9	9,828	9,857	342,979	351,770	442,967,563	1,212,779.1
2017											
Q1: January - March	6,372	4,873,161	6,509	335,364	918.2	8,549	8,552	295,250	307,461	436,004,367	1,193,714.9
Q2: April - June	6,492	4,907,955	6,699	380,166	1,040.8	8,321	8,321	333,289	339,315	444,175,988	1,216,087.6
Q3: July - September	6,604	4,936,448	6,842	301,082	824.3	7,381	7,382	257,802	264,787	451,687,342	1,236,652.5
Q4: October - December	6,793	5,069,944	6,965	249,298	682.5	6,179	6,179	210,674	217,539	454,992,784	1,245,702.4
2018											
Q1: January - March	6,898	5,009,441	7,104	200,269	548.3	4,801	4,801	163,689	166,624	448,081,868	1,226,781.3
Q2: April - June	7,456	5,065,454	7,683	229,828	629.2	4,012	4,013	176,722	181,869	457,522,023	1,252,627.0
Q3: July - September	9,743	5,266,840	9,796	862,835	2,362.3	18,531	18,561	748,101	801,688	481,195,229	1,317,440.7
Q4: October - December	6,056	5,455,501	6,138	333,675	913.6	7,433	7,436	294,019	316,148	484,949,048	1,327,718.1
2019											
Q1: January - March	4,162	5,335,320	4,288	321,860	881.2	8,343	8,348	282,160	296,325	477,391,285	1,307,026.1
Q2: April - June	5,584	5,230,851	5,704	568,113	1,555.4	14,008	14,014	482,718	520,665	473,423,000	1,296,161.5
Q3: July - September	7,868	5,238,302	8,094	568,155	1,555.5	13,795	13,802	466,921	488,144	479,462,629	1,312,697.1
Q4: October - December	8,991	5,398,994	9,224	349,521	956.9	8,785	8,790	279,595	288,995	482,234,381	1,320,285.8
2020											
Q1: January - March	9,178	5,274,674	9,486	411,160	1,125.7	15,892	15,894	324,627	267,299	477,404,777	1,307,063.0
Q2: April - June	6,668	5,314,177	6,889	120,218	329.1	3,878	3,881	95,101	83,410	480,871,974	1,316,555.7
Q3: July - September	3,893	5,342,086	4,039	103,547	283.5	2,981	2,981	91,973	88,288	489,018,992	1,338,861.0
Q4: October - December	3,022	5,497,741	3,098	26,355	72.2	895	895	24,655	23,887	491,696,965	1,346,192.9
Valsartan without Impurity Dispensings											
2012											
Q2: April - June	860	4,295,288	860	309,692	847.9	5,988	5,988	274,737	294,080	260,972,589	714,504.0
Q3: July - September	1,759	4,341,292	1,804	375,714	1,028.6	7,695	7,695	334,330	348,629	397,029,118	1,087,006.5
Q4: October - December	2,236	4,471,611	2,330	322,975	884.3	6,893	6,893	287,137	307,742	400,716,062	1,097,100.8
2013											
Q1: January - March	2,398	4,415,575	2,503	248,538	680.5	5,343	5,343	220,260	230,567	394,745,345	1,080,753.9
Q2: April - June	2,513	4,449,786	2,621	257,878	706.0	5,372	5,372	228,695	240,657	402,433,231	1,101,802.1

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
Q3: July - September	2,612	4,483,237	2,757	283,382	775.9	6,317	6,317	251,738	268,575	409,989,915	1,122,491.2
Q4: October - December	2,698	4,619,995	2,819	226,837	621.0	4,746	4,747	200,254	212,470	413,569,252	1,132,290.9
2014											
Q1: January - March	2,829	4,546,590	2,933	261,154	715.0	6,115	6,115	231,481	246,662	406,707,670	1,113,504.9
Q2: April - June	3,153	4,568,552	3,305	291,558	798.2	5,613	5,613	254,744	271,324	413,184,593	1,131,237.8
Q3: July - September	3,184	4,582,849	3,320	215,689	590.5	4,363	4,365	189,543	195,604	419,143,151	1,147,551.4
Q4: October - December	3,067	4,717,888	3,204	221,079	605.3	4,660	4,660	193,291	205,212	422,263,178	1,156,093.6
2015											
Q1: January - March	3,035	4,645,087	3,149	193,491	529.7	4,517	4,517	169,514	177,698	414,708,818	1,135,410.9
Q2: April - June	3,091	4,665,610	3,218	222,780	609.9	5,451	5,451	195,166	205,663	422,021,595	1,155,432.2
Q3: July - September	3,047	4,685,143	3,170	196,792	538.8	3,998	3,998	173,516	182,137	428,595,018	1,173,429.2
Q4: October - December	3,081	4,814,313	3,211	197,905	541.8	3,976	3,976	171,877	181,286	431,379,127	1,181,051.7
2016											
Q1: January - March	3,128	4,744,390	3,250	188,896	517.2	4,077	4,077	163,253	175,254	429,175,586	1,175,018.7
Q2: April - June	3,234	4,780,488	3,362	182,874	500.7	4,130	4,130	157,535	165,146	432,593,994	1,184,377.8
Q3: July - September	3,224	4,805,865	3,334	146,628	401.4	3,096	3,096	125,546	132,622	439,774,638	1,204,037.3
Q4: October - December	3,199	4,937,563	3,306	118,114	323.4	2,805	2,805	99,561	104,469	442,967,563	1,212,779.1
2017											
Q1: January - March	3,045	4,873,161	3,098	84,402	231.1	2,285	2,285	71,948	71,805	436,004,367	1,193,714.9
Q2: April - June	2,221	4,907,955	2,272	87,454	239.4	2,390	2,390	74,972	76,564	444,175,988	1,216,087.6
Q3: July - September	1,711	4,936,448	1,769	85,049	232.9	2,280	2,281	71,573	74,530	451,687,342	1,236,652.5
Q4: October - December	1,712	5,069,944	1,756	97,708	267.5	1,864	1,864	82,964	89,043	454,992,784	1,245,702.4
2018											
Q1: January - March	1,716	5,009,441	1,766	82,392	225.6	2,271	2,271	68,479	70,481	448,081,868	1,226,781.3
Q2: April - June	2,048	5,065,454	2,097	105,237	288.1	2,219	2,219	85,211	88,532	457,522,023	1,252,627.0
Q3: July - September	5,574	5,266,840	5,625	984,950	2,696.6	23,696	23,697	844,798	915,381	481,195,229	1,317,440.7
Q4: October - December	6,275	5,455,501	6,373	485,075	1,328.1	10,672	10,673	415,034	454,067	484,949,048	1,327,718.1
2019											
Q1: January - March	5,980	5,335,320	6,156	318,817	872.9	8,557	8,567	263,691	281,426	477,391,285	1,307,026.1
Q2: April - June	6,527	5,230,851	6,704	435,351	1,191.9	11,509	11,510	363,572	379,884	473,423,000	1,296,161.5
Q3: July - September	8,323	5,238,302	8,531	595,933	1,631.6	17,721	17,721	478,372	513,654	479,462,629	1,312,697.1
Q4: October - December	10,077	5,398,994	10,274	408,703	1,119.0	8,934	8,935	302,577	358,648	482,234,381	1,320,285.8

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2020											
Q1: January - March	9,079	5,274,674	9,217	120,508	329.9	3,635	3,635	83,426	101,161	477,404,777	1,307,063.0
Q2: April - June	3,615	5,314,177	3,676	27,152	74.3	747	747	17,295	20,095	480,871,974	1,316,555.7
Q3: July - September	837	5,342,086	851	9,633	26.4	436	436	6,716	6,899	489,018,992	1,338,861.0
Q4: October - December	315	5,497,741	319	2,205	6.0	106	106	1,631	1,589	491,696,965	1,346,192.9
Branded Valsartan Dispensings											
2012											
Q2: April - June	4,569	4,295,288	4,569	2,976,680	8,149.7	56,400	56,435	2,743,006	2,835,293	260,972,589	714,504.0
Q3: July - September	9,918	4,341,292	10,209	3,662,760	10,028.1	69,660	69,930	3,373,002	3,467,561	397,029,118	1,087,006.5
Q4: October - December	13,260	4,471,611	13,976	2,925,399	8,009.3	54,449	54,480	2,674,368	2,761,259	400,716,062	1,097,100.8
2013											
Q1: January - March	15,349	4,415,575	16,190	2,765,085	7,570.4	52,935	52,975	2,532,123	2,595,987	394,745,345	1,080,753.9
Q2: April - June	17,442	4,449,786	18,533	3,087,830	8,454.0	58,212	58,296	2,834,984	2,914,377	402,433,231	1,101,802.1
Q3: July - September	18,717	4,483,237	19,781	2,516,765	6,890.5	46,596	46,792	2,304,226	2,363,036	409,989,915	1,122,491.2
Q4: October - December	19,841	4,619,995	20,941	2,465,627	6,750.5	47,362	47,434	2,257,747	2,329,608	413,569,252	1,132,290.9
2014											
Q1: January - March	20,943	4,546,590	22,023	2,414,923	6,611.7	46,449	46,458	2,212,865	2,273,583	406,707,670	1,113,504.9
Q2: April - June	22,583	4,568,552	24,003	3,034,730	8,308.6	59,175	59,215	2,778,604	2,843,524	413,184,593	1,131,237.8
Q3: July - September	23,421	4,582,849	24,600	2,800,899	7,668.4	54,924	54,943	2,567,503	2,635,974	419,143,151	1,147,551.4
Q4: October - December	27,176	4,717,888	28,482	3,938,381	10,782.7	77,799	77,858	3,591,535	3,685,217	422,263,178	1,156,093.6
2015											
Q1: January - March	29,406	4,645,087	30,675	2,999,494	8,212.2	57,741	57,774	2,738,310	2,811,570	414,708,818	1,135,410.9
Q2: April - June	30,231	4,665,610	31,953	2,928,716	8,018.4	52,936	52,947	2,674,149	2,727,473	422,021,595	1,155,432.2
Q3: July - September	29,663	4,685,143	31,098	2,177,553	5,961.8	39,964	40,028	1,979,832	2,042,736	428,595,018	1,173,429.2
Q4: October - December	28,915	4,814,313	30,242	2,212,665	6,057.9	41,718	41,801	2,016,336	2,071,336	431,379,127	1,181,051.7
2016											
Q1: January - March	28,817	4,744,390	30,029	1,997,113	5,467.8	38,707	38,725	1,817,680	1,857,182	429,175,586	1,175,018.7
Q2: April - June	29,358	4,780,488	30,845	2,530,982	6,929.5	45,123	45,167	2,307,268	2,390,553	432,593,994	1,184,377.8
Q3: July - September	29,467	4,805,865	30,815	1,905,697	5,217.5	36,248	36,279	1,731,118	1,800,160	439,774,638	1,204,037.3
Q4: October - December	29,930	4,937,563	31,266	1,950,855	5,341.1	37,394	37,495	1,764,793	1,848,326	442,967,563	1,212,779.1
2017											
Q1: January - March	30,276	4,873,161	31,467	1,776,609	4,864.1	34,486	34,491	1,608,151	1,685,546	436,004,367	1,193,714.9
Q2: April - June	32,622	4,907,955	34,125	3,759,247	10,292.3	117,384	117,865	3,487,536	5,203,826	444,175,988	1,216,087.6

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
Q3: July - September	33,230	4,936,448	34,555	2,750,652	7,530.9	68,970	69,111	2,536,627	3,726,743	451,687,342	1,236,652.5
Q4: October - December	34,392	5,069,944	35,782	2,433,642	6,662.9	62,069	62,373	2,224,750	3,007,612	454,992,784	1,245,702.4
2018											
Q1: January - March	35,516	5,009,441	36,913	2,349,500	6,432.6	60,971	61,094	2,141,942	2,845,536	448,081,868	1,226,781.3
Q2: April - June	38,039	5,065,454	39,785	2,948,218	8,071.8	69,870	70,112	2,690,607	3,488,322	457,522,023	1,252,627.0
Q3: July - September	43,995	5,266,840	45,351	2,939,929	8,049.1	74,761	75,091	2,591,979	3,252,949	481,195,229	1,317,440.7
Q4: October - December	39,447	5,455,501	40,872	2,082,249	5,700.9	53,994	54,342	1,883,573	2,625,701	484,949,048	1,327,718.1
2019											
Q1: January - March	35,542	5,335,320	36,767	1,611,371	4,411.7	44,550	44,733	1,463,132	2,145,900	477,391,285	1,307,026.1
Q2: April - June	35,619	5,230,851	37,164	2,000,607	5,477.4	55,466	55,742	1,820,961	2,630,472	473,423,000	1,296,161.5
Q3: July - September	36,448	5,238,302	37,805	1,769,448	4,844.5	48,551	48,768	1,604,560	2,315,112	479,462,629	1,312,697.1
Q4: October - December	42,047	5,398,994	43,468	2,246,307	6,150.1	61,140	61,347	1,948,949	2,658,802	482,234,381	1,320,285.8
2020											
Q1: January - March	45,559	5,274,674	47,224	1,574,547	4,310.9	46,278	46,453	1,359,410	1,884,611	477,404,777	1,307,063.0
Q2: April - June	46,454	5,314,177	48,868	1,342,200	3,674.7	34,908	35,023	1,110,586	1,441,652	480,871,974	1,316,555.7
Q3: July - September	44,603	5,342,086	46,118	621,103	1,700.5	16,914	16,983	553,895	802,402	489,018,992	1,338,861.0
Q4: October - December	41,205	5,497,741	42,693	225,703	617.9	9,231	9,251	212,160	323,035	491,696,965	1,346,192.9
Unclassified Valsartan Dispensings											
2012											
Q2: April - June	3,159	4,295,288	3,159	1,301,284	3,562.7	31,137	31,295	1,169,519	1,246,613	260,972,589	714,504.0
Q3: July - September	7,071	4,341,292	7,256	1,681,785	4,604.5	44,798	45,048	1,506,088	1,620,911	397,029,118	1,087,006.5
Q4: October - December	11,023	4,471,611	11,401	2,881,233	7,888.4	76,933	77,157	2,609,810	2,732,767	400,716,062	1,097,100.8
2013											
Q1: January - March	13,356	4,415,575	13,856	2,113,492	5,786.4	58,155	58,392	1,909,307	1,995,144	394,745,345	1,080,753.9
Q2: April - June	15,705	4,449,786	16,387	2,110,243	5,777.5	56,782	57,212	1,898,292	2,031,304	402,433,231	1,101,802.1
Q3: July - September	16,982	4,483,237	17,641	1,607,758	4,401.8	43,793	43,935	1,432,927	1,526,096	409,989,915	1,122,491.2
Q4: October - December	17,739	4,619,995	18,466	1,477,998	4,046.5	41,535	41,859	1,317,522	1,419,508	413,569,252	1,132,290.9
2014											
Q1: January - March	18,201	4,546,590	18,891	1,592,427	4,359.8	48,477	48,876	1,427,299	1,507,520	406,707,670	1,113,504.9
Q2: April - June	19,094	4,568,552	19,975	2,170,445	5,942.4	55,239	55,449	1,947,556	2,028,373	413,184,593	1,131,237.8
Q3: July - September	18,920	4,582,849	19,650	1,354,882	3,709.5	36,191	36,305	1,205,643	1,270,443	419,143,151	1,147,551.4
Q4: October - December	19,527	4,717,888	20,250	1,258,888	3,446.6	33,061	33,152	1,089,337	1,158,577	422,263,178	1,156,093.6

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2015											
Q1: January - March	19,014	4,645,087	19,721	1,050,675	2,876.6	32,812	33,046	930,986	984,201	414,708,818	1,135,410.9
Q2: April - June	17,771	4,665,610	18,445	1,855,506	5,080.1	48,334	48,782	1,673,334	1,738,548	422,021,595	1,155,432.2
Q3: July - September	17,285	4,685,143	18,003	1,666,826	4,563.5	41,202	41,502	1,506,696	1,552,884	428,595,018	1,173,429.2
Q4: October - December	17,328	4,814,313	18,002	1,128,407	3,089.4	29,241	29,365	999,246	1,051,796	431,379,127	1,181,051.7
2016											
Q1: January - March	17,759	4,744,390	18,388	1,078,286	2,952.2	28,108	28,217	952,797	992,073	429,175,586	1,175,018.7
Q2: April - June	18,004	4,780,488	18,734	1,168,585	3,199.4	28,298	28,542	1,034,218	1,066,666	432,593,994	1,184,377.8
Q3: July - September	17,373	4,805,865	18,011	846,415	2,317.4	21,601	21,674	742,990	769,424	439,774,638	1,204,037.3
Q4: October - December	16,912	4,937,563	17,449	858,526	2,350.5	22,607	22,711	753,238	787,724	442,967,563	1,212,779.1
2017											
Q1: January - March	17,093	4,873,161	17,606	1,500,515	4,108.2	37,308	37,384	1,359,176	1,392,155	436,004,367	1,193,714.9
Q2: April - June	17,387	4,907,955	18,046	1,453,419	3,979.2	28,705	28,741	1,314,906	1,351,482	444,175,988	1,216,087.6
Q3: July - September	16,559	4,936,448	17,128	731,913	2,003.9	15,843	15,940	634,848	663,648	451,687,342	1,236,652.5
Q4: October - December	16,036	5,069,944	16,578	621,891	1,702.6	12,986	13,040	537,876	553,152	454,992,784	1,245,702.4
2018											
Q1: January - March	15,277	5,009,441	15,807	652,396	1,786.2	13,963	14,041	562,515	583,218	448,081,868	1,226,781.3
Q2: April - June	15,595	5,065,454	16,205	704,580	1,929.0	14,758	14,780	605,608	627,081	457,522,023	1,252,627.0
Q3: July - September	17,896	5,266,840	18,463	1,151,458	3,152.5	27,068	27,506	983,906	1,042,616	481,195,229	1,317,440.7
Q4: October - December	14,883	5,455,501	15,395	849,250	2,325.1	18,536	18,581	731,228	773,632	484,949,048	1,327,718.1
2019											
Q1: January - March	14,112	5,335,320	14,606	689,962	1,889.0	16,576	16,598	580,285	611,961	477,391,285	1,307,026.1
Q2: April - June	14,927	5,230,851	15,511	638,070	1,746.9	13,753	13,791	530,545	556,087	473,423,000	1,296,161.5
Q3: July - September	14,417	5,238,302	14,916	417,206	1,142.2	8,661	8,667	342,485	359,314	479,462,629	1,312,697.1
Q4: October - December	12,080	5,398,994	12,470	276,384	756.7	6,033	6,033	226,101	231,347	482,234,381	1,320,285.8
2020											
Q1: January - March	9,456	5,274,674	9,820	219,930	602.1	5,026	5,030	177,475	185,083	477,404,777	1,307,063.0
Q2: April - June	7,363	5,314,177	7,678	137,005	375.1	3,032	3,032	115,206	117,667	480,871,974	1,316,555.7
Q3: July - September	6,317	5,342,086	6,571	90,579	248.0	2,013	2,013	77,475	78,841	489,018,992	1,338,861.0
Q4: October - December	5,952	5,497,741	6,179	29,478	80.7	933	933	26,820	27,180	491,696,965	1,346,192.9
Recalled Valsartan Dispensings											
2012											
Q2: April - June	8,948	4,295,288	8,950	5,501,199	15,061.5	122,030	123,275	5,055,869	5,419,153	260,972,589	714,504.0

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
Q3: July - September	19,160	4,341,292	19,696	6,378,454	17,463.3	156,897	158,222	5,832,203	6,183,240	397,029,118	1,087,006.5
Q4: October - December	25,341	4,471,611	26,580	5,122,160	14,023.7	133,337	134,571	4,663,342	4,908,369	400,716,062	1,097,100.8
2013											
Q1: January - March	29,042	4,415,575	30,478	4,552,013	12,462.7	122,181	123,203	4,139,891	4,367,599	394,745,345	1,080,753.9
Q2: April - June	33,353	4,449,786	35,246	5,523,028	15,121.2	136,006	136,748	5,036,143	5,341,727	402,433,231	1,101,802.1
Q3: July - September	35,862	4,483,237	37,800	4,595,745	12,582.5	113,971	114,656	4,178,554	4,422,637	409,989,915	1,122,491.2
Q4: October - December	39,502	4,619,995	41,410	5,584,134	15,288.5	134,751	135,673	5,096,721	5,423,469	413,569,252	1,132,290.9
2014											
Q1: January - March	43,104	4,546,590	45,042	4,763,947	13,043.0	118,573	119,614	4,317,717	4,526,238	406,707,670	1,113,504.9
Q2: April - June	46,222	4,568,552	48,808	5,069,990	13,880.9	120,403	121,664	4,592,234	4,878,922	413,184,593	1,131,237.8
Q3: July - September	48,431	4,582,849	50,731	5,146,492	14,090.3	121,449	122,183	4,684,814	4,985,339	419,143,151	1,147,551.4
Q4: October - December	49,681	4,717,888	51,767	4,219,834	11,553.3	101,986	102,913	3,814,631	4,058,331	422,263,178	1,156,093.6
2015											
Q1: January - March	51,119	4,645,087	53,565	5,079,094	13,905.8	127,050	127,949	4,600,785	4,863,826	414,708,818	1,135,410.9
Q2: April - June	52,700	4,665,610	55,327	5,234,557	14,331.4	115,855	116,747	4,739,362	4,977,383	422,021,595	1,155,432.2
Q3: July - September	53,896	4,685,143	56,308	4,092,455	11,204.5	97,890	98,525	3,683,959	3,918,532	428,595,018	1,173,429.2
Q4: October - December	55,168	4,814,313	57,486	3,802,597	10,410.9	89,339	90,330	3,405,205	3,602,544	431,379,127	1,181,051.7
2016											
Q1: January - March	56,272	4,744,390	58,476	3,583,967	9,812.4	85,603	86,130	3,204,897	3,386,161	429,175,586	1,175,018.7
Q2: April - June	58,117	4,780,488	60,821	4,183,826	11,454.7	90,095	90,857	3,740,249	3,916,489	432,593,994	1,184,377.8
Q3: July - September	59,613	4,805,865	62,039	3,668,454	10,043.7	80,483	81,385	3,265,913	3,446,206	439,774,638	1,204,037.3
Q4: October - December	61,600	4,937,563	63,947	3,492,480	9,561.9	78,129	78,643	3,090,869	3,257,747	442,967,563	1,212,779.1
2017											
Q1: January - March	64,434	4,873,161	66,698	3,572,539	9,781.1	78,167	78,582	3,145,261	3,315,222	436,004,367	1,193,714.9
Q2: April - June	66,898	4,907,955	69,869	3,448,379	9,441.1	72,305	72,869	3,007,281	3,146,832	444,175,988	1,216,087.6
Q3: July - September	68,668	4,936,448	71,285	2,567,620	7,029.8	64,179	64,672	2,193,608	2,297,508	451,687,342	1,236,652.5
Q4: October - December	70,824	5,069,944	73,495	2,342,458	6,413.3	55,153	55,557	1,961,709	2,048,748	454,992,784	1,245,702.4
2018											
Q1: January - March	71,754	5,009,441	74,349	1,592,407	4,359.8	31,204	31,340	1,273,497	1,342,348	448,081,868	1,226,781.3
Q2: April - June	73,600	5,065,454	76,678	1,333,424	3,650.7	21,530	21,608	978,956	1,031,100	457,522,023	1,252,627.0
Q3: July - September	67,574	5,266,840	67,670	147,670	404.3	1,972	1,972	110,718	116,191	481,195,229	1,317,440.7
Q4: October - December	20,645	5,455,501	20,687	64,586	176.8	1,551	1,551	54,605	58,577	484,949,048	1,327,718.1

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
2019											
Q1: January - March	1,156	5,335,320	1,179	56,787	155.5	1,369	1,369	47,938	48,844	477,391,285	1,307,026.1
Q2: April - June	930	5,230,851	953	45,797	125.4	1,112	1,114	38,029	39,314	473,423,000	1,296,161.5
Q3: July - September	838	5,238,302	855	37,967	103.9	1,047	1,047	31,862	33,354	479,462,629	1,312,697.1
Q4: October - December	730	5,398,994	744	29,818	81.6	700	701	23,985	25,281	482,234,381	1,320,285.8
2020											
Q1: January - March	6,902	5,274,674	6,940	1,277,809	3,498.5	39,125	39,408	1,125,508	1,203,713	477,404,777	1,307,063.0
Q2: April - June	11,183	5,314,177	11,875	947,755	2,594.8	28,271	28,475	862,941	945,409	480,871,974	1,316,555.7
Q3: July - September	14,945	5,342,086	15,583	888,825	2,433.5	26,368	26,497	828,168	901,251	489,018,992	1,338,861.0
Q4: October - December	17,211	5,497,741	17,728	193,540	529.9	7,082	7,108	183,139	197,164	491,696,965	1,346,192.9
Recalled Angiotensin Receptor Blocker (ARB)-Containing Products (Including Valsartan)											
2012											
Q2: April - June	28,346	4,295,288	28,348	13,525,947	37,032.0	262,390	264,525	12,296,935	13,085,124	260,972,589	714,504.0
Q3: July - September	48,334	4,341,292	49,544	9,683,424	26,511.8	219,518	221,348	8,720,347	9,187,691	397,029,118	1,087,006.5
Q4: October - December	58,020	4,471,611	61,287	7,265,849	19,892.8	178,328	179,675	6,488,131	6,824,107	400,716,062	1,097,100.8
2013											
Q1: January - March	60,754	4,415,575	63,266	5,888,978	16,123.1	150,489	151,656	5,282,850	5,559,324	394,745,345	1,080,753.9
Q2: April - June	63,283	4,449,786	67,007	7,721,517	21,140.4	180,981	181,759	6,947,186	7,313,111	402,433,231	1,101,802.1
Q3: July - September	64,740	4,483,237	67,732	6,425,955	17,593.3	149,687	150,458	5,770,599	6,064,913	409,989,915	1,122,491.2
Q4: October - December	64,926	4,619,995	67,873	6,826,273	18,689.3	159,853	160,932	6,173,308	6,560,836	413,569,252	1,132,290.9
2014											
Q1: January - March	66,624	4,546,590	69,467	6,347,429	17,378.3	155,167	156,437	5,678,724	5,931,526	406,707,670	1,113,504.9
Q2: April - June	72,019	4,568,552	75,601	7,193,742	19,695.4	170,927	172,699	6,443,452	6,824,083	413,184,593	1,131,237.8
Q3: July - September	76,961	4,582,849	80,436	7,091,535	19,415.6	160,805	161,871	6,379,197	6,794,218	419,143,151	1,147,551.4
Q4: October - December	78,445	4,717,888	81,566	5,066,881	13,872.4	119,905	120,894	4,514,386	4,800,424	422,263,178	1,156,093.6
2015											
Q1: January - March	77,033	4,645,087	80,465	5,805,876	15,895.6	143,130	144,061	5,219,108	5,516,632	414,708,818	1,135,410.9
Q2: April - June	69,581	4,665,610	72,906	6,722,007	18,403.9	146,121	147,136	6,081,569	6,382,452	422,021,595	1,155,432.2
Q3: July - September	65,550	4,685,143	68,414	5,165,112	14,141.3	117,611	118,385	4,658,122	4,935,306	428,595,018	1,173,429.2
Q4: October - December	65,837	4,814,313	68,512	4,838,428	13,246.9	110,325	111,414	4,331,327	4,581,853	431,379,127	1,181,051.7
2016											
Q1: January - March	67,540	4,744,390	70,095	4,451,885	12,188.6	105,703	106,469	3,979,979	4,197,949	429,175,586	1,175,018.7
Q2: April - June	70,962	4,780,488	74,124	5,572,234	15,255.9	118,509	119,450	4,991,304	5,229,476	432,593,994	1,184,377.8

Table 2d. Summary of Prevalent Valsartan Use in the Canadian Network for Observational Drug Effect Studies (CNODES) Database Between May 1, 2012 and December 31, 2020, by Year and Quarter

Quarter	Prevalent Users ¹	Eligible Members ²	Prevalent Episodes ¹	Days At Risk	Years at Risk	Adjusted Dispensings	Raw Dispensings	Days Supplied	Amount Supplied	Eligible Member-Days ²	Eligible Member-Years ²
Q3: July - September	73,358	4,805,865	76,266	4,778,908	13,083.9	103,490	104,573	4,261,666	4,514,269	439,774,638	1,204,037.3
Q4: October - December	75,900	4,937,563	78,736	4,331,522	11,859.1	94,206	94,796	3,833,573	4,042,937	442,967,563	1,212,779.1
2017											
Q1: January - March	78,699	4,873,161	81,415	4,153,118	11,370.6	91,300	91,765	3,651,337	3,850,975	436,004,367	1,193,714.9
Q2: April - June	81,486	4,907,955	84,998	4,155,163	11,376.2	86,724	87,297	3,617,504	3,789,480	444,175,988	1,216,087.6
Q3: July - September	83,004	4,936,448	86,069	3,169,556	8,677.8	76,224	76,761	2,711,762	2,850,235	451,687,342	1,236,652.5
Q4: October - December	85,776	5,069,944	88,829	3,154,455	8,636.4	72,757	73,280	2,650,265	2,768,714	454,992,784	1,245,702.4
2018											
Q1: January - March	86,023	5,009,441	88,995	2,115,099	5,790.8	41,134	41,305	1,710,182	1,798,957	448,081,868	1,226,781.3
Q2: April - June	86,594	5,065,454	90,112	1,846,123	5,054.4	33,253	33,429	1,406,468	1,486,955	457,522,023	1,252,627.0
Q3: July - September	79,986	5,266,840	80,453	758,600	2,076.9	14,326	14,394	612,062	646,524	481,195,229	1,317,440.7
Q4: October - December	34,223	5,455,501	34,665	638,187	1,747.3	11,365	11,408	491,833	517,944	484,949,048	1,327,718.1
2019											
Q1: January - March	16,331	5,335,320	16,547	543,153	1,487.1	8,325	8,345	394,151	408,875	477,391,285	1,307,026.1
Q2: April - June	11,491	5,230,851	11,556	69,615	190.6	1,851	1,853	55,729	57,825	473,423,000	1,296,161.5
Q3: July - September	2,093	5,238,302	2,120	55,496	151.9	1,784	1,784	45,211	47,775	479,462,629	1,312,697.1
Q4: October - December	1,122	5,398,994	1,140	38,404	105.1	1,066	1,067	30,001	31,761	482,234,381	1,320,285.8
2020											
Q1: January - March	7,129	5,274,674	7,167	1,283,532	3,514.1	39,324	39,607	1,129,474	1,208,515	477,404,777	1,307,063.0
Q2: April - June	11,325	5,314,177	12,019	954,570	2,613.5	28,478	28,682	867,750	950,154	480,871,974	1,316,555.7
Q3: July - September	15,093	5,342,086	15,737	897,118	2,456.2	26,767	26,898	835,265	908,873	489,018,992	1,338,861.0
Q4: October - December	17,530	5,497,741	18,052	198,451	543.3	7,354	7,382	187,669	202,198	491,696,965	1,346,192.9

¹Total number of users by year quarter may not sum up to total patients in Table 1 because cohort re-entry was allowed, enabling multiple counts for patients with multiple exposure episodes during the study period

²Eligible Members, Member-Days, and Member-Years are reflective of the number of patients that met all cohort entry criteria on at least one day during the query period

Appendix A. Start and End Dates for Each Data Partner as of Request Distribution Date (July 29, 2022)

DP ID	Start Date ¹	End Date ¹
DP01	01/01/1996	12/31/2020
DP02	01/01/2000	12/31/2020
DP03	04/01/1996	12/31/2020
DP04	04/01/1995	12/31/2020

¹The start and end dates are based on the minimum and maximum dates within each DP. The month with the maximum date must have at least 80% of the number of records in the previous month.

Appendix B. List of Generic and Brand Names of Medical Products Used to Define Branded Valsartans in this Request

Generic Name	Brand Name
Branded Valsartan	
valsartan	DIOVAN
valsartan/hydrochlorothiazide	DIOVAN-HCT
sacubitril/valsartan	ENTRESTO
valsartan/hydrochlorothiazide	SANDOZ VALSARTAN HCT

Appendix C. List of Generic Names, Brand Names, and Manufacturers of Medical Products Used to Define Impurity Identified, No Impurity Identified, Branded, and Unclassified Valsartans in this Request

Generic Name	Brand Name	Manufacturer
Valsartan with Impurity		
valsartan	AURO-VALSARTAN	Aurobindo Pharma Limited, Unit-XI
valsartan/hydrochlorothiazide	TEVA-VALSARTAN/HCTZ	Zhejiang Huahai Pharmaceuticals
valsartan	ACT VALSARTAN	Zhejiang Huahai Pharmaceuticals
valsartan	SANDOZ VALSARTAN	Zhejiang Huahai Pharmaceuticals
valsartan/hydrochlorothiazide	TEVA-VALSARTAN/HCTZ	Zhejiang Huahai Pharmaceutical Co., Ltd.
valsartan	MYLAN-VALSARTAN	Mylan Laboratories Limited
valsartan/hydrochlorothiazide	AURO-VALSARTAN HCT	Aurobindo Pharma Limited, Unit-XI
valsartan	AURO-VALSARTAN	Aurobindo Pharma Limited
valsartan	MYLAN	MYLAN
Valsartan without Impurity		
valsartan	TEVA-VALSARTAN	Jubilant Generics Limited
valsartan	TARO-VALSARTAN	Sun Pharmaceutical Industries Limited
valsartan	AURO-VALSARTAN	Aurobindo Pharma Limited, Unit-XI
Recalled Valsartan		
valsartan	ACT VALSARTAN	Zhejiang Huahai Pharmaceuticals
valsartan	SANDOZ VALSARTAN	Zhejiang Huahai Pharmaceuticals
valsartan/hydrochlorothiazide	TEVA-VALSARTAN/HCTZ	Zhejiang Huahai Pharmaceuticals
valsartan	VALSARTAN	Zhejiang Huahai Pharmaceuticals
Unclassified Valsartan		
valsartan	APO-VALSARTAN	
valsartan/hydrochlorothiazide	APO-VALSARTAN/HCTZ	
valsartan/hydrochlorothiazide	AURO-VALSARTAN HCT	
valsartan	AVA-VALSARTAN	
valsartan/hydrochlorothiazide	AVA-VALSARTAN HCT	
valsartan	DOM-VALSARTAN	
valsartan	M-VALSARTAN	
valsartan/hydrochlorothiazide	MYLAN-VALSARTAN HCTZ	
valsartan	NOVO-VALSARTAN	
valsartan/hydrochlorothiazide	NOVO-VALSARTAN/HCTZ	
valsartan	PMS-VALSARTAN	
valsartan/hydrochlorothiazide	PMS-VALSARTAN-HCTZ	
valsartan	Q-VALSARTAN	
valsartan/hydrochlorothiazide	Q-VALSARTAN HCTZ	
valsartan	RIVA-VALSARTAN	
valsartan	TARO-VALSARTAN	
valsartan	TEVA-VALSARTAN	
valsartan	VALSARTAN	
valsartan/hydrochlorothiazide	VALSARTAN HCT	
valsartan/hydrochlorothiazide	VALSARTAN-HCTZ	

Appendix D. List of Generic Names and Manufacturers of Medical Products Used to Define Recalled Non-Valsartan Angiotensin Receptor Blockers (ARBs) in this Request

Generic Name	Manufacturer
Recalled Non-Valsartan ARBs	
irbesartan	TEVA API India Ltd.
irbesartan/hydrochlorothiazide	Aurobindo Pharma Limited, Unit-I
losartan	Hereto Laboratories Limited Unit 1
losartan/hydrochlorothiazide	Hereto Laboratories Limited Unit 1

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
Angina			
I201	Angina pectoris with documented spasm	Diagnosis	ICD-10-CA
I2080	Atypical angina	Diagnosis	ICD-10-CA
I2088	Other forms of angina pectoris	Diagnosis	ICD-10-CA
I209	Angina pectoris, unspecified	Diagnosis	ICD-10-CA
I250	Atherosclerotic cardiovascular disease, so described	Diagnosis	ICD-10-CA
I251	Atherosclerotic heart disease	Diagnosis	ICD-10-CA
I2510	Atherosclerotic heart disease of native coronary artery	Diagnosis	ICD-10-CA
I2511	Atherosclerotic heart disease of autologous vein bypass graft	Diagnosis	ICD-10-CA
I2512	Atherosclerotic heart disease of nonautologous biological bypass graft	Diagnosis	ICD-10-CA
I2513	Atherosclerotic heart disease of artery bypass graft	Diagnosis	ICD-10-CA
I2514	Atherosclerotic heart disease of unspecified type of bypass graft	Diagnosis	ICD-10-CA
I2515	Atherosclerotic heart disease of coronary artery of transplanted heart	Diagnosis	ICD-10-CA
I2519	Atherosclerotic heart disease of unspecified type of vessel, native or graft	Diagnosis	ICD-10-CA
I252	Old myocardial infarction	Diagnosis	ICD-10-CA
I253	Aneurysm of heart	Diagnosis	ICD-10-CA
I254	Coronary artery aneurysm	Diagnosis	ICD-10-CA
I255	Ischaemic cardiomyopathy	Diagnosis	ICD-10-CA
I256	Silent myocardial ischaemia	Diagnosis	ICD-10-CA
I258	Other forms of chronic ischaemic heart disease	Diagnosis	ICD-10-CA
I259	Chronic ischaemic heart disease, unspecified	Diagnosis	ICD-10-CA
Atrial Fibrillation			
I480	Atrial fibrillation	Diagnosis	ICD-10-CA
I4800	Paroxysmal atrial fibrillation	Diagnosis	ICD-10-CA
I4801	Persistent atrial fibrillation	Diagnosis	ICD-10-CA
I4802	Chronic atrial fibrillation	Diagnosis	ICD-10-CA
I481	Atrial flutter	Diagnosis	ICD-10-CA
I483	Typical atrial flutter	Diagnosis	ICD-10-CA
I484	Atypical atrial flutter	Diagnosis	ICD-10-CA
I4890	Atrial fibrillation, unspecified	Diagnosis	ICD-10-CA
I4891	Atrial flutter, unspecified	Diagnosis	ICD-10-CA
Diabetes			
E100	Type 1 diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1010	Type 1 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E10100	Type 1 diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E10101	Type 1 diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1011	Type 1 diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E10110	Type 1 diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E10111	Type 1 diabetes mellitus with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1012	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E10120	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA
E10121	Type 1 diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1020	Type 1 diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10200	Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agent	Diagnosis	ICD-10-CA
E10201	Type 1 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10202	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10203	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10204	Type 1 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10209	Type 1 diabetes mellitus with incipient diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1021	Type 1 diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E10210	Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agent	Diagnosis	ICD-10-CA
E10211	Type 1 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10212	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10213	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10214	Type 1 diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10219	Type 1 diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1022	Type 1 diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E10220	Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10221	Type 1 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E10222	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10223	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10224	Type 1 diabetes mellitus with end stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10229	Type 1 diabetes mellitus with end stage renal disease [ESRD], level of control unspecified	Diagnosis	ICD-10-CA
E1023	Type 1 diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1028	Type 1 diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA
E10280	Type 1 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10281	Type 1 diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10282	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10283	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10284	Type 1 diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10289	Type 1 diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E10290	Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10291	Type 1 diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10292	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10293	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10294	Type 1 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10299	Type 1 diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1030	Type 1 diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E10300	Type 1 diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10301	Type 1 diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10302	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10303	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10304	Type 1 diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10309	Type 1 diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1031	Type 1 diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E10310	Type 1 diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10311	Type 1 diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10312	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10313	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10314	Type 1 diabetes mellitus with preproliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10319	Type 1 diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1032	Type 1 diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E10320	Type 1 diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10321	Type 1 diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10322	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10323	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10324	Type 1 diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10329	Type 1 diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1033	Type 1 diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E10330	Type 1 diabetes mellitus with other retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10331	Type 1 diabetes mellitus with other retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10332	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10333	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10334	Type 1 diabetes mellitus with other retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10339	Type 1 diabetes mellitus with other retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E10340	Type 1 diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10341	Type 1 diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10342	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10343	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10344	Type 1 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10349	Type 1 diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1035	Type 1 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E10350	Type 1 diabetes mellitus with cataract, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10351	Type 1 diabetes mellitus with cataract, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10352	Type 1 diabetes mellitus with cataract, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10353	Type 1 diabetes mellitus with cataract, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10354	Type 1 diabetes mellitus with cataract, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10359	Type 1 diabetes mellitus with cataract, level of control unspecified	Diagnosis	ICD-10-CA
E1036	Type 1 diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1038	Type 1 diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E10380	Type 1 diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10381	Type 1 diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10382	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10383	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10384	Type 1 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10389	Type 1 diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA
E10390	Type 1 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10391	Type 1 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10392	Type 1 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10393	Type 1 diabetes mellitus with ophthalmic complication,unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10394	Type 1 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10399	Type 1 diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1040	Type 1 diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E10400	Type 1 diabetes mellitus with mononeuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10401	Type 1 diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10402	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10403	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10404	Type 1 diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10409	Type 1 diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1041	Type 1 diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA
E10410	Type 1 diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10411	Type 1 diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10412	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10413	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10414	Type 1 diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10419	Type 1 diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1042	Type 1 diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10420	Type 1 diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10421	Type 1 diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10422	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10423	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10424	Type 1 diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10429	Type 1 diabetes mellitus with autonomic neuropathy, level of control unspecified	Diagnosis	ICD-10-CA
E10480	Type 1 diabetes mellitus with other specified neurological complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10481	Type 1 diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10482	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10483	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10484	Type 1 diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10489	Type 1 diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E10490	Type 1 diabetes mellitus with neuropathy unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10491	Type 1 diabetes mellitus with neuropathy unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10492	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10493	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10494	Type 1 diabetes mellitus with neuropathy unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10499	Type 1 diabetes mellitus with neuropathy unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1050	Type 1 diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA
E10500	Type 1 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10501	Type 1 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10502	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10503	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10504	Type 1 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10509	Type 1 diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1051	Type 1 diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10510	Type 1 diabetes mellitus with peripheral angiopathy with gangrene adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10511	Type 1 diabetes mellitus with peripheral angiopathy with gangrene adequately controlled with insulin	Diagnosis	ICD-10-CA
E10512	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10513	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10514	Type 1 diabetes mellitus with peripheral angiopathy with gangrene inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10519	Type 1 diabetes mellitus with peripheral angiopathy with gangrene level of control unspecified	Diagnosis	ICD-10-CA
E1052	Type 1 diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E10580	Type 1 diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10581	Type 1 diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10582	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10583	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10584	Type 1 diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10589	Type 1 diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E10590	Type 1 diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10591	Type 1 diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10592	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10593	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10594	Type 1 diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10599	Type 1 diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1060	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E10600	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10601	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10602	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10603	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10604	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10609	Type 1 diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1061	Type 1 diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E10610	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10611	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10612	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10613	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10614	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10619	Type 1 diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1062	Type 1 diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E10620	Type 1 diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10621	Type 1 diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10622	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10623	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10624	Type 1 diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10629	Type 1 diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1063	Type 1 diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E10630	Type 1 diabetes mellitus with hypoglycemia adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10631	Type 1 diabetes mellitus with hypoglycemia adequately controlled with insulin	Diagnosis	ICD-10-CA
E10632	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10633	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10634	Type 1 diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10639	Type 1 diabetes mellitus with hypoglycemia level of control unspecified	Diagnosis	ICD-10-CA
E1064	Type 1 diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA
E1068	Type 1 diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E10680	Type 1 diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10681	Type 1 diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10682	Type 1 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10683	Type 1 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10684	Type 1 diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10689	Type 1 diabetes mellitus with other specified complication level of control unspecified	Diagnosis	ICD-10-CA
E1070	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic)	Diagnosis	ICD-10-CA
E10700	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10701	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E10702	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10703	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10704	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10709	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1071	Type 1 diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1078	Type 1 diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E10780	Type 1 diabetes mellitus with other specified multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10781	Type 1 diabetes mellitus with other specified multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10782	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10783	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E10784	Type 1 diabetes mellitus with other specified multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10789	Type 1 diabetes mellitus with other specified multiple complications, level of control unspecified	Diagnosis	ICD-10-CA
E109	Type 1 diabetes mellitus without (mention of) complication	Diagnosis	ICD-10-CA
E10900	Type 1 diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E10901	Type 1 diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E10902	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E10903	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E10904	Type 1 diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E10909	Type 1 diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
E110	Type 2 diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1100	Type 2 diabetes mellitus with hyperosmolarity (without coma)	Diagnosis	ICD-10-CA
E1101	Type 2 diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CA
E1110	Type 2 diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E11100	Type 2 diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E11101	Type 2 diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1111	Type 2 diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E11110	Type 2 diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E11111	Type 2 diabetes mellitus with lactic acidosis (alone) with coma	Diagnosis	ICD-10-CA
E1112	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E11120	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA
E11121	Type 2 diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1120	Type 2 diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA
E11200	Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11201	Type 2 diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11202	Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11203	Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11204	Type 2 diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11209	Type 2 diabetes mellitus with incipient diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1121	Type 2 diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E11210	Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11211	Type 2 diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11212	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11213	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11214	Type 2 diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11219	Type 2 diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1122	Type 2 diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E11220	Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11221	Type 2 diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E11222	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11223	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11224	Type 2 diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11229	Type 2 diabetes mellitus with end-stage renal disease [ESRD] ,level of control unspecified	Diagnosis	ICD-10-CA
E1123	Type 2 diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1128	Type 2 diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA
E11280	Type 2 diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11281	Type 2 diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11282	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11283	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11284	Type 2 diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11289	Type 2 diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E11290	Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11291	Type 2 diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11292	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11293	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11294	Type 2 diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11299	Type 2 diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1130	Type 2 diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E11300	Type 2 diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11301	Type 2 diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11302	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11303	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11304	Type 2 diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11309	Type 2 diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E1131	Type 2 diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E11310	Type 2 diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11311	Type 2 diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11312	Type 2 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11313	Type 2 diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11314	Type 2 diabetes mellitus with preproliferative retinopathy inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11319	Type 2 diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1132	Type 2 diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E11320	Type 2 diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11321	Type 2 diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11322	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11323	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11324	Type 2 diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11329	Type 2 diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1133	Type 2 diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E11330	Type 2 diabetes mellitus with other retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11331	Type 2 diabetes mellitus with other retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11332	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11333	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11334	Type 2 diabetes mellitus with other retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11339	Type 2 diabetes mellitus with other retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E11340	Type 2 diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11341	Type 2 diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11342	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11343	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11344	Type 2 diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11349	Type 2 diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1135	Type 2 diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E11350	Type 2 diabetes mellitus with cataract, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11351	Type 2 diabetes mellitus with cataract, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11352	Type 2 diabetes mellitus with cataract, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11353	Type 2 diabetes mellitus with cataract, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11354	Type 2 diabetes mellitus with cataract, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11359	Type 2 diabetes mellitus with cataract, level of control unspecified	Diagnosis	ICD-10-CA
E1136	Type 2 diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1138	Type 2 diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E11380	Type 2 diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11381	Type 2 diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11382	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11383	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11384	Type 2 diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11389	Type 2 diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA
E11390	Type 2 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11391	Type 2 diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11392	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11393	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11394	Type 2 diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11399	Type 2 diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1140	Type 2 diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E11400	Type 2 diabetes mellitus with mononeuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11401	Type 2 diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11402	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11403	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11404	Type 2 diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11409	Type 2 diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1141	Type 2 diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11410	Type 2 diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11411	Type 2 diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11412	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11413	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11414	Type 2 diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11419	Type 2 diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1142	Type 2 diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA
E11420	Type 2 diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11421	Type 2 diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11422	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11423	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11424	Type 2 diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11429	Type 2 diabetes mellitus with autonomic neuropathy level of control unspecified	Diagnosis	ICD-10-CA
E11480	Type 2 diabetes mellitus with other specified neurological complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11481	Type 2 diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11482	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11483	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11484	Type 2 diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11489	Type 2 diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E11490	Type 2 diabetes mellitus with neurological complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11491	Type 2 diabetes mellitus with neurological complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11492	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11493	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11494	Type 2 diabetes mellitus with neurological complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11499	Type 2 diabetes mellitus with neurological complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1150	Type 2 diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11500	Type 2 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11501	Type 2 diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11502	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11503	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11504	Type 2 diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11509	Type 2 diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1151	Type 2 diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA
E11510	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11511	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11512	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11513	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11514	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11519	Type 2 diabetes mellitus with peripheral angiopathy with gangrene, level of control unspecified	Diagnosis	ICD-10-CA
E1152	Type 2 diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E11580	Type 2 diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11581	Type 2 diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11582	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11583	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11584	Type 2 diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11589	Type 2 diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E11590	Type 2 diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11591	Type 2 diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11592	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11593	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11594	Type 2 diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11599	Type 2 diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1160	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E11600	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet and oral agents	Diagnosis	ICD-10-CA
E11601	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11602	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11603	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11604	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11609	Type 2 diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1161	Type 2 diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E11610	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11611	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11612	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11613	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11614	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11619	Type 2 diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1162	Type 2 diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E11620	Type 2 diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11621	Type 2 diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11622	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11623	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11624	Type 2 diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11629	Type 2 diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1163	Type 2 diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E11630	Type 2 diabetes mellitus with hypoglycemia adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E11631	Type 2 diabetes mellitus with hypoglycemia adequately controlled with insulin	Diagnosis	ICD-10-CA
E11632	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11633	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11634	Type 2 diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11639	Type 2 diabetes mellitus with hypoglycemia level of control unspecified	Diagnosis	ICD-10-CA
E1164	Type 2 diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA
E1168	Type 2 diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E11680	Type 2 diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11681	Type 2 diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11682	Type 2 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11683	Type 2 diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11684	Type 2 diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11689	Type 2 diabetes mellitus with other specified complication level of control unspecified	Diagnosis	ICD-10-CA
E1170	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic)	Diagnosis	ICD-10-CA
E11700	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11701	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E11702	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11703	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11704	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11709	Type 2 diabetes mellitus with foot ulcer (angiopathic)(neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1171	Type 2 diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1178	Type 2 diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E11780	Type 2 diabetes mellitus with other multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11781	Type 2 diabetes mellitus with other multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11782	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11783	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11784	Type 2 diabetes mellitus with other multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11789	Type 2 diabetes mellitus with other multiple complications, level of control unspecified	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E119	Type 2 diabetes mellitus without (mention of) complications	Diagnosis	ICD-10-CA
E11900	Type 2 diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E11901	Type 2 diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E11902	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E11903	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E11904	Type 2 diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E11909	Type 2 diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
E130	Other specified diabetes mellitus with coma	Diagnosis	ICD-10-CA
E1300	Other specified diabetes mellitus with hyperosmolarity (without coma)	Diagnosis	ICD-10-CA
E1301	Other specified diabetes mellitus with hyperosmolarity with coma	Diagnosis	ICD-10-CA
E1310	Other specified diabetes mellitus with ketoacidosis	Diagnosis	ICD-10-CA
E13100	Other specified diabetes mellitus with ketoacidosis (alone) without coma	Diagnosis	ICD-10-CA
E13101	Other specified diabetes mellitus with ketoacidosis (alone) with coma	Diagnosis	ICD-10-CA
E1311	Other specified diabetes mellitus with lactic acidosis	Diagnosis	ICD-10-CA
E13110	Other specified diabetes mellitus with lactic acidosis (alone) without coma	Diagnosis	ICD-10-CA
E13111	Other specified diabetes mellitus with lactic acidosis (alone) with coma	Diagnosis	ICD-10-CA
E1312	Other specified diabetes mellitus with ketoacidosis with lactic acidosis	Diagnosis	ICD-10-CA
E13120	Other specified diabetes mellitus with ketoacidosis with lactic acidosis without coma	Diagnosis	ICD-10-CA
E13121	Other specified diabetes mellitus with ketoacidosis with lactic acidosis with coma	Diagnosis	ICD-10-CA
E1320	Other specified diabetes mellitus with incipient diabetic nephropathy	Diagnosis	ICD-10-CA
E13200	Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13201	Other specified diabetes mellitus with incipient diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13202	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13203	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13204	Other specified diabetes mellitus with incipient diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13209	Other specified diabetes mellitus with incipient diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1321	Other specified diabetes mellitus with established diabetic nephropathy	Diagnosis	ICD-10-CA
E13210	Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13211	Other specified diabetes mellitus with established diabetic nephropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13212	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13213	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13214	Other specified diabetes mellitus with established diabetic nephropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13219	Other specified diabetes mellitus with established diabetic nephropathy, level of control unspecified	Diagnosis	ICD-10-CA
E1322	Other specified diabetes mellitus with end-stage renal disease [ESRD]	Diagnosis	ICD-10-CA
E13220	Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13221	Other specified diabetes mellitus with end-stage renal disease [ESRD], adequately controlled with insulin	Diagnosis	ICD-10-CA
E13222	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13223	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13224	Other specified diabetes mellitus with end-stage renal disease [ESRD], inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13229	Other specified diabetes mellitus with end-stage renal disease [ESRD], level of control unspecified	Diagnosis	ICD-10-CA
E1323	Other specified diabetes mellitus with established or advanced kidney disease	Diagnosis	ICD-10-CA
E1328	Other specified diabetes mellitus with other specified kidney complication not elsewhere classified	Diagnosis	ICD-10-CA
E13280	Other specified diabetes mellitus with other specified renal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13281	Other specified diabetes mellitus with other specified renal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13282	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13283	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13284	Other specified diabetes mellitus with other specified renal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13289	Other specified diabetes mellitus with other specified renal complication, level of control unspecified	Diagnosis	ICD-10-CA
E13290	Other specified diabetes mellitus with renal complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13291	Other specified diabetes mellitus with renal complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13292	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13293	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13294	Other specified diabetes mellitus with renal complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13299	Other specified diabetes mellitus with renal complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1330	Other specified diabetes mellitus with background retinopathy	Diagnosis	ICD-10-CA
E13300	Other specified diabetes mellitus with background retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13301	Other specified diabetes mellitus with background retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13302	Other specified diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13303	Other specified diabetes mellitus with background retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13304	Other specified diabetes mellitus with background retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13309	Other specified diabetes mellitus with background retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1331	Other specified diabetes mellitus with preproliferative retinopathy	Diagnosis	ICD-10-CA
E13310	Other specified diabetes mellitus with preproliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13311	Other specified diabetes mellitus with preproliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13312	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13313	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13314	Other specified diabetes mellitus with preproliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13319	Other specified diabetes mellitus with preproliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1332	Other specified diabetes mellitus with proliferative retinopathy	Diagnosis	ICD-10-CA
E13320	Other specified diabetes mellitus with proliferative retinopathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13321	Other specified diabetes mellitus with proliferative retinopathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13322	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13323	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13324	Other specified diabetes mellitus with proliferative retinopathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13329	Other specified diabetes mellitus with proliferative retinopathy, level of control unspecified	Diagnosis	ICD-10-CA
E1333	Other specified diabetes mellitus with other retinopathy	Diagnosis	ICD-10-CA
E13330	Other specified diabetes mellitus with other retinopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13331	Other specified diabetes mellitus with other retinopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13332	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13333	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13334	Other specified diabetes mellitus with other retinopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13339	Other specified diabetes mellitus with other retinopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E13340	Other specified diabetes mellitus with advanced ophthalmic disease, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13341	Other specified diabetes mellitus with advanced ophthalmic disease, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13342	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13343	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13344	Other specified diabetes mellitus with advanced ophthalmic disease, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13349	Other specified diabetes mellitus with advanced ophthalmic disease, level of control unspecified	Diagnosis	ICD-10-CA
E1335	Other specified diabetes mellitus with diabetic cataract	Diagnosis	ICD-10-CA
E13350	Other specified diabetes mellitus with cataract adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13351	Other specified diabetes mellitus with cataract adequately controlled with insulin	Diagnosis	ICD-10-CA
E13352	Other specified diabetes mellitus with cataract inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13353	Other specified diabetes mellitus with cataract inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13354	Other specified diabetes mellitus with cataract inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13359	Other specified diabetes mellitus with cataract level of control unspecified	Diagnosis	ICD-10-CA
E1336	Other specified diabetes mellitus with advanced ophthalmic disease	Diagnosis	ICD-10-CA
E1338	Other specified diabetes mellitus with other specified ophthalmic complication not elsewhere classified	Diagnosis	ICD-10-CA
E13380	Other specified diabetes mellitus with other specified ophthalmic complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13381	Other specified diabetes mellitus with other specified ophthalmic complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13382	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet and oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13383	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with diet and oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13384	Other specified diabetes mellitus with other specified ophthalmic complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13389	Other specified diabetes mellitus with other specified ophthalmic complication, level of control unspecified	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13390	Other specified diabetes mellitus with ophthalmic complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13391	Other specified diabetes mellitus with ophthalmic complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13392	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13393	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13394	Other specified diabetes mellitus with ophthalmic complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13399	Other specified diabetes mellitus with ophthalmic complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1340	Other specified diabetes mellitus with mononeuropathy	Diagnosis	ICD-10-CA
E13400	Other specified diabetes mellitus with mononeuropathy NEC, adequately controlled with diet and oral agents	Diagnosis	ICD-10-CA
E13401	Other specified diabetes mellitus with mononeuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13402	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13403	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13404	Other specified diabetes mellitus with mononeuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13409	Other specified diabetes mellitus with mononeuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1341	Other specified diabetes mellitus with polyneuropathy	Diagnosis	ICD-10-CA
E13410	Other specified diabetes mellitus with polyneuropathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13411	Other specified diabetes mellitus with polyneuropathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13412	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13413	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13414	Other specified diabetes mellitus with polyneuropathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13419	Other specified diabetes mellitus with polyneuropathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1342	Other specified diabetes mellitus with autonomic neuropathy	Diagnosis	ICD-10-CA
E13420	Other specified diabetes mellitus with autonomic neuropathy, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13421	Other specified diabetes mellitus with autonomic neuropathy, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13422	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13423	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13424	Other specified diabetes mellitus with autonomic neuropathy, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13429	Other specified diabetes mellitus with autonomic neuropathy, level of control unspecified	Diagnosis	ICD-10-CA
E13480	Other specified diabetes mellitus with other specified neurological complication ,adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13481	Other specified diabetes mellitus with other specified neurological complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13482	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13483	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13484	Other specified diabetes mellitus with other specified neurological complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13489	Other specified diabetes mellitus with other specified neurological complication, level of control unspecified	Diagnosis	ICD-10-CA
E13490	Other specified diabetes mellitus with neurological complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13491	Other specified diabetes mellitus with neurological complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13492	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13493	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13494	Other specified diabetes mellitus with neurological complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13499	Other specified diabetes mellitus with neurological complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1350	Other specified diabetes mellitus with peripheral angiopathy	Diagnosis	ICD-10-CA
E13500	Other specified diabetes mellitus with peripheral angiopathy NEC, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13501	Other specified diabetes mellitus with peripheral angiopathy NEC, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13502	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13503	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13504	Other specified diabetes mellitus with peripheral angiopathy NEC, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13509	Other specified diabetes mellitus with peripheral angiopathy NEC, level of control unspecified	Diagnosis	ICD-10-CA
E1351	Other specified diabetes mellitus with peripheral angiopathy with gangrene	Diagnosis	ICD-10-CA
E13510	Other specified diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13511	Other specified diabetes mellitus with peripheral angiopathy with gangrene, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13512	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13513	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13514	Other specified diabetes mellitus with peripheral angiopathy with gangrene, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13519	Other specified diabetes mellitus with peripheral angiopathy with gangrene, level of control unspecified	Diagnosis	ICD-10-CA
E1352	Other specified diabetes mellitus with certain circulatory complications	Diagnosis	ICD-10-CA
E13580	Other specified diabetes mellitus with other specified circulatory complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13581	Other specified diabetes mellitus with other specified circulatory complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13582	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13583	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13584	Other specified diabetes mellitus with other specified circulatory complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13589	Other specified diabetes mellitus with other specified circulatory complication, level of control unspecified	Diagnosis	ICD-10-CA
E13590	Other specified diabetes mellitus with circulatory complication unspecified, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13591	Other specified diabetes mellitus with circulatory complication unspecified, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13592	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13593	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13594	Other specified diabetes mellitus with circulatory complication unspecified, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13599	Other specified diabetes mellitus with circulatory complication unspecified, level of control unspecified	Diagnosis	ICD-10-CA
E1360	Other specified diabetes mellitus with musculoskeletal and connective tissue complication	Diagnosis	ICD-10-CA
E13600	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13601	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13602	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13603	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13604	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13609	Other specified diabetes mellitus with musculoskeletal and connective tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1361	Other specified diabetes mellitus with skin and subcutaneous tissue complication	Diagnosis	ICD-10-CA
E13610	Other specified diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13611	Other specified diabetes mellitus with skin and subcutaneous tissue complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13612	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13613	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13614	Other specified diabetes mellitus with skin and subcutaneous tissue complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13619	Other specified diabetes mellitus with skin and subcutaneous tissue complication, level of control unspecified	Diagnosis	ICD-10-CA
E1362	Other specified diabetes mellitus with periodontal complication	Diagnosis	ICD-10-CA
E13620	Other specified diabetes mellitus with periodontal complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13621	Other specified diabetes mellitus with periodontal complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13622	Other specified diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13623	Other specified diabetes mellitus with periodontal complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13624	Other specified diabetes mellitus with periodontal complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13629	Other specified diabetes mellitus with periodontal complication, level of control unspecified	Diagnosis	ICD-10-CA
E1363	Other specified diabetes mellitus with hypoglycaemia	Diagnosis	ICD-10-CA
E13630	Other specified diabetes mellitus with hypoglycemia, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13631	Other specified diabetes mellitus with hypoglycemia, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13632	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13633	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13634	Other specified diabetes mellitus with hypoglycemia, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13639	Other specified diabetes mellitus with hypoglycemia, level of control unspecified	Diagnosis	ICD-10-CA
E1364	Other specified diabetes mellitus with poor control, so described	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E1368	Other specified diabetes mellitus with other specified complication, not elsewhere classified	Diagnosis	ICD-10-CA
E13680	Other specified diabetes mellitus with other specified complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13681	Other specified diabetes mellitus with other specified complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13682	Other specified diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13683	Other specified diabetes mellitus with other specified complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13684	Other specified diabetes mellitus with other specified complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13689	Other specified diabetes mellitus with other specified complication, level of control unspecified	Diagnosis	ICD-10-CA
E1370	Other specified diabetes mellitus with foot ulcer (angiopathic) (neuropathic)	Diagnosis	ICD-10-CA
E13700	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13701	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), adequately controlled with insulin	Diagnosis	ICD-10-CA
E13702	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13703	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13704	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13709	Other specified diabetes mellitus with foot ulcer (angiopathic)(neuropathic), level of control unspecified	Diagnosis	ICD-10-CA
E1371	Other specified diabetes mellitus with foot ulcer (angiopathic) (neuropathic) with gangrene	Diagnosis	ICD-10-CA
E1378	Other specified diabetes mellitus with multiple other complications	Diagnosis	ICD-10-CA
E13780	Other specified diabetes mellitus with other specified multiple complications, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA
E13781	Other specified diabetes mellitus with other specified multiple complications, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13782	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13783	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13784	Other specified diabetes mellitus with other specified multiple complications, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13789	Other specified diabetes mellitus with other specified multiple complications, level of control unspecified	Diagnosis	ICD-10-CA
E139	Other specified diabetes mellitus without (mention of) complication	Diagnosis	ICD-10-CA
E13900	Other specified diabetes mellitus without (mention of) complication, adequately controlled with diet or oral agents	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code Category	Code Type
E13901	Other specified diabetes mellitus without (mention of) complication, adequately controlled with insulin	Diagnosis	ICD-10-CA
E13902	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents (and insulin not used to stabilize)	Diagnosis	ICD-10-CA
E13903	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with diet or oral agents but adequately controlled with insulin	Diagnosis	ICD-10-CA
E13904	Other specified diabetes mellitus without (mention of) complication, inadequately controlled with insulin	Diagnosis	ICD-10-CA
E13909	Other specified diabetes mellitus without (mention of) complication, level of control unspecified	Diagnosis	ICD-10-CA
Heart Failure			
I09.9	Rheumatic Heart Disease, unspecified (Reumatic: carditis; Heart Failure)	Diagnosis	ICD-10-CA
I11	Hypertensive heart disease	Diagnosis	ICD-10-CA
I13	Hypertensive heart and renal disease	Diagnosis	ICD-10-CA
I500	Congestive heart failure	Diagnosis	ICD-10-CA
I501	Left ventricular failure	Diagnosis	ICD-10-CA
I509	Heart failure, unspecified	Diagnosis	ICD-10-CA
Hyperlipidemia			
E780	Pure hypercholesterolaemia	Diagnosis	ICD-10-CA
E781	Pure hyperglyceridaemia	Diagnosis	ICD-10-CA
E782	Mixed hyperlipidaemia	Diagnosis	ICD-10-CA
E783	Hyperchylomicronaemia	Diagnosis	ICD-10-CA
E784	Other hyperlipidaemia	Diagnosis	ICD-10-CA
E785	Hyperlipidaemia, unspecified	Diagnosis	ICD-10-CA
E786	Lipoprotein deficiency	Diagnosis	ICD-10-CA
E788	Other disorders of lipoprotein metabolism	Diagnosis	ICD-10-CA
E789	Disorder of lipoprotein metabolism, unspecified	Diagnosis	ICD-10-CA
272	Disorders of lipid metabolism (e.g., hypercholesterolemia, lipoprotein disorders)	Diagnosis	ICD-9-CM
Hypertension			
I100	Benign hypertension	Diagnosis	ICD-10-CA
I101	Malignant hypertension	Diagnosis	ICD-10-CA
I11	Hypertensive heart disease	Diagnosis	ICD-10-CA
I12	Hypertensive renal disease	Diagnosis	ICD-10-CA
I13	Hypertensive heart and renal disease	Diagnosis	ICD-10-CA
I1500	Renovascular hypertension, benign or unspecified	Diagnosis	ICD-10-CA
I1501	Renovascular hypertension, malignant	Diagnosis	ICD-10-CA
I1510	Hypertension secondary to other renal disorders, benign or unspecified	Diagnosis	ICD-10-CA
I1511	Hypertension secondary to other renal disorders, malignant	Diagnosis	ICD-10-CA
I1520	Hypertension secondary to endocrine disorders, benign or unspecified	Diagnosis	ICD-10-CA
I1521	Hypertension secondary to endocrine disorders, malignant	Diagnosis	ICD-10-CA
I1580	Other secondary hypertension, benign or unspecified	Diagnosis	ICD-10-CA
I1581	Other secondary hypertension, malignant	Diagnosis	ICD-10-CA
I1590	Secondary hypertension, benign or unspecified	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I1591	Secondary hypertension, unspecified, malignant	Diagnosis	ICD-10-CA
I674	Hypertensive encephalopathy	Diagnosis	ICD-10-CA
362	Hypertensive retinopathy and other retinal diseases not specifically listed	Diagnosis	ICD-9-CM
Myocardial Infarction			
I210	Acute transmural myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I211	Acute transmural myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I212	Acute transmural myocardial infarction of other sites	Diagnosis	ICD-10-CA
I213	Acute transmural myocardial infarction of unspecified site	Diagnosis	ICD-10-CA
I214	Acute subendocardial myocardial infarction	Diagnosis	ICD-10-CA
I2140	Acute subendocardial myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I2141	Acute subendocardial myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I2142	Acute subendocardial myocardial infarction of other sites	Diagnosis	ICD-10-CA
I2149	Acute subendocardial myocardial infarction, unspecified site	Diagnosis	ICD-10-CA
I219	Acute myocardial infarction, unspecified	Diagnosis	ICD-10-CA
I220	Subsequent myocardial infarction of anterior wall	Diagnosis	ICD-10-CA
I221	Subsequent myocardial infarction of inferior wall	Diagnosis	ICD-10-CA
I228	Subsequent myocardial infarction of other sites	Diagnosis	ICD-10-CA
I229	Subsequent myocardial infarction of unspecified site	Diagnosis	ICD-10-CA
Renal Disorders			
M321	Systemic lupus erythematosus with organ or system involvement	Diagnosis	ICD-10-CA
M350	Sicca syndrome	Diagnosis	ICD-10-CA
N000	Acute nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N001	Acute nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N002	Acute nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N003	Acute nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N004	Acute nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N005	Acute nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N006	Acute nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N007	Acute nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N008	Acute nephritic syndrome, other	Diagnosis	ICD-10-CA
N009	Acute nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N010	Rapidly progressive nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N011	Rapidly progressive nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N012	Rapidly progressive nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N013	Rapidly progressive nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N014	Rapidly progressive nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N015	Rapidly progressive nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N016	Rapidly progressive nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N017	Rapidly progressive nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N018	Rapidly progressive nephritic syndrome, other	Diagnosis	ICD-10-CA
N019	Rapidly progressive nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N020	Recurrent and persistent haematuria, minor glomerular abnormality	Diagnosis	ICD-10-CA
N021	Recurrent and persistent haematuria, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N022	Recurrent and persistent haematuria, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N023	Recurrent and persistent haematuria, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N024	Recurrent and persistent haematuria, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N025	Recurrent and persistent haematuria, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N026	Recurrent and persistent haematuria, dense deposit disease	Diagnosis	ICD-10-CA
N027	Recurrent and persistent haematuria, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N028	Recurrent and persistent haematuria, other	Diagnosis	ICD-10-CA
N029	Recurrent and persistent haematuria, unspecified	Diagnosis	ICD-10-CA
N030	Chronic nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N031	Chronic nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N032	Chronic nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N033	Chronic nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N034	Chronic nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N035	Chronic nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N036	Chronic nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N037	Chronic nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N038	Chronic nephritic syndrome, other	Diagnosis	ICD-10-CA
N039	Chronic nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N040	Nephrotic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N041	Nephrotic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N042	Nephrotic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N043	Nephrotic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N044	Nephrotic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N045	Nephrotic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N046	Nephrotic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N047	Nephrotic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N048	Nephrotic syndrome, other	Diagnosis	ICD-10-CA
N049	Nephrotic syndrome, unspecified	Diagnosis	ICD-10-CA
N050	Unspecified nephritic syndrome, minor glomerular abnormality	Diagnosis	ICD-10-CA
N051	Unspecified nephritic syndrome, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N052	Unspecified nephritic syndrome, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N053	Unspecified nephritic syndrome, diffuse mesangial proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N054	Unspecified nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis	Diagnosis	ICD-10-CA
N055	Unspecified nephritic syndrome, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N056	Unspecified nephritic syndrome, dense deposit disease	Diagnosis	ICD-10-CA
N057	Unspecified nephritic syndrome, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N058	Unspecified nephritic syndrome, other	Diagnosis	ICD-10-CA
N059	Unspecified nephritic syndrome, unspecified	Diagnosis	ICD-10-CA
N070	Hereditary nephropathy, not elsewhere classified, minor glomerular abnormality	Diagnosis	ICD-10-CA
N071	Hereditary nephropathy, not elsewhere classified, focal and segmental glomerular lesions	Diagnosis	ICD-10-CA
N072	Hereditary nephropathy, not elsewhere classified, diffuse membranous glomerulonephritis	Diagnosis	ICD-10-CA
N073	Hereditary nephropathy, not elsewhere classified, diffuse mesangial proliferative glomeruloneph	Diagnosis	ICD-10-CA
N074	Hereditary nephropathy, not elsewhere classified, diffuse endocapillary proliferative glomerulon	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N075	Hereditary nephropathy, not elsewhere classified, diffuse mesangiocapillary glomerulonephritis	Diagnosis	ICD-10-CA
N076	Hereditary nephropathy, not elsewhere classified, dense deposit disease	Diagnosis	ICD-10-CA
N077	Hereditary nephropathy, not elsewhere classified, diffuse crescentic glomerulonephritis	Diagnosis	ICD-10-CA
N078	Hereditary nephropathy, not elsewhere classified, other	Diagnosis	ICD-10-CA
N079	Hereditary nephropathy, not elsewhere classified, unspecified	Diagnosis	ICD-10-CA
N080	Glomerular disorders in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N081	Glomerular disorders in neoplastic diseases	Diagnosis	ICD-10-CA
N082	Glomerular disorders in blood diseases and disorders involving the immune mechanism	Diagnosis	ICD-10-CA
N083	Glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N0831	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 1	Diagnosis	ICD-10-CA
N0832	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 2	Diagnosis	ICD-10-CA
N0833	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 3	Diagnosis	ICD-10-CA
N0834	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 4	Diagnosis	ICD-10-CA
N0835	Glomerular disorders in diabetes mellitus, chronic kidney disease, stage 5	Diagnosis	ICD-10-CA
N0838	Other glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N0839	Unspecified glomerular disorders in diabetes mellitus	Diagnosis	ICD-10-CA
N084	Glomerular disorders in other endocrine, nutritional and metabolic diseases	Diagnosis	ICD-10-CA
N085	Glomerular disorders in systemic connective tissue disorders	Diagnosis	ICD-10-CA
N088	Glomerular disorders in other diseases classified elsewhere	Diagnosis	ICD-10-CA
N110	Nonobstructive reflux-associated chronic pyelonephritis	Diagnosis	ICD-10-CA
N111	Chronic obstructive pyelonephritis	Diagnosis	ICD-10-CA
N118	Other chronic tubulo-interstitial nephritis	Diagnosis	ICD-10-CA
N119	Chronic tubulo-interstitial nephritis, unspecified	Diagnosis	ICD-10-CA
N12	Tubulo-interstitial nephritis, not specified as acute or chronic	Diagnosis	ICD-10-CA
N130	Hydronephrosis with ureteropelvic junction obstruction	Diagnosis	ICD-10-CA
N131	Hydronephrosis with ureteral stricture, not elsewhere classified	Diagnosis	ICD-10-CA
N132	Hydronephrosis with renal and ureteral calculous obstruction	Diagnosis	ICD-10-CA
N133	Other and unspecified hydronephrosis	Diagnosis	ICD-10-CA
N134	Hydroureter	Diagnosis	ICD-10-CA
N135	Kinking and stricture of ureter without hydronephrosis	Diagnosis	ICD-10-CA
N136	Pyonephrosis	Diagnosis	ICD-10-CA
N137	Vesicoureteral-reflux-associated uropathy	Diagnosis	ICD-10-CA
N138	Other obstructive and reflux uropathy	Diagnosis	ICD-10-CA
N139	Obstructive and reflux uropathy, unspecified	Diagnosis	ICD-10-CA
N140	Analgesic nephropathy	Diagnosis	ICD-10-CA
N141	Nephropathy induced by other drugs, medicaments and biological substances	Diagnosis	ICD-10-CA
N142	Nephropathy induced by unspecified drug, medicament or biological substance	Diagnosis	ICD-10-CA
N143	Nephropathy induced by heavy metals	Diagnosis	ICD-10-CA
N144	Toxic nephropathy, not elsewhere classified	Diagnosis	ICD-10-CA
N150	Balkan nephropathy	Diagnosis	ICD-10-CA
N151	Renal and perinephric abscess	Diagnosis	ICD-10-CA
N158	Other specified renal tubulo-interstitial diseases	Diagnosis	ICD-10-CA
N159	Renal tubulo-interstitial disease, unspecified	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
N160	Renal tubulo-interstitial disorders in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N161	Renal tubulo-interstitial disorders in neoplastic diseases	Diagnosis	ICD-10-CA
N162	Renal tubulo-interstitial disorders in blood diseases and disorders involving the immune mechanism	Diagnosis	ICD-10-CA
N163	Renal tubulo-interstitial disorders in metabolic diseases	Diagnosis	ICD-10-CA
N164	Renal tubulo-interstitial disorders in systemic connective tissue disorders	Diagnosis	ICD-10-CA
N165	Renal tubulo-interstitial disorders in transplant rejection	Diagnosis	ICD-10-CA
N168	Renal tubulo-interstitial disorders in other diseases classified elsewhere	Diagnosis	ICD-10-CA
N170	Acute renal failure with tubular necrosis	Diagnosis	ICD-10-CA
N171	Acute renal failure with acute cortical necrosis	Diagnosis	ICD-10-CA
N172	Acute renal failure with medullary necrosis	Diagnosis	ICD-10-CA
N178	Other acute renal failure	Diagnosis	ICD-10-CA
N179	Acute renal failure, unspecified	Diagnosis	ICD-10-CA
N180	End-stage renal disease	Diagnosis	ICD-10-CA
N181	Chronic kidney disease, stage 1	Diagnosis	ICD-10-CA
N182	Chronic kidney disease, stage 2	Diagnosis	ICD-10-CA
N183	Chronic kidney disease, stage 3	Diagnosis	ICD-10-CA
N184	Chronic kidney disease, stage 4	Diagnosis	ICD-10-CA
N185	Chronic kidney disease, stage 5	Diagnosis	ICD-10-CA
N188	Other chronic renal failure	Diagnosis	ICD-10-CA
N189	Chronic kidney disease, unspecified	Diagnosis	ICD-10-CA
N19	Unspecified kidney failure	Diagnosis	ICD-10-CA
N250	Renal osteodystrophy	Diagnosis	ICD-10-CA
N251	Nephrogenic diabetes insipidus	Diagnosis	ICD-10-CA
N258	Other disorders resulting from impaired renal tubular function	Diagnosis	ICD-10-CA
N259	Disorder resulting from impaired renal tubular function, unspecified	Diagnosis	ICD-10-CA
N280	Ischaemia and infarction of kidney	Diagnosis	ICD-10-CA
N281	Cyst of kidney, acquired	Diagnosis	ICD-10-CA
N2880	Hypertrophy of kidney	Diagnosis	ICD-10-CA
N2881	Megaloureter	Diagnosis	ICD-10-CA
N2882	Nephroptosis	Diagnosis	ICD-10-CA
N2883	Pyelitis cystica	Diagnosis	ICD-10-CA
N2884	Pyeloureteritis cystica	Diagnosis	ICD-10-CA
N2885	Ureteritis cystica	Diagnosis	ICD-10-CA
N2888	Other specified disorders of kidney and ureter	Diagnosis	ICD-10-CA
N289	Disorder of kidney and ureter, unspecified	Diagnosis	ICD-10-CA
N290	Late syphilis of kidney	Diagnosis	ICD-10-CA
N291	Other disorders of kidney and ureter in infectious and parasitic diseases classified elsewhere	Diagnosis	ICD-10-CA
N298	Other disorders of kidney and ureter in other diseases classified elsewhere	Diagnosis	ICD-10-CA
588.81	Secondary Hyperparathyroidism (of renal organ)	Diagnosis	ICD-9-CM
590.8	Pyelonephritis, unspecified	Diagnosis	ICD-9-CM
590.80	Other pyelonephritis or pyonephrosis not specified as acute or chronic	Diagnosis	ICD-9-CM
590.81	Pyelitis or pyelonephritis in diseases classified elsewhere	Diagnosis	ICD-9-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
590.9	Infection of kidney, unspecified	Diagnosis	ICD-9-CM
593.0	Nephroptosis	Diagnosis	ICD-9-CM
593.2	Cyst of kidney, acquired	Diagnosis	ICD-9-CM
593.3	Stricture or kinking of ureter	Diagnosis	ICD-9-CM
593.6	Postural proteinuria	Diagnosis	ICD-9-CM
593.82	Ureteral fistula	Diagnosis	ICD-9-CM
599.7	Hematuria	Diagnosis	ICD-9-CM
599.70	Hematuria, unspecified	Diagnosis	ICD-9-CM
599.71	Gross hematuria	Diagnosis	ICD-9-CM

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	Code Type
		Category	
Stroke			
I600	Subarachnoid haemorrhage from carotid siphon and bifurcation	Diagnosis	ICD-10-CA
I601	Subarachnoid haemorrhage from middle cerebral artery	Diagnosis	ICD-10-CA
I602	Subarachnoid haemorrhage from anterior communicating artery	Diagnosis	ICD-10-CA
I603	Subarachnoid haemorrhage from posterior communicating artery	Diagnosis	ICD-10-CA
I604	Subarachnoid haemorrhage from basilar artery	Diagnosis	ICD-10-CA
I605	Subarachnoid haemorrhage from vertebral artery	Diagnosis	ICD-10-CA
I606	Subarachnoid haemorrhage from other intracranial arteries	Diagnosis	ICD-10-CA
I607	Subarachnoid haemorrhage from intracranial artery, unspecified	Diagnosis	ICD-10-CA
I608	Other subarachnoid haemorrhage	Diagnosis	ICD-10-CA
I609	Subarachnoid haemorrhage, unspecified	Diagnosis	ICD-10-CA
I610	Intracerebral haemorrhage in hemisphere, subcortical	Diagnosis	ICD-10-CA
I611	Intracerebral haemorrhage in hemisphere, cortical	Diagnosis	ICD-10-CA
I612	Intracerebral haemorrhage in hemisphere, unspecified	Diagnosis	ICD-10-CA
I613	Intracerebral haemorrhage in brain stem	Diagnosis	ICD-10-CA
I614	Intracerebral haemorrhage in cerebellum	Diagnosis	ICD-10-CA
I615	Intracerebral haemorrhage, intraventricular	Diagnosis	ICD-10-CA
I616	Intracerebral haemorrhage, multiple localized	Diagnosis	ICD-10-CA
I618	Other intracerebral haemorrhage	Diagnosis	ICD-10-CA
I619	Intracerebral haemorrhage, unspecified	Diagnosis	ICD-10-CA
I620	Subdural haemorrhage (acute)(nontraumatic)	Diagnosis	ICD-10-CA
I621	Nontraumatic extradural haemorrhage	Diagnosis	ICD-10-CA
I629	Intracranial haemorrhage (nontraumatic), unspecified	Diagnosis	ICD-10-CA
I630	Cerebral infarction due to thrombosis of precerebral arteries	Diagnosis	ICD-10-CA
I631	Cerebral infarction due to embolism of precerebral arteries	Diagnosis	ICD-10-CA
I632	Cerebral infarction due to unspecified occlusion or stenosis of precerebral arteries	Diagnosis	ICD-10-CA
I633	Cerebral infarction due to thrombosis of cerebral arteries	Diagnosis	ICD-10-CA
I634	Cerebral infarction due to embolism of cerebral arteries	Diagnosis	ICD-10-CA
I635	Cerebral infarction due to unspecified occlusion or stenosis of cerebral arteries	Diagnosis	ICD-10-CA
I636	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic	Diagnosis	ICD-10-CA
I638	Other cerebral infarction	Diagnosis	ICD-10-CA
I639	Cerebral infarction, unspecified	Diagnosis	ICD-10-CA
I64	Stroke, not specified as haemorrhage or infarction	Diagnosis	ICD-10-CA
I650	Occlusion and stenosis of vertebral artery	Diagnosis	ICD-10-CA
I651	Occlusion and stenosis of basilar artery	Diagnosis	ICD-10-CA
I652	Occlusion and stenosis of carotid artery	Diagnosis	ICD-10-CA
I653	Occlusion and stenosis of multiple and bilateral precerebral arteries	Diagnosis	ICD-10-CA
I658	Occlusion and stenosis of other precerebral artery	Diagnosis	ICD-10-CA
I659	Occlusion and stenosis of unspecified precerebral artery	Diagnosis	ICD-10-CA
I660	Occlusion and stenosis of middle cerebral artery	Diagnosis	ICD-10-CA
I661	Occlusion and stenosis of anterior cerebral artery	Diagnosis	ICD-10-CA
I662	Occlusion and stenosis of posterior cerebral artery	Diagnosis	ICD-10-CA
I663	Occlusion and stenosis of cerebellar arteries	Diagnosis	ICD-10-CA

Appendix E. List of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Tenth Revision, with Canadian Enhancements (ICD-10-CA) Diagnosis Codes Used to Define Baseline Characteristics in this Request

Code	Description	Code	
		Category	Code Type
I664	Occlusion and stenosis of multiple and bilateral cerebral arteries	Diagnosis	ICD-10-CA
I668	Occlusion and stenosis of other cerebral artery	Diagnosis	ICD-10-CA
I669	Occlusion and stenosis of unspecified cerebral artery	Diagnosis	ICD-10-CA
I670	Dissection of cerebral arteries, nonruptured	Diagnosis	ICD-10-CA
I671	Cerebral aneurysm, nonruptured	Diagnosis	ICD-10-CA
I672	Cerebral atherosclerosis	Diagnosis	ICD-10-CA
432	Other and unspecified intracranial hemorrhage	Diagnosis	ICD-9-CM
432.0	Nontraumatic extradural hemorrhage	Diagnosis	ICD-9-CM
432.1	Subdural hemorrhage	Diagnosis	ICD-9-CM
432.9	Unspecified intracerebral hemorrhage	Diagnosis	ICD-9-CM
435	Transient cerebral ischemia	Diagnosis	ICD-9-CM
435.0	Basil artery syndrome	Diagnosis	ICD-9-CM
435.1	Vertebral artery syndrome	Diagnosis	ICD-9-CM
435.2	Subclavian steal syndrome	Diagnosis	ICD-9-CM
435.3	Vertebrobasilar artery syndrome	Diagnosis	ICD-9-CM
435.8	Other specified transient cerebral ischemias	Diagnosis	ICD-9-CM
435.9	Unspecified transient cerebral ischemia	Diagnosis	ICD-9-CM
436	Acute, but ill-defined, cerebrovascular disease	Diagnosis	ICD-9-CM

Appendix F. Specifications Defining Parameters for this Request

This request estimated the prevalent utilization for no impurity identified, impurity identified, recalled, and unclassified valsartan over time.

Query period: 05/01/2012 - 11/30/2021

Coverage requirement: Medical and drug (DNPR: drug only)

Pre-index enrollment requirement: 183 days

Post-index enrollment requirement: 0 days

Enrollment gap: 45 days

Age groups: 18-44, 45-64, 65+ years

Sex groups: Male, Female

Censor output categorization: 1-183, 184-365, 366-730, 731-1095, 1096-1460, 1461-1825, 1826+

Stratified output: Age group

Year*month

Year*quarter

Envelope macro: No reclassification

Freeze data: No

Additional programming: Episodes that cross multiple quarters will be counted in each quarter
(reuses custom programming from cder_mpl1p_wp044)

Truncate primary episode upon first occurrence of secondary event

Automatically-created prevalent cohort does drops non-exposure definition incidence requirements

	Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4	Primary Cohort 5	Primary Cohort 6	Primary Cohort 7
	All Valsartan	Valsartan without Impurity	Valsartan with Impurity	Recalled Valsartan	Branded Valsartan	Unclassified Valsartan	All Recalled ARBs (including Valsartan)
Exposure	Valsartan (without impurity, with impurity, recalled, unclassified, branded)	Valsartan (without impurity)	Valsartan (with impurity)	Valsartan (recall)	Valsartan (branded)	Valsartan (unclassified)	Recalled ARBs (Losartan, Irbesartan, Valsartan)

Appendix F. Specifications Defining Parameters for this Request

Drug/Exposure		Primary Cohort 1 All Valsartan	Primary Cohort 2 Valsartan without Impurity	Primary Cohort 3 Valsartan with Impurity	Primary Cohort 4 Recalled Valsartan	Primary Cohort 5 Branded Valsartan	Primary Cohort 6 Unclassified Valsartan	Primary Cohort 7 All Recalled ARBs (including Valsartan)
	Care Setting	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Incident with respect to:	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Cohort Definition	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)	Cohort includes all valid exposure episodes during query period (02)
	Exposure Episode Truncation Criteria	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation	*Death; *Data Partner end date; *Query end date; *Disenrollment; *Product discontinuation
	Exposure Episode Gap	30 days	30 days	30 days	30 days	30 days	30 days	30 days
	Exposure Extension Period	30 days	30 days	30 days	30 days	30 days	30 days	30 days
	Minimum Episode Duration	1 day	1 day	1 day	1 day	1 day	1 day	1 day
	Minimum Days Supplied	1 day	1 day	1 day	1 day	1 day	1 day	1 day
		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4	Primary Cohort 5	Primary Cohort 6	Primary Cohort 7

Appendix F. Specifications Defining Parameters for this Request

Stockpiling		All Valsartan	Valsartan without Impurity	Valsartan with Impurity	Recalled Valsartan	Branded Valsartan	Unclassified Valsartan	All Recalled ARBs (including Valsartan)
	Intention-to-Treat Days	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Prevalent Cohort creation	Yes	Yes	Yes	Yes	Yes	Yes	Yes
	Same Day Dispensing (Days Supplied)	Sum	Sum	Sum	Sum	Sum	Sum	Sum
	Same Day Dispensing (Amount Supplied)	Sum	Sum	Sum	Sum	Sum	Sum	Sum
	Range of Allowable Days Supplied	Any	Any	Any	Any	Any	Any	Any
	Range of Allowable Amount Supplied	Any	Any	Any	Any	Any	Any	Any
	Overlap Percentage Processing	33% overlap	33% overlap	33% overlap	33% overlap	33% overlap	33% overlap	33% overlap
	Output Baseline Table	Yes	Yes	Yes	Yes	Yes	Yes	Yes
		Primary Cohort 1	Primary Cohort 2	Primary Cohort 3	Primary Cohort 4	Primary Cohort 5	Primary Cohort 6	Primary Cohort 7

Appendix F. Specifications Defining Parameters for this Request

		All Valsartan	Valsartan without Impurity	Valsartan with Impurity	Recalled Valsartan	Branded Valsartan	Unclassified Valsartan	All Recalled ARBs (including Valsartan)
Baseline Covariates	Covariates	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke	Angina, atrial fibrillation, diabetes, heart failure, hyperlipidemia, hypertension, myocardial infarction, renal disorders, stroke
	Care Setting /PDX	N/A	N/A	N/A	N/A	N/A	N/A	N/A
	Covariate evaluation window (days)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)	(-183, 0)

N/A: Not Applicable